BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lowe SW, Bodis S, McClatchey A, Remington L, Ruley HE, Fisher DE, Housman DE, Jacks T. p53 status and the efficacy of cancer therapy in vivo. Science. 1994;266:807-810. [PMID: 7973635 DOI: 10.1126/science.7973635] [Cited by in Crossref: 997] [Cited by in F6Publishing: 954] [Article Influence: 35.6] [Reference Citation Analysis]
Number Citing Articles
1 Phillips JL, Buermeyer AB, Nguyen BD, Loehr C, Kolluri SK. Loss of the aryl hydrocarbon receptor increases tumorigenesis in p53-deficient mice. Toxicol Appl Pharmacol 2022;:116191. [PMID: 35926564 DOI: 10.1016/j.taap.2022.116191] [Reference Citation Analysis]
2 Chen L, Cao L, Zhan M, Li J, Wang D, Laurent R, Mignani S, Caminade AM, Majoral JP, Shi X. Engineered Stable Bioactive Per Se Amphiphilic Phosphorus Dendron Nanomicelles as a Highly Efficient Drug Delivery System To Take Down Breast Cancer In Vivo. Biomacromolecules 2022. [PMID: 35694854 DOI: 10.1021/acs.biomac.2c00197] [Reference Citation Analysis]
3 Marney C, Anderson E, Baum R, Schmitt A. A Unique Spectrum of Spontaneous Tumors in Dino Knockout Mice Identifies Tissue-Specific Requirements for Tumor Suppression. Cells 2022;11:1818. [DOI: 10.3390/cells11111818] [Reference Citation Analysis]
4 Ha J, Prela O, Carpizo DR, Loh SN. p53 and Zinc: A Malleable Relationship. Front Mol Biosci 2022;9:895887. [DOI: 10.3389/fmolb.2022.895887] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Granowicz EM, Jonas BA. Targeting TP53-Mutated Acute Myeloid Leukemia: Research and Clinical Developments. OTT 2022;Volume 15:423-36. [DOI: 10.2147/ott.s265637] [Reference Citation Analysis]
6 Izutsu M, Domoto T, Kamoshida S, Ohsaki H, Matsuoka H, Umeki Y, Shiogama K, Hirayama M, Suda K, Uyama I. Expression status of p53 and organic cation transporter 1 is correlated with poor response to preoperative chemotherapy in esophageal squamous cell carcinoma. World J Surg Oncol 2022;20:105. [PMID: 35365176 DOI: 10.1186/s12957-022-02571-9] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Batur T, Argundogan A, Keles U, Mutlu Z, Alotaibi H, Senturk S, Ozturk M. AXL Knock-Out in SNU475 Hepatocellular Carcinoma Cells Provides Evidence for Lethal Effect Associated with G2 Arrest and Polyploidization. Int J Mol Sci 2021;22:13247. [PMID: 34948046 DOI: 10.3390/ijms222413247] [Reference Citation Analysis]
8 Sharifi-Rad J, Quispe C, Patra JK, Singh YD, Panda MK, Das G, Adetunji CO, Michael OS, Sytar O, Polito L, Živković J, Cruz-Martins N, Klimek-Szczykutowicz M, Ekiert H, Choudhary MI, Ayatollahi SA, Tynybekov B, Kobarfard F, Muntean AC, Grozea I, Daştan SD, Butnariu M, Szopa A, Calina D. Paclitaxel: Application in Modern Oncology and Nanomedicine-Based Cancer Therapy. Oxid Med Cell Longev 2021;2021:3687700. [PMID: 34707776 DOI: 10.1155/2021/3687700] [Reference Citation Analysis]
9 Jaiswal SK, Raj S, DePamphilis ML. Developmental Acquisition of p53 Functions. Genes (Basel) 2021;12:1675. [PMID: 34828285 DOI: 10.3390/genes12111675] [Reference Citation Analysis]
10 Kong X, Yu D, Wang Z, Li S. Relationship between p53 status and the bioeffect of ionizing radiation. Oncol Lett 2021;22:661. [PMID: 34386083 DOI: 10.3892/ol.2021.12922] [Reference Citation Analysis]
11 Shi T, van Soest DMK, Polderman PE, Burgering BMT, Dansen TB. DNA damage and oxidant stress activate p53 through differential upstream signaling pathways. Free Radic Biol Med 2021;172:298-311. [PMID: 34144191 DOI: 10.1016/j.freeradbiomed.2021.06.013] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
12 Kishi S, Nishiguchi Y, Honoki K, Mori S, Fujiwara-Tani R, Sasaki T, Fujii K, Kawahara I, Goto K, Nakashima C, Kido A, Tanaka Y, Luo Y, Kuniyasu H. Role of Glycated High Mobility Group Box-1 in Gastric Cancer. Int J Mol Sci 2021;22:5185. [PMID: 34068442 DOI: 10.3390/ijms22105185] [Reference Citation Analysis]
13 Lei G, Zhang Y, Hong T, Zhang X, Liu X, Mao C, Yan Y, Koppula P, Cheng W, Sood AK, Liu J, Gan B. Ferroptosis as a mechanism to mediate p53 function in tumor radiosensitivity. Oncogene 2021;40:3533-47. [PMID: 33927351 DOI: 10.1038/s41388-021-01790-w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
14 Arfin S, Jha NK, Jha SK, Kesari KK, Ruokolainen J, Roychoudhury S, Rathi B, Kumar D. Oxidative Stress in Cancer Cell Metabolism. Antioxidants (Basel) 2021;10:642. [PMID: 33922139 DOI: 10.3390/antiox10050642] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
15 Li H, Wang J, Huang K, Zhang T, Gao L, Yang S, Yi W, Niu Y, Liu H, Wang Z, Wang G, Tao K, Wang L, Cai K. Nkx2.5 Functions as a Conditional Tumor Suppressor Gene in Colorectal Cancer Cells via Acting as a Transcriptional Coactivator in p53-Mediated p21 Expression. Front Oncol 2021;11:648045. [PMID: 33869046 DOI: 10.3389/fonc.2021.648045] [Reference Citation Analysis]
16 Huang YS, Hsu WC, Lin CH, Lo SN, Cheng CN, Lin MS, Lee TW, Chang CH, Lan KL. Bi-Functional Radiotheranostics of 188Re-Liposome-Fcy-hEGF for Radio- and Chemo-Therapy of EGFR-Overexpressing Cancer Cells. Int J Mol Sci 2021;22:1902. [PMID: 33672989 DOI: 10.3390/ijms22041902] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Gilleran JA, Yu X, Blayney AJ, Bencivenga AF, Na B, Augeri DJ, Blanden AR, Kimball SD, Loh SN, Roberge JY, Carpizo DR. Benzothiazolyl and Benzoxazolyl Hydrazones Function as Zinc Metallochaperones to Reactivate Mutant p53. J Med Chem 2021;64:2024-45. [PMID: 33538587 DOI: 10.1021/acs.jmedchem.0c01360] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
18 Wummer B, Woodworth D, Flores C. Brain stem gliomas and current landscape. J Neurooncol 2021;151:21-8. [PMID: 33398531 DOI: 10.1007/s11060-020-03655-w] [Reference Citation Analysis]
19 Sadiq Z, Varghese E, Büsselberg D. Cisplatin's dual-effect on the circadian clock triggers proliferation and apoptosis. Neurobiol Sleep Circadian Rhythms 2020;9:100054. [PMID: 33364523 DOI: 10.1016/j.nbscr.2020.100054] [Reference Citation Analysis]
20 Kumar RJ, Chao HX, Simpson DA, Feng W, Cho MG, Roberts VR, Sullivan AR, Shah SJ, Wozny AS, Fagan-Solis K, Kumar S, Luthman A, Ramsden DA, Purvis JE, Gupta GP. Dual inhibition of DNA-PK and DNA polymerase theta overcomes radiation resistance induced by p53 deficiency. NAR Cancer 2020;2:zcaa038. [PMID: 33385162 DOI: 10.1093/narcan/zcaa038] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
21 Shi T, Dansen TB. Reactive Oxygen Species Induced p53 Activation: DNA Damage, Redox Signaling, or Both? Antioxidants & Redox Signaling 2020;33:839-59. [DOI: 10.1089/ars.2020.8074] [Cited by in Crossref: 36] [Cited by in F6Publishing: 31] [Article Influence: 18.0] [Reference Citation Analysis]
22 Richartz N, Duthil E, Ford A, Naderi EH, Bhagwat S, Gilljam KM, Burman MM, Ruud E, Blomhoff HK, Skah S. Targeting cyclooxygenase by indomethacin decelerates progression of acute lymphoblastic leukemia in a xenograft model. Blood Adv 2019;3:3181-90. [PMID: 31698450 DOI: 10.1182/bloodadvances.2019000473] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
23 Saxena K, Dinardo C, Daver N, Konopleva M. Harnessing Apoptosis in AML. Clinical Lymphoma Myeloma and Leukemia 2020;20:S61-4. [DOI: 10.1016/s2152-2650(20)30464-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Saxena K, Konopleva M. An expert overview of emerging therapies for acute myeloid leukemia: novel small molecules targeting apoptosis, p53, transcriptional regulation and metabolism. Expert Opin Investig Drugs 2020;29:973-88. [PMID: 32746655 DOI: 10.1080/13543784.2020.1804856] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
25 Ji MT, Nie J, Nie XF, Hu WT, Pei HL, Wan JM, Wang AQ, Zhou GM, Zhang ZL, Chang L, Li BY. 1α,25(OH)2D3 Radiosensitizes Cancer Cells by Activating the NADPH/ROS Pathway. Front Pharmacol 2020;11:945. [PMID: 32848720 DOI: 10.3389/fphar.2020.00945] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
26 Shen CC, Cheng WY, Lee CH, Dai XJ, Chiao MT, Liang YJ, Hsieh WY, Mao TF, Lin GS, Chen SR, Liu BS, Chen JP. Both p53 codon 72 Arg/Arg and pro/Arg genotypes in glioblastoma multiforme are associated with a better prognosis in bevacizumab treatment. BMC Cancer 2020;20:709. [PMID: 32727419 DOI: 10.1186/s12885-020-07210-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
27 Thapa B, Kc R, Uludağ H. TRAIL therapy and prospective developments for cancer treatment. J Control Release 2020;326:335-49. [PMID: 32682900 DOI: 10.1016/j.jconrel.2020.07.013] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
28 Zhou X, Hao Q, Lu H. Mutant p53 in cancer therapy-the barrier or the path. J Mol Cell Biol. 2019;11:293-305. [PMID: 30508182 DOI: 10.1093/jmcb/mjy072] [Cited by in Crossref: 64] [Cited by in F6Publishing: 63] [Article Influence: 32.0] [Reference Citation Analysis]
29 Jaiswal SK, Oh JJ, DePamphilis ML. Cell cycle arrest and apoptosis are not dependent on p53 prior to p53-dependent embryonic stem cell differentiation. Stem Cells 2020;38:1091-106. [PMID: 32478947 DOI: 10.1002/stem.3199] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
30 Hunter AM, Sallman DA. Targeting TP53 Mutations in Myelodysplastic Syndromes. Hematology/Oncology Clinics of North America 2020;34:421-40. [DOI: 10.1016/j.hoc.2019.11.004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
31 Kang DY, Sp N, Jo ES, Rugamba A, Hong DY, Lee HG, Yoo JS, Liu Q, Jang KJ, Yang YM. The Inhibitory Mechanisms of Tumor PD-L1 Expression by Natural Bioactive Gallic Acid in Non-Small-Cell Lung Cancer (NSCLC) Cells. Cancers (Basel) 2020;12:E727. [PMID: 32204508 DOI: 10.3390/cancers12030727] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 8.0] [Reference Citation Analysis]
32 Aouiche C, Chen B, Shang X. Predicting Stage-Specific Recurrent Aberrations From Somatic Copy Number Dataset. Front Genet 2020;11:160. [PMID: 32174978 DOI: 10.3389/fgene.2020.00160] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
33 Daitoku N, Miyamoto Y, Sakamoto Y, Tokunaga R, Hiyoshi Y, Nagai Y, Iwatsuki M, Iwagami S, Yoshida N, Baba H. Prognostic significance of serum p53 antibody according to KRAS status in metastatic colorectal cancer patients. Int J Clin Oncol 2020;25:651-9. [PMID: 31834556 DOI: 10.1007/s10147-019-01599-4] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
34 Pitolli C, Wang Y, Mancini M, Shi Y, Melino G, Amelio I. Do Mutations Turn p53 into an Oncogene? Int J Mol Sci. 2019;20:6241. [PMID: 31835684 DOI: 10.3390/ijms20246241] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 9.0] [Reference Citation Analysis]
35 Fulciniti M, Lin CY, Samur MK, Lopez MA, Singh I, Lawlor MA, Szalat RE, Ott CJ, Avet-Loiseau H, Anderson KC, Young RA, Bradner JE, Munshi NC. Non-overlapping Control of Transcriptome by Promoter- and Super-Enhancer-Associated Dependencies in Multiple Myeloma. Cell Rep 2018;25:3693-3705.e6. [PMID: 30590042 DOI: 10.1016/j.celrep.2018.12.016] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
36 Robinson AM, Rathore R, Redlich NJ, Adkins DR, VanArsdale T, Van Tine BA, Michel LS. Cisplatin exposure causes c-Myc-dependent resistance to CDK4/6 inhibition in HPV-negative head and neck squamous cell carcinoma. Cell Death Dis 2019;10:867. [PMID: 31727874 DOI: 10.1038/s41419-019-2098-8] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
37 Li X, Xu Q, Zhang P, Zhao X, Wang Y. Cutaneous microenvironment responsive microneedle patch for rapid gene release to treat subdermal tumor. Journal of Controlled Release 2019;314:72-80. [DOI: 10.1016/j.jconrel.2019.10.016] [Cited by in Crossref: 21] [Cited by in F6Publishing: 11] [Article Influence: 7.0] [Reference Citation Analysis]
38 Williams DS, Mouradov D, Browne C, Palmieri M, Elliott MJ, Nightingale R, Fang CG, Li R, Mariadason JM, Faragher I, Jones IT, Churilov L, Tebbutt NC, Gibbs P, Sieber OM. Overexpression of TP53 protein is associated with the lack of adjuvant chemotherapy benefit in patients with stage III colorectal cancer. Mod Pathol 2020;33:483-95. [DOI: 10.1038/s41379-019-0353-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
39 Zong Y, Li Q, Zhang F, Xian X, Wang S, Xia J, Li J, Tuo Z, Xiao G, Liu L, Li G, Zhang S, Wu G, Liu J. SDH5 Depletion Enhances Radiosensitivity by Regulating p53: A New Method for Noninvasive Prediction of Radiotherapy Response. Theranostics 2019;9:6380-95. [PMID: 31588224 DOI: 10.7150/thno.34443] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
40 Zaman S, Yu X, Bencivenga AF, Blanden AR, Liu Y, Withers T, Na B, Blayney AJ, Gilleran J, Boothman DA, Loh SN, Kimball SD, Carpizo DR. Combinatorial Therapy of Zinc Metallochaperones with Mutant p53 Reactivation and Diminished Copper Binding. Mol Cancer Ther 2019;18:1355-65. [PMID: 31196889 DOI: 10.1158/1535-7163.MCT-18-1080] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
41 Hunter AM, Sallman DA. Current status and new treatment approaches in TP53 mutated AML. Best Pract Res Clin Haematol 2019;32:134-44. [PMID: 31203995 DOI: 10.1016/j.beha.2019.05.004] [Cited by in Crossref: 16] [Cited by in F6Publishing: 20] [Article Influence: 5.3] [Reference Citation Analysis]
42 Paul P, Malakar AK, Chakraborty S. The significance of gene mutations across eight major cancer types. Mutat Res Rev Mutat Res 2019;781:88-99. [PMID: 31416581 DOI: 10.1016/j.mrrev.2019.04.004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
43 Xia KK, Lyu Y, Yuan WT, Wang GX, Stratton H, Zhang SJ, Wu J. Nanocarriers of Fe3O4 as a Novel Method for Delivery of the Antineoplastic Agent Doxorubicin Into HeLa Cells in vitro. Front Oncol 2019;9:250. [PMID: 31110964 DOI: 10.3389/fonc.2019.00250] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
44 Mullan PB, Bingham V, Haddock P, Irwin GW, Kay E, McQuaid S, Buckley NE. NUP98 - a novel predictor of response to anthracycline-based chemotherapy in triple negative breast cancer. BMC Cancer 2019;19:236. [PMID: 30935371 DOI: 10.1186/s12885-019-5407-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
45 Al-Aamri HM, Ku H, Irving HR, Tucci J, Meehan-Andrews T, Bradley C. Time dependent response of daunorubicin on cytotoxicity, cell cycle and DNA repair in acute lymphoblastic leukaemia. BMC Cancer 2019;19:179. [PMID: 30813936 DOI: 10.1186/s12885-019-5377-y] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 6.3] [Reference Citation Analysis]
46 Lugli E, Kvistborg P, Galletti G. Cancer neoantigens targeted by adoptive T cell transfer: private no more. J Clin Invest 2019;129:949-51. [PMID: 30714989 DOI: 10.1172/JCI126295] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
47 Du Y, Li L, Chen H, Wang C, Qian X, Feng Y, Zhang L, Chen F. A novel all-trans retinoic acid derivative inhibits proliferation and induces apoptosis of myelodysplastic syndromes cell line SKM-1 cells via up-regulating p53. International Immunopharmacology 2018;65:561-70. [DOI: 10.1016/j.intimp.2018.10.041] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
48 Ariës IM, Bodaar K, Karim SA, Chonghaile TN, Hinze L, Burns MA, Pfirrmann M, Degar J, Landrigan JT, Balbach S, Peirs S, Menten B, Isenhart R, Stevenson KE, Neuberg DS, Devidas M, Loh ML, Hunger SP, Teachey DT, Rabin KR, Winter SS, Dunsmore KP, Wood BL, Silverman LB, Sallan SE, Van Vlierberghe P, Orkin SH, Knoechel B, Letai AG, Gutierrez A. PRC2 loss induces chemoresistance by repressing apoptosis in T cell acute lymphoblastic leukemia. J Exp Med 2018;215:3094-114. [PMID: 30404791 DOI: 10.1084/jem.20180570] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
49 Babiker A, Almatroudi A, Allemailem K, Husain N, Alsammani M, Alsahli M, Rahmani A. Clinicopathologic Aspects of Squamous Cell Carcinoma of the Uterine Cervix: Role of PTEN, BCL2 and P53. Applied Sciences 2018;8:2124. [DOI: 10.3390/app8112124] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
50 Abrantes ABP, Dias GC, Souza-Pinto NC, Baptista MS. p53-Dependent and p53-Independent Responses of Cells Challenged by Photosensitization. Photochem Photobiol 2019;95:355-63. [PMID: 30240018 DOI: 10.1111/php.13019] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
51 Barnoud T, Budina-Kolomets A, Basu S, Leu JI, Good M, Kung CP, Liu J, Liu Q, Villanueva J, Zhang R, George DL, Murphy ME. Tailoring Chemotherapy for the African-Centric S47 Variant of TP53. Cancer Res 2018;78:5694-705. [PMID: 30115697 DOI: 10.1158/0008-5472.CAN-18-1327] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
52 Allison SJ, Cooke D, Davidson FS, Elliott PIP, Faulkner RA, Griffiths HBS, Harper OJ, Hussain O, Owen-Lynch PJ, Phillips RM, Rice CR, Shepherd SL, Wheelhouse RT. Ruthenium-Containing Linear Helicates and Mesocates with Tuneable p53-Selective Cytotoxicity in Colorectal Cancer Cells. Angew Chem Int Ed Engl 2018;57:9799-804. [PMID: 29863754 DOI: 10.1002/anie.201805510] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 5.8] [Reference Citation Analysis]
53 Allison SJ, Cooke D, Davidson FS, Elliott PIP, Faulkner RA, Griffiths HBS, Harper OJ, Hussain O, Owen-lynch PJ, Phillips RM, Rice CR, Shepherd SL, Wheelhouse RT. Ruthenium-Containing Linear Helicates and Mesocates with Tuneable p53-Selective Cytotoxicity in Colorectal Cancer Cells. Angew Chem 2018;130:9947-52. [DOI: 10.1002/ange.201805510] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
54 Janic A, Valente LJ, Wakefield MJ, Di Stefano L, Milla L, Wilcox S, Yang H, Tai L, Vandenberg CJ, Kueh AJ, Mizutani S, Brennan MS, Schenk RL, Lindqvist LM, Papenfuss AT, O’connor L, Strasser A, Herold MJ. DNA repair processes are critical mediators of p53-dependent tumor suppression. Nat Med 2018;24:947-53. [DOI: 10.1038/s41591-018-0043-5] [Cited by in Crossref: 61] [Cited by in F6Publishing: 60] [Article Influence: 15.3] [Reference Citation Analysis]
55 Mendoza-anaya D, Flores-díaz E, Mondragón-galicia G, Fernández-garcía ME, Salinas-rodríguez E, Karthik TVK, Rodríguez-lugo V. The role of Eu on the thermoluminescence induced by gamma radiation in nano hydroxyapatite. J Mater Sci: Mater Electron 2018;29:15579-86. [DOI: 10.1007/s10854-018-9147-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
56 Liu J, Song L, Liu S, Jiang Q, Liu Q, Li N, Wang ZG, Ding B. A DNA-Based Nanocarrier for Efficient Gene Delivery and Combined Cancer Therapy. Nano Lett 2018;18:3328-34. [PMID: 29708760 DOI: 10.1021/acs.nanolett.7b04812] [Cited by in Crossref: 110] [Cited by in F6Publishing: 86] [Article Influence: 27.5] [Reference Citation Analysis]
57 Legler K, Hauser C, Egberts JH, Willms A, Heneweer C, Boretius S, Röcken C, Glüer CC, Becker T, Kluge M, Hill O, Gieffers C, Fricke H, Kalthoff H, Lemke J, Trauzold A. The novel TRAIL-receptor agonist APG350 exerts superior therapeutic activity in pancreatic cancer cells. Cell Death Dis 2018;9:445. [PMID: 29670075 DOI: 10.1038/s41419-018-0478-0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
58 Wu X, Shen Y. PMN inhibits colorectal cancer cells through inducing mitotic arrest and p53-dependent apoptosis via the inhibition of tubulin polymerization. Biochem Biophys Res Commun 2018;499:927-33. [PMID: 29626471 DOI: 10.1016/j.bbrc.2018.04.021] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
59 Guarneri V, Barbieri E, Piacentini F, Giovannelli S, Ficarra G, Frassoldati A, Maiorana A, D'amico R, Conte P. Predictive and Prognostic Role of P53 According to Tumor Phenotype in Breast Cancer Patients Treated with Preoperative Chemotherapy: A Single-Institution Analysis. Int J Biol Markers 2010;25:104-11. [DOI: 10.1177/172460081002500208] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.8] [Reference Citation Analysis]
60 Li X, Peterson YK, Inks ES, Himes RA, Li J, Zhang Y, Kong X, Chou CJ. Class I HDAC Inhibitors Display Different Antitumor Mechanism in Leukemia and Prostatic Cancer Cells Depending on Their p53 Status. J Med Chem 2018;61:2589-603. [PMID: 29499113 DOI: 10.1021/acs.jmedchem.8b00136] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 6.5] [Reference Citation Analysis]
61 Yamashita K, Makino T, Tanaka K, Yamasaki M, Yamamoto M, Miyazaki Y, Takahashi T, Kurokawa Y, Nakajima K, Takiguchi S, Mori M, Doki Y. Peritherapeutic Serum p53 Antibody Titers are Predictors of Survival in Patients with Esophageal Squamous Cell Carcinoma Undergoing Neoadjuvant Chemotherapy and Surgery. World J Surg 2017;41:1566-74. [PMID: 28108772 DOI: 10.1007/s00268-017-3894-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
62 Frères P, Bouznad N, Servais L, Josse C, Wenric S, Poncin A, Thiry J, Moonen M, Oury C, Lancellotti P, Bours V, Jerusalem G. Variations of circulating cardiac biomarkers during and after anthracycline-containing chemotherapy in breast cancer patients. BMC Cancer 2018;18:102. [PMID: 29378531 DOI: 10.1186/s12885-018-4015-4] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 6.3] [Reference Citation Analysis]
63 Portugal J, Bataller M, Mansilla S. Cell Death Pathways in Response to Antitumor Therapy. Tumori 2009;95:409-21. [DOI: 10.1177/030089160909500401] [Cited by in Crossref: 35] [Cited by in F6Publishing: 17] [Article Influence: 8.8] [Reference Citation Analysis]
64 Fijołek J, Wiatr E, Rowińska-zakrzewska E, Giedronowicz D, Langfort R, Chabowski M, Orłowski T, Roszkowski K. p53 and HER2/neu Expression in Relation to Chemotherapy Response in Patients with Non-Small Cell Lung Cancer. Int J Biol Markers 2006;21:81-7. [DOI: 10.1177/172460080602100203] [Cited by in Crossref: 18] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
65 Kozomara R, Brankovic-magic M, Jovic N, Stosic S, Magic Z. Prognostic Significance of TP53 Mutations in Oral Squamous Cell Carcinoma with Human Papilloma virus Infection. Int J Biol Markers 2007;22:252-7. [DOI: 10.1177/172460080702200403] [Cited by in Crossref: 5] [Article Influence: 1.3] [Reference Citation Analysis]
66 Carroll BL, Bonica J, Shamseddine AA, Hannun YA, Obeid LM. A role for caspase-2 in sphingosine kinase 1 proteolysis in response to doxorubicin in breast cancer cells - implications for the CHK1-suppressed pathway. FEBS Open Bio 2018;8:27-40. [PMID: 29321954 DOI: 10.1002/2211-5463.12344] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
67 Noda M, Okumura H, Uchikado Y, Omoto I, Sasaki K, Kita Y, Mori S, Owaki T, Arigami T, Uenosono Y, Nakajo A, Kijima Y, Ishigami S, Maemura K, Natsugoe S. Correlation Between Biomarker Candidate Proteins with the Effect of Neoadjuvant Chemoradiation Therapy on Esophageal Squamous Cell Carcinoma. Ann Surg Oncol 2018;25:449-55. [DOI: 10.1245/s10434-017-6271-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
68 Huang CY, Ju DT, Chang CF, Muralidhar Reddy P, Velmurugan BK. A review on the effects of current chemotherapy drugs and natural agents in treating non-small cell lung cancer. Biomedicine (Taipei). 2017;7:23. [PMID: 29130448 DOI: 10.1051/bmdcn/2017070423] [Cited by in Crossref: 150] [Cited by in F6Publishing: 131] [Article Influence: 30.0] [Reference Citation Analysis]
69 Emmanouilidi A, Falasca M. Targeting PDK1 for Chemosensitization of Cancer Cells. Cancers (Basel) 2017;9:E140. [PMID: 29064423 DOI: 10.3390/cancers9100140] [Cited by in Crossref: 36] [Cited by in F6Publishing: 34] [Article Influence: 7.2] [Reference Citation Analysis]
70 Thapa B, Bahadur Kc R, Uludağ H. Novel targets for sensitizing breast cancer cells to TRAIL-induced apoptosis with siRNA delivery: Novel targets for sensitizing breast cancer cells. Int J Cancer 2018;142:597-606. [DOI: 10.1002/ijc.31079] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 3.4] [Reference Citation Analysis]
71 Yuan YG, Gurunathan S. Combination of graphene oxide-silver nanoparticle nanocomposites and cisplatin enhances apoptosis and autophagy in human cervical cancer cells. Int J Nanomedicine 2017;12:6537-58. [PMID: 28919753 DOI: 10.2147/IJN.S125281] [Cited by in Crossref: 44] [Cited by in F6Publishing: 23] [Article Influence: 8.8] [Reference Citation Analysis]
72 Sam MR, Pourpak RS. Regulation of p53 and survivin by prodigiosin compound derived from Serratia marcescens contribute to caspase-3-dependent apoptosis in acute lymphoblastic leukemia cells. Hum Exp Toxicol 2018;37:608-17. [PMID: 28681618 DOI: 10.1177/0960327117718052] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
73 Moloney JN, Cotter TG. ROS signalling in the biology of cancer. Semin Cell Dev Biol. 2018;80:50-64. [PMID: 28587975 DOI: 10.1016/j.semcdb.2017.05.023] [Cited by in Crossref: 450] [Cited by in F6Publishing: 450] [Article Influence: 90.0] [Reference Citation Analysis]
74 K.c. RB, Thapa B, Valencia-serna J, Aliabadi HM, Uludağ H. Nucleic acid combinations: A new frontier for cancer treatment. Journal of Controlled Release 2017;256:153-69. [DOI: 10.1016/j.jconrel.2017.04.029] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 3.2] [Reference Citation Analysis]
75 Taylor NJ, Nikolaishvili-Feinberg N, Midkiff BR, Conway K, Millikan RC, Geradts J. Rational Manual and Automated Scoring Thresholds for the Immunohistochemical Detection of TP53 Missense Mutations in Human Breast Carcinomas. Appl Immunohistochem Mol Morphol 2016;24:398-404. [PMID: 26200835 DOI: 10.1097/PAI.0000000000000207] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
76 Vasudeva V, Tenkanidiyoor YS, Radhakrishna V, Shivappa P, Lakshman SP, Fernandes R, Patali KA. Palliative effects of lutein intervention in gamma-radiation-induced cellular damages in Swiss albino mice. Indian J Pharmacol 2017;49:26-33. [PMID: 28458419 DOI: 10.4103/0253-7613.201013] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
77 Khan MKA, Akhtar S, Arif JM. Structural Insight into the Mechanism of Dibenzo[a,l]pyrene and Benzo[a]pyrene-Mediated Cell Proliferation Using Molecular Docking Simulations. Interdiscip Sci Comput Life Sci 2018;10:653-73. [DOI: 10.1007/s12539-017-0226-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
78 Ji S, Zhu L, Gao Y, Zhang X, Yan Y, Cen J, Li R, Zeng R, Liao L, Hou C, Gao Y, Gao S, Wei G, Hui L. Baf60b-mediated ATM-p53 activation blocks cell identity conversion by sensing chromatin opening. Cell Res 2017;27:642-56. [PMID: 28303890 DOI: 10.1038/cr.2017.36] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
79 Seshacharyulu P, Baine MJ, Souchek JJ, Menning M, Kaur S, Yan Y, Ouellette MM, Jain M, Lin C, Batra SK. Biological determinants of radioresistance and their remediation in pancreatic cancer. Biochim Biophys Acta Rev Cancer 2017;1868:69-92. [PMID: 28249796 DOI: 10.1016/j.bbcan.2017.02.003] [Cited by in Crossref: 27] [Cited by in F6Publishing: 31] [Article Influence: 5.4] [Reference Citation Analysis]
80 Burkhart RA, Ronnekleiv-Kelly SM, Pawlik TM. Personalized therapy in hepatocellular carcinoma: Molecular markers of prognosis and therapeutic response. Surg Oncol. 2017;26:138-145. [PMID: 28577719 DOI: 10.1016/j.suronc.2017.01.009] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 5.6] [Reference Citation Analysis]
81 Friesen WJ, Trotta CR, Tomizawa Y, Zhuo J, Johnson B, Sierra J, Roy B, Weetall M, Hedrick J, Sheedy J, Takasugi J, Moon YC, Babu S, Baiazitov R, Leszyk JD, Davis TW, Colacino JM, Peltz SW, Welch EM. The nucleoside analog clitocine is a potent and efficacious readthrough agent. RNA 2017;23:567-77. [PMID: 28096517 DOI: 10.1261/rna.060236.116] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
82 Ravegnini G, Sammarini G, Nannini M, Pantaleo MA, Biasco G, Hrelia P, Angelini S. Gastrointestinal stromal tumors (GIST): Facing cell death between autophagy and apoptosis. Autophagy 2017;13:452-63. [PMID: 28055310 DOI: 10.1080/15548627.2016.1256522] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 5.4] [Reference Citation Analysis]
83 Akpinar B, Bracht EV, Reijnders D, Safarikova B, Jelinkova I, Grandien A, Vaculova AH, Zhivotovsky B, Olsson M. 5-Fluorouracil-induced RNA stress engages a TRAIL-DISC-dependent apoptosis axis facilitated by p53. Oncotarget 2015;6:43679-97. [PMID: 26544897 DOI: 10.18632/oncotarget.6030] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
84 Chen KS, Kwon WS, Kim J, Heo SJ, Kim HS, Kim HK, Kim SH, Lee WS, Chung HC, Rha SY, Hwang TH. A novel TP53-KPNA3 translocation defines a de novo treatment-resistant clone in osteosarcoma. Cold Spring Harb Mol Case Stud 2016;2:a000992. [PMID: 27626065 DOI: 10.1101/mcs.a000992] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
85 Hamdane N, Herdman C, Mars JC, Stefanovsky V, Tremblay MG, Moss T. Depletion of the cisplatin targeted HMGB-box factor UBF selectively induces p53-independent apoptotic death in transformed cells. Oncotarget 2015;6:27519-36. [PMID: 26317157 DOI: 10.18632/oncotarget.4823] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
86 Hassan CE, Webster TJ. The effect of red-allotrope selenium nanoparticles on head and neck squamous cell viability and growth. Int J Nanomedicine 2016;11:3641-54. [PMID: 27536104 DOI: 10.2147/IJN.S105173] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
87 Robbins P. p53 and Breast Cancer. Int J Surg Pathol 1996;4:93-110. [DOI: 10.1177/106689699600400206] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
88 Xu C, Yu B, Hu H, Nizam MN, Yuan W, Ma J, Xu FJ. PGMA-based gene carriers with lipid molecules. Biomater Sci 2016;4:1233-43. [PMID: 27374783 DOI: 10.1039/c6bm00360e] [Cited by in Crossref: 15] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
89 . Extended Abstracts. Toxicol Pathol 1997;25:674-96. [DOI: 10.1177/019262339702500633] [Reference Citation Analysis]
90 Nguyen NH, Park HJ, Yang SS, Choi KS, Lee JS. Anti-cancer efficacy of nonthermal plasma dissolved in a liquid, liquid plasma in heterogeneous cancer cells. Sci Rep 2016;6:29020. [PMID: 27364630 DOI: 10.1038/srep29020] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 4.5] [Reference Citation Analysis]
91 Pirollo KF, Nemunaitis J, Leung PK, Nunan R, Adams J, Chang EH. Safety and Efficacy in Advanced Solid Tumors of a Targeted Nanocomplex Carrying the p53 Gene Used in Combination with Docetaxel: A Phase 1b Study. Mol Ther 2016;24:1697-706. [PMID: 27357628 DOI: 10.1038/mt.2016.135] [Cited by in Crossref: 51] [Cited by in F6Publishing: 45] [Article Influence: 8.5] [Reference Citation Analysis]
92 Perz E, Kuhn JG. Review : p53 in the pathogenesis, diagnosis, and treatment of cancer. J Oncol Pharm Pract 1998;4:75-102. [DOI: 10.1177/107815529800400201] [Reference Citation Analysis]
93 Masterson L, Winder DM, Ball SL, Vaughan K, Lehmann M, Scholtz LU, Sterling JC, Sudhoff HH, Goon PK. Molecular analyses of unselected head and neck cancer cases demonstrates that human papillomavirus transcriptional activity is positively associated with survival and prognosis. BMC Cancer 2016;16:367. [PMID: 27296171 DOI: 10.1186/s12885-016-2398-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
94 Yegin EG, Oymaci E, Karatay E, Coker A. Progress in surgical and nonsurgical approaches for hepatocellular carcinoma treatment. Hepatobiliary & Pancreatic Diseases International 2016;15:234-56. [DOI: 10.1016/s1499-3872(16)60097-8] [Cited by in Crossref: 28] [Cited by in F6Publishing: 15] [Article Influence: 4.7] [Reference Citation Analysis]
95 Tachtsidis A, McInnes LM, Jacobsen N, Thompson EW, Saunders CM. Minimal residual disease in breast cancer: an overview of circulating and disseminated tumour cells. Clin Exp Metastasis 2016;33:521-50. [PMID: 27189371 DOI: 10.1007/s10585-016-9796-8] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 2.5] [Reference Citation Analysis]
96 Naveen B, Mudiraj A, Khamushavalli G, Babu PP, Nagarajan R. Concise total synthesis of water soluble metatacarboline A, C, D, E and F and its anticancer activity. Eur J Med Chem 2016;113:167-78. [PMID: 26927685 DOI: 10.1016/j.ejmech.2016.02.033] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
97 Srdic-rajic T, Tisma-miletic N, Cavic M, Kanjer K, Savikin K, Galun D, Konic-ristic A, Zoranovic T. Sensitization of K562 Leukemia Cells to Doxorubicin by the Viscum album Extract: VISCUM ALBUM ENHANCES DOXORUBICIN ANTITUMOR EFFECTS. Phytother Res 2016;30:485-95. [DOI: 10.1002/ptr.5554] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
98 Koshino A, Goto-Koshino Y, Setoguchi A, Ohno K, Tsujimoto H. Mutation of p53 Gene and Its Correlation with the Clinical Outcome in Dogs with Lymphoma. J Vet Intern Med 2016;30:223-9. [PMID: 26678182 DOI: 10.1111/jvim.13807] [Cited by in Crossref: 19] [Cited by in F6Publishing: 12] [Article Influence: 2.7] [Reference Citation Analysis]
99 Liu XC, Gao JM, Liu S, Liu L, Wang JR, Qu XJ, Cai B, Wang SL. Targeting apoptosis is the major battle field for killing cancers. World J Transl Med 2015; 4(3): 69-77 [DOI: 10.5528/wjtm.v4.i3.69] [Reference Citation Analysis]
100 Garrastazu Pereira G, Lawson AJ, Buttini F, Sonvico F. Loco-regional administration of nanomedicines for the treatment of lung cancer. Drug Deliv 2016;23:2881-96. [PMID: 26585837 DOI: 10.3109/10717544.2015.1114047] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
101 Frères P, Josse C, Bovy N, Boukerroucha M, Struman I, Bours V, Jerusalem G. Neoadjuvant Chemotherapy in Breast Cancer Patients Induces miR-34a and miR-122 Expression. J Cell Physiol 2015;230:473-81. [PMID: 25078559 DOI: 10.1002/jcp.24730] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 3.6] [Reference Citation Analysis]
102 Sahin IH, Iacobuzio-Donahue CA, O’Reilly EM. Molecular signature of pancreatic adenocarcinoma: an insight from genotype to phenotype and challenges for targeted therapy. Expert Opin Ther Targets. 2016;20:341-359. [PMID: 26439702 DOI: 10.1517/14728222.2016.1094057] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 3.1] [Reference Citation Analysis]
103 Murray V, Taylor CB, Gero AM, Lutze-Mann LH. The influence of p53 status on the cytotoxicity of fluorinated pyrimidine L-nucleosides. Chem Biol Interact 2015;240:102-9. [PMID: 26296760 DOI: 10.1016/j.cbi.2015.08.010] [Reference Citation Analysis]
104 Liu XL, Wang H, Zhang L, Wang YL, Wang J, Wang P, He X, He YJ. Anticancer effects of crude extract from Melia toosendan Sieb. et Zucc on hepatocellular carcinoma in vitro and in vivo. Chin J Integr Med 2016;22:362-9. [PMID: 26383159 DOI: 10.1007/s11655-015-2084-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
105 Zack TI, Schumacher SE, Carter SL, Cherniack AD, Saksena G, Tabak B, Lawrence MS, Zhsng CZ, Wala J, Mermel CH. Pan-cancer patterns of somatic copy number alteration. Nat Genet. 2013;45:1134-1140. [PMID: 24071852 DOI: 10.1038/ng.2760] [Cited by in Crossref: 1141] [Cited by in F6Publishing: 958] [Article Influence: 163.0] [Reference Citation Analysis]
106 Vymetalkova V, Soucek P, Kunicka T, Jiraskova K, Brynychova V, Pardini B, Novosadova V, Polivkova Z, Kubackova K, Kozevnikovova R, Ambrus M, Vodickova L, Naccarati A, Vodicka P. Genotype and Haplotype Analyses of TP53 Gene in Breast Cancer Patients: Association with Risk and Clinical Outcomes. PLoS One 2015;10:e0134463. [PMID: 26226484 DOI: 10.1371/journal.pone.0134463] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
107 Kampan NC, Madondo MT, McNally OM, Quinn M, Plebanski M. Paclitaxel and Its Evolving Role in the Management of Ovarian Cancer. Biomed Res Int 2015;2015:413076. [PMID: 26137480 DOI: 10.1155/2015/413076] [Reference Citation Analysis]
108 Kampan NC, Madondo MT, McNally OM, Quinn M, Plebanski M. Paclitaxel and Its Evolving Role in the Management of Ovarian Cancer. Biomed Res Int 2015;2015:413076. [PMID: 26137480 DOI: 10.1155/2015/413076] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
109 Kampan NC, Madondo MT, McNally OM, Quinn M, Plebanski M. Paclitaxel and Its Evolving Role in the Management of Ovarian Cancer. Biomed Res Int 2015;2015:413076. [PMID: 26137480 DOI: 10.1155/2015/413076] [Cited by in Crossref: 103] [Cited by in F6Publishing: 97] [Article Influence: 14.7] [Reference Citation Analysis]
110 Park S, Park W, Na K. Tumor Intracellular-Environment Responsive Materials Shielded Nano-Complexes for Highly Efficient Light-Triggered Gene Delivery without Cargo Gene Damage. Adv Funct Mater 2015;25:3472-82. [DOI: 10.1002/adfm.201500737] [Cited by in Crossref: 52] [Cited by in F6Publishing: 45] [Article Influence: 7.4] [Reference Citation Analysis]
111 Liu X, He Y, Li F, Huang Q, Kato TA, Hall RP, Li CY. Caspase-3 promotes genetic instability and carcinogenesis. Mol Cell 2015;58:284-96. [PMID: 25866249 DOI: 10.1016/j.molcel.2015.03.003] [Cited by in Crossref: 121] [Cited by in F6Publishing: 111] [Article Influence: 17.3] [Reference Citation Analysis]
112 Won KJ, Lee KP, Yu S, Lee D, Lee DY, Lee HM, Kim J, Jung SH, Baek S, Kim B. Ketoconazole induces apoptosis in rat cardiomyocytes through reactive oxygen species-mediated parkin overexpression. Arch Toxicol 2015;89:1871-80. [PMID: 25787151 DOI: 10.1007/s00204-015-1502-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
113 Hu T, Li C, Zhang Y, Wang L, Peng L, Cheng H, Wang W, Chu Y, Xu M, Cheng T, Yuan W. Phosphoinositide-dependent kinase 1 regulates leukemia stem cell maintenance in MLL-AF9-induced murine acute myeloid leukemia. Biochem Biophys Res Commun 2015;459:692-8. [PMID: 25769952 DOI: 10.1016/j.bbrc.2015.03.007] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
114 Guan X, Li Y, Jiao Z, Lin L, Chen J, Guo Z, Tian H, Chen X. Codelivery of Antitumor Drug and Gene by a pH-Sensitive Charge-Conversion System. ACS Appl Mater Interfaces 2015;7:3207-15. [DOI: 10.1021/am5078123] [Cited by in Crossref: 53] [Cited by in F6Publishing: 54] [Article Influence: 7.6] [Reference Citation Analysis]
115 Chen S, Zhang D. Friend or foe: Endoplasmic reticulum protein 29 (ERp29) in epithelial cancer. FEBS Open Bio 2015;5:91-8. [PMID: 25709888 DOI: 10.1016/j.fob.2015.01.004] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
116 Speidel D. The role of DNA damage responses in p53 biology. Arch Toxicol 2015;89:501-17. [PMID: 25618545 DOI: 10.1007/s00204-015-1459-z] [Cited by in Crossref: 94] [Cited by in F6Publishing: 87] [Article Influence: 13.4] [Reference Citation Analysis]
117 Lien JC, Huang CC, Lu TJ, Tseng CH, Sung PJ, Lee HZ, Bao BY, Kuo YH, Lu TL. Naphthoquinone derivative PPE8 induces endoplasmic reticulum stress in p53 null H1299 cells. Oxid Med Cell Longev 2015;2015:453679. [PMID: 25685256 DOI: 10.1155/2015/453679] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
118 Thaler S, Thiede G, Hengstler JG, Schad A, Schmidt M, Sleeman JP. The proteasome inhibitor Bortezomib (Velcade) as potential inhibitor of estrogen receptor-positive breast cancer: ER+ breast cancer therapy. Int J Cancer 2015;137:686-97. [DOI: 10.1002/ijc.29404] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 3.6] [Reference Citation Analysis]
119 Ping Y, Guo J, Ejima H, Chen X, Richardson JJ, Sun H, Caruso F. pH-Responsive Capsules Engineered from Metal-Phenolic Networks for Anticancer Drug Delivery. Small 2015;11:2032-6. [DOI: 10.1002/smll.201403343] [Cited by in Crossref: 142] [Cited by in F6Publishing: 127] [Article Influence: 20.3] [Reference Citation Analysis]
120 Słotwiński R, Dąbrowska A, Lech G, Słodkowski M, Słotwińska SM. Gene expression disorders of innate antibacterial signaling pathway in pancreatic cancer patients: implications for leukocyte dysfunction and tumor progression. Cent Eur J Immunol 2014;39:498-507. [PMID: 26155170 DOI: 10.5114/ceji.2014.47736] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
121 Loskutova KS, Kirillina MP, Lushnikova EL, Nepomnyashchikh LM. Immunohistochemical study of apoptotic marker p53 as a prognostic factor in breast cancer. Bull Exp Biol Med 2014;158:84-7. [PMID: 25403404 DOI: 10.1007/s10517-014-2698-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
122 Voorneveld PW, Kodach LL, Jacobs RJ, van Noesel CJ, Peppelenbosch MP, Korkmaz KS, Molendijk I, Dekker E, Morreau H, van Pelt GW, Tollenaar RA, Mesker W, Hawinkels LJ, Paauwe M, Verspaget HW, Geraets DT, Hommes DW, Offerhaus GJ, van den Brink GR, Ten Dijke P, Hardwick JC. The BMP pathway either enhances or inhibits the Wnt pathway depending on the SMAD4 and p53 status in CRC. Br J Cancer 2015;112:122-30. [PMID: 25393365 DOI: 10.1038/bjc.2014.560] [Cited by in Crossref: 42] [Cited by in F6Publishing: 38] [Article Influence: 5.3] [Reference Citation Analysis]
123 Schwarzenbach H. The potential of circulating nucleic acids as components of companion diagnostics for predicting and monitoring chemotherapy response. Expert Rev Mol Diagn 2015;15:267-75. [PMID: 25382372 DOI: 10.1586/14737159.2015.980817] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
124 Kim MH, Kim H. Oncogenes and tumor suppressors regulate glutamine metabolism in cancer cells. J Cancer Prev 2013;18:221-6. [PMID: 25337549 DOI: 10.15430/jcp.2013.18.3.221] [Cited by in Crossref: 28] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
125 Gañán-Gómez I, Estañ-Omaña MC, Sancho P, Aller P, Boyano-Adánez MC. Mechanisms of resistance to apoptosis in the human acute promyelocytic leukemia cell line NB4. Ann Hematol 2015;94:379-92. [PMID: 25322811 DOI: 10.1007/s00277-014-2237-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
126 Yu H, Yue X, Zhao Y, Li X, Wu L, Zhang C, Liu Z, Lin K, Xu-Monette ZY, Young KH, Liu J, Shen Z, Feng Z, Hu W. LIF negatively regulates tumour-suppressor p53 through Stat3/ID1/MDM2 in colorectal cancers. Nat Commun 2014;5:5218. [PMID: 25323535 DOI: 10.1038/ncomms6218] [Cited by in Crossref: 77] [Cited by in F6Publishing: 86] [Article Influence: 9.6] [Reference Citation Analysis]
127 Gibbons DL, Byers LA, Kurie JM. Smoking, p53 mutation, and lung cancer. Mol Cancer Res 2014;12:3-13. [PMID: 24442106 DOI: 10.1158/1541-7786.MCR-13-0539] [Cited by in Crossref: 125] [Cited by in F6Publishing: 82] [Article Influence: 15.6] [Reference Citation Analysis]
128 Mitha AT, Rekha MR. Multifunctional polymeric nanoplexes for anticancer co-delivery of p53 and mitoxantrone. J Mater Chem B 2014;2:8005-16. [DOI: 10.1039/c4tb01298d] [Cited by in Crossref: 10] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
129 Zaha DC. Significance of immunohistochemistry in breast cancer. World J Clin Oncol. 2014;5:382-392. [PMID: 25114853 DOI: 10.5306/wjco.v5.i3.382.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
130 Zaha DC. Significance of immunohistochemistry in breast cancer. World J Clin Oncol 2014; 5(3): 382-392 [PMID: 25114853 DOI: 10.5306/wjco.v5.i3.382] [Cited by in CrossRef: 108] [Cited by in F6Publishing: 90] [Article Influence: 13.5] [Reference Citation Analysis]
131 Cao W, Zhang JL, Feng DY, Liu XW, Li Y, Wang LF, Yao LB, Zhang H, Zhang J. The effect of adenovirus-conjugated NDRG2 on p53-mediated apoptosis of hepatocarcinoma cells through attenuation of nucleotide excision repair capacity. Biomaterials 2014;35:993-1003. [PMID: 24383128 DOI: 10.1016/j.biomaterials.2013.09.096] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 2.0] [Reference Citation Analysis]
132 Shiloach T, Berens C, Danke C, Waiskopf O, Perlman R, Ben-Yehuda D. tLivin displays flexibility by promoting alternative cell death mechanisms. PLoS One 2014;9:e101075. [PMID: 24960127 DOI: 10.1371/journal.pone.0101075] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
133 Lemke J, von Karstedt S, Zinngrebe J, Walczak H. Getting TRAIL back on track for cancer therapy. Cell Death Differ 2014;21:1350-64. [PMID: 24948009 DOI: 10.1038/cdd.2014.81] [Cited by in Crossref: 297] [Cited by in F6Publishing: 282] [Article Influence: 37.1] [Reference Citation Analysis]
134 Milczarek M, Filip-Psurska B, Swiętnicki W, Kutner A, Wietrzyk J. Vitamin D analogs combined with 5-fluorouracil in human HT-29 colon cancer treatment. Oncol Rep 2014;32:491-504. [PMID: 24919507 DOI: 10.3892/or.2014.3247] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 4.4] [Reference Citation Analysis]
135 Donzelli S, Mori F, Biagioni F, Bellissimo T, Pulito C, Muti P, Strano S, Blandino G. MicroRNAs: short non-coding players in cancer chemoresistance. Mol Cell Ther 2014;2:16. [PMID: 26056584 DOI: 10.1186/2052-8426-2-16] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 2.9] [Reference Citation Analysis]
136 Allen MA, Andrysik Z, Dengler VL, Mellert HS, Guarnieri A, Freeman JA, Sullivan KD, Galbraith MD, Luo X, Kraus WL, Dowell RD, Espinosa JM. Global analysis of p53-regulated transcription identifies its direct targets and unexpected regulatory mechanisms. Elife 2014;3:e02200. [PMID: 24867637 DOI: 10.7554/eLife.02200] [Cited by in Crossref: 158] [Cited by in F6Publishing: 130] [Article Influence: 19.8] [Reference Citation Analysis]
137 Boss MK, Bristow R, Dewhirst MW. Linking the history of radiation biology to the hallmarks of cancer. Radiat Res 2014;181:561-77. [PMID: 24811865 DOI: 10.1667/RR13675.1] [Cited by in Crossref: 29] [Cited by in F6Publishing: 9] [Article Influence: 3.6] [Reference Citation Analysis]
138 Xu HY, Xu WL, Wang LQ, Chen MB, Shen HL. Relationship between p53 status and response to chemotherapy in patients with gastric cancer: a meta-analysis. PLoS One. 2014;9:e95371. [PMID: 24740294 DOI: 10.1371/journal.pone.0095371] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
139 Choi W, Porten S, Kim S, Willis D, Plimack ER, Hoffman-Censits J, Roth B, Cheng T, Tran M, Lee IL, Melquist J, Bondaruk J, Majewski T, Zhang S, Pretzsch S, Baggerly K, Siefker-Radtke A, Czerniak B, Dinney CP, McConkey DJ. Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell 2014;25:152-65. [PMID: 24525232 DOI: 10.1016/j.ccr.2014.01.009] [Cited by in Crossref: 895] [Cited by in F6Publishing: 824] [Article Influence: 111.9] [Reference Citation Analysis]
140 Rao CV, Patlolla JM, Qian L, Zhang Y, Brewer M, Mohammed A, Desai D, Amin S, Lightfoot S, Kopelovich L. Chemopreventive effects of the p53-modulating agents CP-31398 and Prima-1 in tobacco carcinogen-induced lung tumorigenesis in A/J mice. Neoplasia 2013;15:1018-27. [PMID: 24027427 DOI: 10.1593/neo.131256] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
141 Yang P, Du CW, Kwan M, Liang SX, Zhang GJ. The impact of p53 in predicting clinical outcome of breast cancer patients with visceral metastasis. Sci Rep 2013;3:2246. [PMID: 23873310 DOI: 10.1038/srep02246] [Cited by in Crossref: 51] [Cited by in F6Publishing: 48] [Article Influence: 6.4] [Reference Citation Analysis]
142 Gorlick R, Banerjee D. Fluoropyrimidine resistance in colon cancer. Expert Review of Anticancer Therapy 2014;2:409-16. [DOI: 10.1586/14737140.2.4.409] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
143 Todd R, Lunec J. Molecular pathology and potential therapeutic targets in soft-tissue sarcoma. Expert Review of Anticancer Therapy 2014;8:939-48. [DOI: 10.1586/14737140.8.6.939] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
144 Rosser CJ, Benedict WF, Dinney CP. Gene therapy for superficial bladder cancer. Expert Review of Anticancer Therapy 2014;1:531-40. [DOI: 10.1586/14737140.1.4.531] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
145 Lemke J, von Karstedt S, Abd El Hay M, Conti A, Arce F, Montinaro A, Papenfuss K, El-Bahrawy MA, Walczak H. Selective CDK9 inhibition overcomes TRAIL resistance by concomitant suppression of cFlip and Mcl-1. Cell Death Differ 2014;21:491-502. [PMID: 24362439 DOI: 10.1038/cdd.2013.179] [Cited by in Crossref: 75] [Cited by in F6Publishing: 77] [Article Influence: 8.3] [Reference Citation Analysis]
146 Kelleher FC, Rao A, Maguire A. Circadian molecular clocks and cancer. Cancer Lett 2014;342:9-18. [PMID: 24099911 DOI: 10.1016/j.canlet.2013.09.040] [Cited by in Crossref: 146] [Cited by in F6Publishing: 126] [Article Influence: 16.2] [Reference Citation Analysis]
147 Simone CB 2nd, John-Aryankalayil M, Palayoor ST, Makinde AY, Cerna D, Falduto MT, Magnuson SR, Coleman CN. mRNA Expression Profiles for Prostate Cancer following Fractionated Irradiation Are Influenced by p53 Status. Transl Oncol 2013;6:573-85. [PMID: 24151538 DOI: 10.1593/tlo.13241] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
148 Jorfi S, Inal JM. The role of microvesicles in cancer progression and drug resistance. Biochem Soc Trans 2013;41:293-8. [PMID: 23356300 DOI: 10.1042/BST20120273] [Cited by in Crossref: 24] [Cited by in F6Publishing: 14] [Article Influence: 2.7] [Reference Citation Analysis]
149 Montero J, Dutta C, van Bodegom D, Weinstock D, Letai A. p53 regulates a non-apoptotic death induced by ROS. Cell Death Differ 2013;20:1465-74. [PMID: 23703322 DOI: 10.1038/cdd.2013.52] [Cited by in Crossref: 77] [Cited by in F6Publishing: 78] [Article Influence: 8.6] [Reference Citation Analysis]
150 Timofeev O, Schlereth K, Wanzel M, Braun A, Nieswandt B, Pagenstecher A, Rosenwald A, Elsässer HP, Stiewe T. p53 DNA binding cooperativity is essential for apoptosis and tumor suppression in vivo. Cell Rep 2013;3:1512-25. [PMID: 23665223 DOI: 10.1016/j.celrep.2013.04.008] [Cited by in Crossref: 56] [Cited by in F6Publishing: 51] [Article Influence: 6.2] [Reference Citation Analysis]
151 Wang EY, Gang H, Aviv Y, Dhingra R, Margulets V, Kirshenbaum LA. p53 mediates autophagy and cell death by a mechanism contingent on Bnip3. Hypertension 2013;62:70-7. [PMID: 23648705 DOI: 10.1161/HYPERTENSIONAHA.113.01028] [Cited by in Crossref: 54] [Cited by in F6Publishing: 36] [Article Influence: 6.0] [Reference Citation Analysis]
152 Okumura H, Uchikado Y, Setoyama T, Matsumoto M, Owaki T, Ishigami S, Natsugoe S. Biomarkers for predicting the response of esophageal squamous cell carcinoma to neoadjuvant chemoradiation therapy. Surg Today. 2014;44:421-428. [PMID: 23605218 DOI: 10.1007/s00595-013-0580-y] [Cited by in Crossref: 45] [Cited by in F6Publishing: 44] [Article Influence: 5.0] [Reference Citation Analysis]
153 Lee JY, Kim HJ, Yoon NA, Lee WH, Min YJ, Ko BK, Lee BJ, Lee A, Cha HJ, Cho WJ, Park JW. Tumor suppressor p53 plays a key role in induction of both tristetraprolin and let-7 in human cancer cells. Nucleic Acids Res. 2013;41:5614-5625. [PMID: 23595149 DOI: 10.1093/nar/gkt222] [Cited by in Crossref: 38] [Cited by in F6Publishing: 37] [Article Influence: 4.2] [Reference Citation Analysis]
154 Xu Q, Leong J, Chua QY, Chi YT, Chow PK, Pack DW, Wang CH. Combined modality doxorubicin-based chemotherapy and chitosan-mediated p53 gene therapy using double-walled microspheres for treatment of human hepatocellular carcinoma. Biomaterials 2013;34:5149-62. [PMID: 23578555 DOI: 10.1016/j.biomaterials.2013.03.044] [Cited by in Crossref: 62] [Cited by in F6Publishing: 55] [Article Influence: 6.9] [Reference Citation Analysis]
155 Gottschalk B, Klein A. Restoration of wild-type p53 in drug-resistant mouse breast cancer cells leads to differential gene expression, but is not sufficient to overcome the malignant phenotype. Mol Cell Biochem 2013;379:213-27. [DOI: 10.1007/s11010-013-1643-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
156 Alphonse G, Maalouf M, Battiston-Montagne P, Ardail D, Beuve M, Rousson R, Taucher-Scholz G, Fournier C, Rodriguez-Lafrasse C. p53-independent early and late apoptosis is mediated by ceramide after exposure of tumor cells to photon or carbon ion irradiation. BMC Cancer 2013;13:151. [PMID: 23530619 DOI: 10.1186/1471-2407-13-151] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 2.4] [Reference Citation Analysis]
157 Zhang SS, Huang QY, Yang H, Xie X, Luo KJ, Wen J, Cai XL, Yang F, Hu Y, Fu JH. Correlation of p53 status with the response to chemotherapy-based treatment in esophageal cancer: a meta-analysis. Ann Surg Oncol. 2013;20:2419-2427. [PMID: 23515910 DOI: 10.1245/s10434-012-2859-4] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 2.3] [Reference Citation Analysis]
158 Gogolin S, Ehemann V, Becker G, Brueckner LM, Dreidax D, Bannert S, Nolte I, Savelyeva L, Bell E, Westermann F. CDK4 inhibition restores G(1)-S arrest in MYCN-amplified neuroblastoma cells in the context of doxorubicin-induced DNA damage. Cell Cycle 2013;12:1091-104. [PMID: 23462184 DOI: 10.4161/cc.24091] [Cited by in Crossref: 38] [Cited by in F6Publishing: 32] [Article Influence: 4.2] [Reference Citation Analysis]
159 Loriaux PM, Hoffmann A. A protein turnover signaling motif controls the stimulus-sensitivity of stress response pathways. PLoS Comput Biol 2013;9:e1002932. [PMID: 23468615 DOI: 10.1371/journal.pcbi.1002932] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
160 Bernardi A, Frozza RL, Hoppe JB, Salbego C, Pohlmann AR, Battastini AM, Guterres SS. The antiproliferative effect of indomethacin-loaded lipid-core nanocapsules in glioma cells is mediated by cell cycle regulation, differentiation, and the inhibition of survival pathways. Int J Nanomedicine 2013;8:711-28. [PMID: 23440594 DOI: 10.2147/IJN.S40284] [Cited by in Crossref: 20] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
161 Vaughan CA, Singh S, Windle B, Yeudall WA, Frum R, Grossman SR, Deb SP, Deb S. Gain-of-Function Activity of Mutant p53 in Lung Cancer through Up-Regulation of Receptor Protein Tyrosine Kinase Axl. Genes Cancer. 2012;3:491-502. [PMID: 23264849 DOI: 10.1177/1947601912462719] [Cited by in Crossref: 41] [Cited by in F6Publishing: 43] [Article Influence: 4.1] [Reference Citation Analysis]
162 Shamanna RA, Hoque M, Pe'ery T, Mathews MB. Induction of p53, p21 and apoptosis by silencing the NF90/NF45 complex in human papilloma virus-transformed cervical carcinoma cells. Oncogene 2013;32:5176-85. [PMID: 23208500 DOI: 10.1038/onc.2012.533] [Cited by in Crossref: 43] [Cited by in F6Publishing: 45] [Article Influence: 4.3] [Reference Citation Analysis]
163 Soengas MS. Mitophagy or how to control the Jekyll and Hyde embedded in mitochondrial metabolism: implications for melanoma progression and drug resistance. Pigment Cell Melanoma Res 2012;25:721-31. [DOI: 10.1111/pcmr.12021] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
164 Dioufa N, Chatzistamou I, Farmaki E, Papavassiliou AG, Kiaris H. p53 antagonizes the unfolded protein response and inhibits ground glass hepatocyte development during endoplasmic reticulum stress. Exp Biol Med (Maywood) 2012;237:1173-80. [DOI: 10.1258/ebm.2012.012140] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.0] [Reference Citation Analysis]
165 Kim J, Lee S, Chang B, Jin D, Jung S, Park M, Han Y, Yang Y, Il Kim K, Lim J, Kang Y, Lee M. Enhanced antitumor activity of vitamin C via p53 in Cancer cells. Free Radical Biology and Medicine 2012;53:1607-15. [DOI: 10.1016/j.freeradbiomed.2012.07.079] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 2.9] [Reference Citation Analysis]
166 Sereno M, De Castro J, Cejas P, García-Cabezas MA, Belda C, Casado E, Feliu J, Gómez C, López M, Barón MG. Expression profile as predictor of relapse after adjuvant treatment in gastric cancer. J Gastrointest Cancer. 2012;43:181-189. [PMID: 21360269 DOI: 10.1007/s12029-011-9267-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
167 Jackson JG, Pant V, Li Q, Chang LL, Quintás-Cardama A, Garza D, Tavana O, Yang P, Manshouri T, Li Y, El-Naggar AK, Lozano G. p53-mediated senescence impairs the apoptotic response to chemotherapy and clinical outcome in breast cancer. Cancer Cell 2012;21:793-806. [PMID: 22698404 DOI: 10.1016/j.ccr.2012.04.027] [Cited by in Crossref: 203] [Cited by in F6Publishing: 182] [Article Influence: 20.3] [Reference Citation Analysis]
168 Svyatchenko VA, Tarasova MV, Netesov SV, Chumakov PM. Oncolytic adenoviruses in anticancer therapy: Current status and prospects. Mol Biol 2012;46:496-507. [DOI: 10.1134/s0026893312040103] [Cited by in Crossref: 7] [Article Influence: 0.7] [Reference Citation Analysis]
169 Walerych D, Napoli M, Collavin L, Del Sal G. The rebel angel: mutant p53 as the driving oncogene in breast cancer. Carcinogenesis 2012;33:2007-17. [PMID: 22822097 DOI: 10.1093/carcin/bgs232] [Cited by in Crossref: 171] [Cited by in F6Publishing: 161] [Article Influence: 17.1] [Reference Citation Analysis]
170 Chen MB, Zhu YQ, Xu JY, Wang LQ, Liu CY, Ji ZY, Lu PH. Value of TP53 status for predicting response to neoadjuvant chemotherapy in breast cancer: a meta-analysis. PLoS One 2012;7:e39655. [PMID: 22768103 DOI: 10.1371/journal.pone.0039655] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 2.0] [Reference Citation Analysis]
171 Kast K, Krause M, Schuler M, Friedrich K, Thamm B, Bier A, Distler W, Krüger S. Late onset Li-Fraumeni Syndrome with bilateral breast cancer and other malignancies: case report and review of the literature. BMC Cancer 2012;12:217. [PMID: 22672556 DOI: 10.1186/1471-2407-12-217] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
172 Zanotto-filho A, Braganhol E, Edelweiss MI, Behr GA, Zanin R, Schröder R, Simões-pires A, Battastini AMO, Moreira JCF. The curry spice curcumin selectively inhibits cancer cells growth in vitro and in preclinical model of glioblastoma. The Journal of Nutritional Biochemistry 2012;23:591-601. [DOI: 10.1016/j.jnutbio.2011.02.015] [Cited by in Crossref: 78] [Cited by in F6Publishing: 79] [Article Influence: 7.8] [Reference Citation Analysis]
173 Rejeeth C, Salem A. Novel luminescent silica nanoparticles (LSN): p53 gene delivery system in breast cancer in vitro and in vivo. J Pharm Pharmacol 2016;68:305-15. [PMID: 27085860 DOI: 10.1111/j.2042-7158.2012.01547.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
174 Chakrabarti A, Gupta K, Sharma JP, Yang J, Agarwal A, Glick A, Zhang Y, Agarwal M, Agarwal MK, Wald DN. ATP depletion triggers acute myeloid leukemia differentiation through an ATR/Chk1 protein-dependent and p53 protein-independent pathway. J Biol Chem 2012;287:23635-43. [PMID: 22621920 DOI: 10.1074/jbc.M111.312801] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
175 Biesaga B, Niemiec J, Ziobro M. Microvessel density and status of p53 protein as potential prognostic factors for adjuvant anthracycline chemotherapy in retrospective analysis of early breast cancer patients group. Pathol Oncol Res 2012;18:949-60. [PMID: 22549273 DOI: 10.1007/s12253-012-9525-9] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
176 Zhou X, Zhang GY, Wang J, Lu SL, Cao J, Sun LZ. A novel bridge between oxidative stress and immunity: the interaction between hydrogen peroxide and human leukocyte antigen G in placental trophoblasts during preeclampsia. Am J Obstet Gynecol 2012;206:447.e7-16. [PMID: 22542123 DOI: 10.1016/j.ajog.2012.03.013] [Cited by in Crossref: 24] [Cited by in F6Publishing: 29] [Article Influence: 2.4] [Reference Citation Analysis]
177 Singhal A, Jayaraman M, Dhanasekaran DN, Kohli V. Molecular and serum markers in hepatocellular carcinoma: Predictive tools for prognosis and recurrence. Critical Reviews in Oncology/Hematology 2012;82:116-40. [DOI: 10.1016/j.critrevonc.2011.05.005] [Cited by in Crossref: 51] [Cited by in F6Publishing: 44] [Article Influence: 5.1] [Reference Citation Analysis]
178 Galmarini D, Galmarini CM, Galmarini FC. Cancer chemotherapy: a critical analysis of its 60 years of history. Crit Rev Oncol Hematol 2012;84:181-99. [PMID: 22542531 DOI: 10.1016/j.critrevonc.2012.03.002] [Cited by in Crossref: 46] [Cited by in F6Publishing: 44] [Article Influence: 4.6] [Reference Citation Analysis]
179 Xie Q, Liang BL, Wu YH, Zhang J, Chen MW, Liu HY, Gu XF, Xu J. Synergistic anticancer effect of rAd/P53 combined with 5-fluorouracil or iodized oil in the early therapeutic response of human colon cancer in vivo. Gene. 2012;499:303-308. [PMID: 22441128 DOI: 10.1016/j.gene.2012.02.007] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
180 Weige CC, Allred KF, Armstrong CM, Allred CD. P53 mediates estradiol induced activation of apoptosis and DNA repair in non-malignant colonocytes. The Journal of Steroid Biochemistry and Molecular Biology 2012;128:113-20. [DOI: 10.1016/j.jsbmb.2011.10.010] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
181 Giovannetti E, Erozenci A, Smit J, Danesi R, Peters GJ. Molecular mechanisms underlying the role of microRNAs (miRNAs) in anticancer drug resistance and implications for clinical practice. Critical Reviews in Oncology/Hematology 2012;81:103-22. [DOI: 10.1016/j.critrevonc.2011.03.010] [Cited by in Crossref: 93] [Cited by in F6Publishing: 90] [Article Influence: 9.3] [Reference Citation Analysis]
182 Reinhardt HC, Schumacher B. The p53 network: cellular and systemic DNA damage responses in aging and cancer. Trends Genet. 2012;28:128-136. [PMID: 22265392 DOI: 10.1016/j.tig.2011.12.002] [Cited by in Crossref: 301] [Cited by in F6Publishing: 279] [Article Influence: 30.1] [Reference Citation Analysis]
183 Safa M, Kazemi A, Zaker F, Razmkhah F. Cyclic AMP-induced p53 destabilization is independent of EPAC in pre-B acute lymphoblastic leukemia cells in vitro. J Recept Signal Transduct Res 2011;31:256-63. [PMID: 21619452 DOI: 10.3109/10799893.2011.578140] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
184 Ochiai H, Ohishi T, Osumi K, Tokuyama J, Urakami H, Seki S, Shimada A, Matsui A, Isobe Y, Murata Y. Reevaluation of serum p53 antibody as a tumor marker in colorectal cancer patients. Surg Today. 2012;42:164-168. [PMID: 22075664 DOI: 10.1007/s00595-011-0044-1] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
185 Jiang D, Brady CA, Johnson TM, Lee EY, Park EJ, Scott MP, Attardi LD. Full p53 transcriptional activation potential is dispensable for tumor suppression in diverse lineages. Proc Natl Acad Sci U S A 2011;108:17123-8. [PMID: 21969549 DOI: 10.1073/pnas.1111245108] [Cited by in Crossref: 57] [Cited by in F6Publishing: 55] [Article Influence: 5.2] [Reference Citation Analysis]
186 Horbay R, Stoika R. Giant cell formation: the way to cell death or cell survival? Open Life Sciences 2011;6:675-84. [DOI: 10.2478/s11535-011-0058-0] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
187 Qi X, Chang Z, Song J, Gao G, Shen Z. Adenovirus-mediated p53 gene therapy reverses resistance of breast cancer cells to adriamycin. Anticancer Drugs. 2011;22:556-562. [PMID: 21637162 DOI: 10.1097/cad.0b013e328345b4e7] [Cited by in Crossref: 15] [Cited by in F6Publishing: 4] [Article Influence: 1.4] [Reference Citation Analysis]
188 Gessi M, von Bueren AO, Rutkowski S, Pietsch T. p53 expression predicts dismal outcome for medulloblastoma patients with metastatic disease. J Neurooncol 2012;106:135-41. [PMID: 21796446 DOI: 10.1007/s11060-011-0648-8] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 1.9] [Reference Citation Analysis]
189 Wang Z, Sun Y. Targeting p53 for Novel Anticancer Therapy. Transl Oncol 2010;3:1-12. [PMID: 20165689 DOI: 10.1593/tlo.09250] [Cited by in Crossref: 160] [Cited by in F6Publishing: 142] [Article Influence: 14.5] [Reference Citation Analysis]
190 Jong R, Davis AM, Mendes MG, Wunder JS, Bell RS, Kandel R. Proliferative activity (ki-67 expression) and outcome in high grade osteosarcoma: a study of 27 cases. Sarcoma 2000;4:47-55. [PMID: 18521434 DOI: 10.1155/S1357714X00000086] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
191 Sun J, McKallip RJ. Plumbagin treatment leads to apoptosis in human K562 leukemia cells through increased ROS and elevated TRAIL receptor expression. Leuk Res 2011;35:1402-8. [PMID: 21741707 DOI: 10.1016/j.leukres.2011.06.018] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 3.0] [Reference Citation Analysis]
192 Ray RM, Bhattacharya S, Johnson LR. Mdm2 inhibition induces apoptosis in p53 deficient human colon cancer cells by activating p73- and E2F1-mediated expression of PUMA and Siva-1. Apoptosis. 2011;16:35-44. [PMID: 20812030 DOI: 10.1007/s10495-010-0538-0] [Cited by in Crossref: 58] [Cited by in F6Publishing: 60] [Article Influence: 5.3] [Reference Citation Analysis]
193 Lu X, Wang Q, Xu F, Tang G, Yang W. A cationic prodrug/therapeutic gene nanocomplex for the synergistic treatment of tumors. Biomaterials 2011;32:4849-56. [DOI: 10.1016/j.biomaterials.2011.03.022] [Cited by in Crossref: 51] [Cited by in F6Publishing: 48] [Article Influence: 4.6] [Reference Citation Analysis]
194 Lara JF, Thor AD, Dressler LG, Broadwater G, Bleiweiss IJ, Edgerton S, Cowan D, Goldstein LJ, Martino S, Ingle JN, Henderson IC, Norton L, Winer EP, Hudis CA, Ellis MJ, Berry DA, Hayes DF; Cancer and Leukemia Group B. p53 Expression in node-positive breast cancer patients: results from the Cancer and Leukemia Group B 9344 Trial (159905). Clin Cancer Res 2011;17:5170-8. [PMID: 21693655 DOI: 10.1158/1078-0432.CCR-11-0484] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 2.2] [Reference Citation Analysis]
195 Iyer J, Moghe S, Furukawa M, Tsai M. What's Nu(SAP) in mitosis and cancer? Cellular Signalling 2011;23:991-8. [DOI: 10.1016/j.cellsig.2010.11.006] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 2.5] [Reference Citation Analysis]
196 Farmaki E, Mkrtchian S, Papazian I, Papavassiliou A, Kiaris H. ERp29 regulates response to doxorubicin by a PERK-mediated mechanism. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research 2011;1813:1165-71. [DOI: 10.1016/j.bbamcr.2011.03.003] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 1.8] [Reference Citation Analysis]
197 Lee JH, Sancar A. Circadian clock disruption improves the efficacy of chemotherapy through p73-mediated apoptosis. Proc Natl Acad Sci U S A 2011;108:10668-72. [PMID: 21628572 DOI: 10.1073/pnas.1106284108] [Cited by in Crossref: 44] [Cited by in F6Publishing: 40] [Article Influence: 4.0] [Reference Citation Analysis]
198 Mahaira LG, Tsimplouli C, Sakellaridis N, Alevizopoulos K, Demetzos C, Han Z, Pantazis P, Dimas K. The labdane diterpene sclareol (labd-14-ene-8, 13-diol) induces apoptosis in human tumor cell lines and suppression of tumor growth in vivo via a p53-independent mechanism of action. Eur J Pharmacol 2011;666:173-82. [PMID: 21620827 DOI: 10.1016/j.ejphar.2011.04.065] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 1.9] [Reference Citation Analysis]
199 Bonnefoi H, Piccart M, Bogaerts J, Mauriac L, Fumoleau P, Brain E, Petit T, Rouanet P, Jassem J, Blot E, Zaman K, Cufer T, Lortholary A, Lidbrink E, André S, Litière S, Lago LD, Becette V, Cameron DA, Bergh J, Iggo R; EORTC 10994/BIG 1-00 Study Investigators. TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial. Lancet Oncol 2011;12:527-39. [PMID: 21570352 DOI: 10.1016/S1470-2045(11)70094-8] [Cited by in Crossref: 93] [Cited by in F6Publishing: 41] [Article Influence: 8.5] [Reference Citation Analysis]
200 Varna M, Bousquet G, Plassa LF, Bertheau P, Janin A. TP53 status and response to treatment in breast cancers. J Biomed Biotechnol 2011;2011:284584. [PMID: 21760703 DOI: 10.1155/2011/284584] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 2.4] [Reference Citation Analysis]
201 Guan YS, Liu Y, He Q, Li X, Yang L, Hu Y, La Z. p53 gene therapy in combination with transcatheter arterial chemoembolization for HCC: One-year follow-up. World J Gastroenterol 2011; 17(16): 2143-2149 [PMID: 21547136 DOI: 10.3748/wjg.v17.i16.2143] [Cited by in CrossRef: 31] [Cited by in F6Publishing: 30] [Article Influence: 2.8] [Reference Citation Analysis]
202 Chrisanthar R, Knappskog S, Løkkevik E, Anker G, Ostenstad B, Lundgren S, Risberg T, Mjaaland I, Skjønsberg G, Aas T, Schlichting E, Fjösne HE, Nysted A, Lillehaug JR, Lønning PE. Predictive and prognostic impact of TP53 mutations and MDM2 promoter genotype in primary breast cancer patients treated with epirubicin or paclitaxel. PLoS One 2011;6:e19249. [PMID: 21556366 DOI: 10.1371/journal.pone.0019249] [Cited by in Crossref: 49] [Cited by in F6Publishing: 44] [Article Influence: 4.5] [Reference Citation Analysis]
203 Spolverato G, Pucciarelli S, Bertorelle R, De Rossi A, Nitti D. Predictive factors of the response of rectal cancer to neoadjuvant radiochemotherapy. Cancers (Basel) 2011;3:2176-94. [PMID: 24212803 DOI: 10.3390/cancers3022176] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 1.7] [Reference Citation Analysis]
204 Morinaka A, Funato Y, Uesugi K, Miki H. Oligomeric peroxiredoxin-I is an essential intermediate for p53 to activate MST1 kinase and apoptosis. Oncogene. 2011;30:4208-4218. [PMID: 21516123 DOI: 10.1038/onc.2011.139] [Cited by in Crossref: 61] [Cited by in F6Publishing: 59] [Article Influence: 5.5] [Reference Citation Analysis]
205 Shah MY, Pan X, Fix LN, Farwell MA, Zhang B. 5-fluorouracil drug alters the microrna expression profiles in MCF-7 breast cancer cells. J Cell Physiol 2011;226:1868-78. [DOI: 10.1002/jcp.22517] [Cited by in Crossref: 39] [Cited by in F6Publishing: 35] [Article Influence: 3.5] [Reference Citation Analysis]
206 Pang H, Cai L, Yang Y, Chen X, Sui G, Zhao C. Knockdown of Osteopontin Chemosensitizes MDA-MB-231 Cells to Cyclophosphamide by Enhancing Apoptosis Through Activating p38 MAPK Pathway. Cancer Biotherapy and Radiopharmaceuticals 2011;26:165-73. [DOI: 10.1089/cbr.2010.0838] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 3.1] [Reference Citation Analysis]
207 Martinez JD. Restoring p53 tumor suppressor activity as an anticancer therapeutic strategy. Future Oncol 2010;6:1857-62. [PMID: 21142860 DOI: 10.2217/fon.10.132] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
208 Kim IK, Lee JH, Kim HS, Kwon OJ, Shim BS. A novel function of haptoglobin: haptoglobin-haemoglobin complex induces apoptosis of hepatocarcinomatous Hep 3B cells. Scandinavian Journal of Clinical and Laboratory Investigation 2011;55:529-35. [DOI: 10.1080/00365519509075391] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
209 Kovacevic Z, Sivagurunathan S, Mangs H, Chikhani S, Zhang D, Richardson DR. The metastasis suppressor, N-myc downstream regulated gene 1 (NDRG1), upregulates p21 via p53-independent mechanisms. Carcinogenesis 2011;32:732-40. [PMID: 21398495 DOI: 10.1093/carcin/bgr046] [Cited by in Crossref: 67] [Cited by in F6Publishing: 64] [Article Influence: 6.1] [Reference Citation Analysis]
210 Mincberg M, Gopas J, Tal J. Minute virus of mice (MVMp) infection and NS1 expression induce p53 independent apoptosis in transformed rat fibroblast cells. Virology 2011;412:233-43. [DOI: 10.1016/j.virol.2010.12.035] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
211 Raspollini MR, Sardi I, Giunti L, Di Lollo S, Baroni G, Stomaci N, Menghetti I, Franchi A. Plasmacytoid urothelial carcinoma of the urinary bladder: clinicopathologic, immunohistochemical, ultrastructural, and molecular analysis of a case series. Hum Pathol 2011;42:1149-58. [PMID: 21334719 DOI: 10.1016/j.humpath.2010.11.011] [Cited by in Crossref: 45] [Cited by in F6Publishing: 38] [Article Influence: 4.1] [Reference Citation Analysis]
212 Jiang H, Pritchard JR, Williams RT, Lauffenburger DA, Hemann MT. A mammalian functional-genetic approach to characterizing cancer therapeutics. Nat Chem Biol 2011;7:92-100. [PMID: 21186347 DOI: 10.1038/nchembio.503] [Cited by in Crossref: 74] [Cited by in F6Publishing: 64] [Article Influence: 6.2] [Reference Citation Analysis]
213 Calviño E, Pajuelo L, de Eribe Casas JAO, Manjón JL, Tejedor MC, Herráez A, Alonso MD, Diez JC. Cytotoxic action of Ganoderma lucidum on interleukin-3 dependent lymphoma DA-1 cells: involvement of apoptosis proteins. Phytother Res 2011;25:25-32. [DOI: 10.1002/ptr.3202] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
214 Floquet C, Deforges J, Rousset JP, Bidou L. Rescue of non-sense mutated p53 tumor suppressor gene by aminoglycosides. Nucleic Acids Res 2011;39:3350-62. [PMID: 21149266 DOI: 10.1093/nar/gkq1277] [Cited by in Crossref: 83] [Cited by in F6Publishing: 77] [Article Influence: 6.9] [Reference Citation Analysis]
215 Sagawa Y, Fujitoh A, Nishi H, Ito H, Yudate T, Isaka K. Establishment of three cisplatin-resistant endometrial cancer cell lines using two methods of cisplatin exposure. Tumour Biol 2011;32:399-408. [PMID: 21113744 DOI: 10.1007/s13277-010-0133-6] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
216 Zanotto-Filho A, Braganhol E, Schröder R, de Souza LH, Dalmolin RJ, Pasquali MA, Gelain DP, Battastini AM, Moreira JC. NFκB inhibitors induce cell death in glioblastomas. Biochem Pharmacol 2011;81:412-24. [PMID: 21040711 DOI: 10.1016/j.bcp.2010.10.014] [Cited by in Crossref: 82] [Cited by in F6Publishing: 84] [Article Influence: 6.8] [Reference Citation Analysis]
217 Hussain AR, Uddin S, Ahmed M, Bu R, Ahmed SO, Abubaker J, Sultana M, Ajarim D, Al-Dayel F, Bavi PP, Al-Kuraya KS. Prognostic significance of XIAP expression in DLBCL and effect of its inhibition on AKT signalling. J Pathol 2010;222:180-90. [PMID: 20632385 DOI: 10.1002/path.2747] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 3.0] [Reference Citation Analysis]
218 Zhang X, Gu L, Li J, Shah N, He J, Yang L, Hu Q, Zhou M. Degradation of MDM2 by the interaction between berberine and DAXX leads to potent apoptosis in MDM2-overexpressing cancer cells. Cancer Res 2010;70:9895-904. [PMID: 20935220 DOI: 10.1158/0008-5472.CAN-10-1546] [Cited by in Crossref: 78] [Cited by in F6Publishing: 45] [Article Influence: 6.5] [Reference Citation Analysis]
219 Henríquez-hernández LA, Murias-rosales A, González-hernández A, de León AC, Díaz-chico N, Fernández-pérez L. Distribution of TYMS, MTHFR, p53 and MDR1 gene polymorphisms in patients with breast cancer treated with neoadjuvant chemotherapy. Cancer Epidemiology 2010;34:634-8. [DOI: 10.1016/j.canep.2010.06.013] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
220 Gomes NP, Espinosa JM. Disparate chromatin landscapes and kinetics of inactivation impact differential regulation of p53 target genes. Cell Cycle 2010;9:3428-37. [PMID: 20818159 DOI: 10.4161/cc.9.17.12998] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
221 Pickard MR, Edwards SE, Cooper CS, Williams GT. Apoptosis regulators Fau and Bcl-G are down-regulated in prostate cancer. Prostate 2010;70:1513-23. [DOI: 10.1002/pros.21186] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
222 Azmi AS, Philip PA, Aboukameel A, Wang Z, Banerjee S, Zafar SF, Goustin AS, Almhanna K, Yang D, Sarkar FH. Reactivation of p53 by novel MDM2 inhibitors: implications for pancreatic cancer therapy. Curr Cancer Drug Targets. 2010;10:319-331. [PMID: 20370686 DOI: 10.2174/156800910791190229] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 2.8] [Reference Citation Analysis]
223 Zhang JF, He ML, Qi Dong WD, Chen YC, Lin MC, Leung PC, Zhang YO, Kung HF. Aqueous extracts of Fructus Ligustri Lucidi enhance the sensitivity of human colorectal carcinoma DLD-1 cells to doxorubicin-induced apoptosis via Tbx3 suppression. Integr Cancer Ther. 2011;10:85-91. [PMID: 20702496 DOI: 10.1177/1534735410373921] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
224 Levitzki A, Klein S. Signal transduction therapy of cancer. Molecular Aspects of Medicine 2010;31:287-329. [DOI: 10.1016/j.mam.2010.04.001] [Cited by in Crossref: 53] [Cited by in F6Publishing: 47] [Article Influence: 4.4] [Reference Citation Analysis]
225 Hofmann ER, Nallar SC, Lin L, D'Cunha J, Lindner DJ, Weihua X, Kalvakolanu DV. Identification and characterization of GRIM-1, a cell-death-associated gene product. J Cell Sci 2010;123:2781-91. [PMID: 20663920 DOI: 10.1242/jcs.070250] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
226 Scott N, Martin I, Jack AS, Dixon MF, Quirke P. Genes mediating programmed cell death: an immunohistochemical study of bcl-2, c-myc and p53 expression in colorectal neoplasia. Clin Mol Pathol 1996;49:M151-8. [PMID: 16696064 DOI: 10.1136/mp.49.3.m151] [Cited by in Crossref: 11] [Cited by in F6Publishing: 3] [Article Influence: 0.9] [Reference Citation Analysis]
227 Cho SJ, Chen X. Myosin VI is differentially regulated by DNA damage in p53- and cell type-dependent manners. J Biol Chem 2010;285:27159-66. [PMID: 20576604 DOI: 10.1074/jbc.M110.142117] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
228 Díaz-Cruz ES, Furth PA. Deregulated estrogen receptor alpha and p53 heterozygosity collaborate in the development of mammary hyperplasia. Cancer Res. 2010;70:3965-3974. [PMID: 20466998 DOI: 10.1158/0008-5472.CAN-09-3450] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 1.6] [Reference Citation Analysis]
229 Shang X, Vasudevan SA, Yu Y, Ge N, Ludwig AD, Wesson CL, Wang K, Burlingame SM, Zhao YJ, Rao PH, Lu X, Russell HV, Okcu MF, Hicks MJ, Shohet JM, Donehower LA, Nuchtern JG, Yang J. Dual-specificity phosphatase 26 is a novel p53 phosphatase and inhibits p53 tumor suppressor functions in human neuroblastoma. Oncogene 2010;29:4938-46. [PMID: 20562916 DOI: 10.1038/onc.2010.244] [Cited by in Crossref: 46] [Cited by in F6Publishing: 41] [Article Influence: 3.8] [Reference Citation Analysis]
230 Chen YL, Eriksson S, Chang ZF. Regulation and functional contribution of thymidine kinase 1 in repair of DNA damage. J Biol Chem 2010;285:27327-35. [PMID: 20554529 DOI: 10.1074/jbc.M110.137042] [Cited by in Crossref: 46] [Cited by in F6Publishing: 32] [Article Influence: 3.8] [Reference Citation Analysis]
231 Wolter J, Angelini P, Irwin M. p53 family: Therapeutic targets in neuroblastoma. Future Oncol 2010;6:429-44. [PMID: 20222799 DOI: 10.2217/fon.09.176] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
232 Haynes NM, Hawkins ED, Li M, Mclaughlin NM, Hämmerling GJ, Schwendener R, Winoto A, Wensky A, Yagita H, Takeda K, Kershaw MH, Darcy PK, Smyth MJ. CD11c + Dendritic Cells and B Cells Contribute to the Tumoricidal Activity of Anti-DR5 Antibody Therapy in Established Tumors. J I 2010;185:532-41. [DOI: 10.4049/jimmunol.0903624] [Cited by in Crossref: 42] [Cited by in F6Publishing: 35] [Article Influence: 3.5] [Reference Citation Analysis]
233 Fishler T, Li YY, Wang RH, Kim HS, Sengupta K, Vassilopoulos A, Lahusen T, Xu X, Lee MH, Liu Q, Elledge SJ, Ried T, Deng CX. Genetic instability and mammary tumor formation in mice carrying mammary-specific disruption of Chk1 and p53. Oncogene 2010;29:4007-17. [PMID: 20473325 DOI: 10.1038/onc.2010.163] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 2.8] [Reference Citation Analysis]
234 Patutina OA, Mironova NL, Popova NA, Kaledin VI, Nikolin VP, Vlassov VV, Zenkova MA. The siRNA targeted to mdr1b and mdr1a mRNAs in vivo sensitizes murine lymphosarcoma to chemotherapy. BMC Cancer 2010;10:204. [PMID: 20470373 DOI: 10.1186/1471-2407-10-204] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
235 Holländer GA, Krenger W, Blazar BR. Emerging strategies to boost thymic function. Curr Opin Pharmacol 2010;10:443-53. [PMID: 20447867 DOI: 10.1016/j.coph.2010.04.008] [Cited by in Crossref: 50] [Cited by in F6Publishing: 42] [Article Influence: 4.2] [Reference Citation Analysis]
236 Suvasini R, Somasundaram K. Essential role of PI3-kinase pathway in p53-mediated transcription: Implications in cancer chemotherapy. Oncogene 2010;29:3605-18. [PMID: 20418912 DOI: 10.1038/onc.2010.123] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
237 Ladanyi M, Gorlick R. Molecular Pathology and Molecular Pharmacology of Osteosarcoma. Pediatric Pathology & Molecular Medicine 2010;19:391-413. [DOI: 10.1080/15513810009168647] [Cited by in Crossref: 17] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
238 Cillessen SA, Meijer CJ, Notoya M, Ossenkoppele GJ, Oudejans JJ. Molecular targeted therapies for diffuse large B-cell lymphoma based on apoptosis profiles. J Pathol 2010;220:509-20. [PMID: 20087881 DOI: 10.1002/path.2670] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.4] [Reference Citation Analysis]
239 Bhutia SK, Mallick SK, Maiti TK. Tumour escape mechanisms and their therapeutic implications in combination tumour therapy. Cell Biol Int 2010;34:553-63. [DOI: 10.1042/cbi20090206] [Cited by in Crossref: 16] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
240 Fan LL, Sun GP, Wei W, Wang ZG, Ge L, Fu WZ, Wang H. Melatonin and Doxorubicin synergistically induce cell apoptosis in human hepatoma cell lines. World J Gastroenterol 2010; 16(12): 1473-1481 [PMID: 20333787 DOI: 10.3748/wjg.v16.i12.1473] [Cited by in CrossRef: 78] [Cited by in F6Publishing: 69] [Article Influence: 6.5] [Reference Citation Analysis]
241 Blaho JA. Oncoapoptosis: a novel molecular therapeutic for cancer treatment. IUBMB Life 2010;62:87-91. [PMID: 19937971 DOI: 10.1002/iub.274] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
242 Zheng T, Wang J, Song X, Meng X, Pan S, Jiang H, Liu L. Nutlin-3 cooperates with doxorubicin to induce apoptosis of human hepatocellular carcinoma cells through p53 or p73 signaling pathways. J Cancer Res Clin Oncol 2010;136:1597-604. [PMID: 20174822 DOI: 10.1007/s00432-010-0817-8] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 2.6] [Reference Citation Analysis]
243 Tominaga T, Iwahashi M, Takifuji K, Hotta T, Yokoyama S, Matsuda K, Higashiguchi T, Oku Y, Nasu T, Yamaue H. Combination of p53 codon 72 polymorphism and inactive p53 mutation predicts chemosensitivity to 5-fluorouracil in colorectal cancer. Int J Cancer 2010;126:1691-701. [PMID: 19810096 DOI: 10.1002/ijc.24929] [Cited by in Crossref: 5] [Cited by in F6Publishing: 12] [Article Influence: 0.4] [Reference Citation Analysis]
244 Orgad S, Dimant H, Dor-On E, Azriel-Rosenfeld R, Benhar I, Solomon B. TAR1, a human anti-p53 single-chain antibody, restores tumor suppressor function to mutant p53 variants. J Immunother 2010;33:146-54. [PMID: 20139776 DOI: 10.1097/CJI.0b013e3181be14dc] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
245 Chen X, Wong P, Radany E, Wong JY. HDAC inhibitor, valproic acid, induces p53-dependent radiosensitization of colon cancer cells. Cancer Biother Radiopharm 2009;24:689-99. [PMID: 20025549 DOI: 10.1089/cbr.2009.0629] [Cited by in Crossref: 61] [Cited by in F6Publishing: 60] [Article Influence: 5.1] [Reference Citation Analysis]
246 Kühnel F, Gürlevik E, Wirth TC, Strüver N, Malek NP, Müller-Schilling M, Manns MP, Carnero A, Zender L, Kubicka S. Targeting of p53-transcriptional dysfunction by conditionally replicating adenovirus is not limited by p53-homologues. Mol Ther 2010;18:936-46. [PMID: 20040911 DOI: 10.1038/mt.2009.298] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
247 Makino T, Yamasaki M, Miyata H, Yoshioka S, Takiguchi S, Fujiwara Y, Nakajima K, Nishida T, Mori M, Doki Y. p53 Mutation status predicts pathological response to chemoradiotherapy in locally advanced esophageal cancer. Ann Surg Oncol. 2010;17:804-811. [PMID: 19885698 DOI: 10.1245/s10434-009-0786-9] [Cited by in Crossref: 33] [Cited by in F6Publishing: 35] [Article Influence: 2.5] [Reference Citation Analysis]
248 Chen J, Huang XF. Activation of p53 for the treatment of cancer. J Cell Biochem. 2009;107:567-568. [PMID: 19415675 DOI: 10.1002/jcb.22187] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
249 Fuchs D, Heinold A, Opelz G, Daniel V, Naujokat C. Salinomycin induces apoptosis and overcomes apoptosis resistance in human cancer cells. Biochem Biophys Res Commun 2009;390:743-9. [PMID: 19835841 DOI: 10.1016/j.bbrc.2009.10.042] [Cited by in Crossref: 128] [Cited by in F6Publishing: 124] [Article Influence: 9.8] [Reference Citation Analysis]
250 Moxley KM, Chengedza S, Benbrook DM. Induction of death receptor ligand-mediated apoptosis in epithelial ovarian carcinoma: The search for sensitizing agents. Gynecol Oncol 2009;115:438-42. [PMID: 19804900 DOI: 10.1016/j.ygyno.2009.09.007] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
251 Krizhanovsky V, Lowe SW. Stem cells: The promises and perils of p53. Nature. 2009;460:1085-1086. [PMID: 19713919 DOI: 10.1038/4601085a] [Cited by in Crossref: 205] [Cited by in F6Publishing: 206] [Article Influence: 15.8] [Reference Citation Analysis]
252 Ferrari D, Codecà C, Fiore J, Moneghini L, Bosari S, Foa P. Biomolecular markers in cancer of the tongue. J Oncol 2009;2009:412908. [PMID: 19696947 DOI: 10.1155/2009/412908] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 0.9] [Reference Citation Analysis]
253 Turinetto V, Porcedda P, Orlando L, De Marchi M, Amoroso A, Giachino C. The cyclin-dependent kinase inhibitor 5, 6-dichloro-1-beta-D-ribofuranosylbenzimidazole induces nongenotoxic, DNA replication-independent apoptosis of normal and leukemic cells, regardless of their p53 status. BMC Cancer 2009;9:281. [PMID: 19674456 DOI: 10.1186/1471-2407-9-281] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
254 Ollikainen H, Syrjänen S, Koskela K, Pelliniemit TT, Pulkki K. p53 gene mutations are rare in patients but common in patient-originating cell lines in multiple myeloma. Scandinavian Journal of Clinical and Laboratory Investigation 2009;57:281-9. [DOI: 10.3109/00365519709099401] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
255 Satoh T, Sasatomi E, Yamasaki F, Ishida H, Wu L, Tokunaga O. Multinucleated variant endothelial cells (MVECs) of human aorta: Expression of tumor suppressor gene p53 and relationship to atherosclerosis and aging. Endothelium 2009;6:123-32. [DOI: 10.3109/10623329809072199] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
256 Norberg T, Jansson T, Sjøgren S, Mårtensson C, Andréasson I, Fjällskog ML, Lindman H, Nordgren H, Lindgren A, Holmberg L, Bergh J. Overview on human breast cancer with focus on prognostic and predictive factors with special attention on the tumour suppressor gene p53. Acta Oncol 1996;35 Suppl 5:96-102. [PMID: 9142977 DOI: 10.3109/02841869609083980] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
257 Kyndi M, Sørensen FB, Knudsen H, Alsner J, Overgaard M, Nielsen HM, Overgaard J. Impact of BCL2 and p53 on postmastectomy radiotherapy response in high-risk breast cancer. A subgroup analysis of DBCG82 b&c. Acta Oncol 2008;47:608-17. [PMID: 18465329 DOI: 10.1080/02841860802050746] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
258 Ding H, Fisher DE. Induction of apoptosis in cancer: new therapeutic opportunities. Annals of Medicine 2009;34:451-69. [DOI: 10.1080/078538902321012405] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 2.5] [Reference Citation Analysis]
259 Hennig EM, Kvinnsland S, Holm R, Nesland JM. Significant difference in p53 and p21 protein immunoreactivity in HPV 16 positive and HPV negative breast carcinomas. Acta Oncol 1999;38:931-8. [PMID: 10606422 DOI: 10.1080/028418699432617] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]
260 C. Watson, Y.-m. Di, M. S. Orr, F. N. Influence of ionizing radiation on proliferation, c-myc expression and the induction of apoptotic cell death in two breast tumour cell lines differing in p53 status. International Journal of Radiation Biology 2009;72:547-59. [DOI: 10.1080/095530097143059] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 1.9] [Reference Citation Analysis]
261 Lawrence TS. Fluorodeoxyuridine-mediated cytotoxicity and radiosensitization require S phase progression. International Journal of Radiation Biology 2009;70:273-80. [DOI: 10.1080/095530096145003] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 2.3] [Reference Citation Analysis]
262 Jaffrézou J, Bettaïeb A, Levade T, Laurent G. Antitumor Agent-Induced Apoptosis in Myeloid Leukemia Cells: A Controlled Suicide. Leukemia & Lymphoma 2009;29:453-63. [DOI: 10.3109/10428199809050905] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
263 Matherly LH, Taub JW. Molecular and Cellular Correlates of Methotrexate Response in Childhood Acute Lymphoblastic Leukemia. Leukemia & Lymphoma 2009;35:1-20. [DOI: 10.3109/10428199909145701] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
264 Al-salam S, Al-ashari M. Expression of Galectin-3, CD138, p16INK4a, and TTF-1 in Mucinous Bronchioloalveolar Adenocarcinoma After Hodgkin Lymphoma. Applied Immunohistochemistry & Molecular Morphology 2009;17:351-6. [DOI: 10.1097/pai.0b013e31818a9d90] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
265 Haines DS. The mdm2 Proto-Oncogene. Leukemia & Lymphoma 2009;26:227-38. [DOI: 10.3109/10428199709051772] [Cited by in Crossref: 32] [Cited by in F6Publishing: 35] [Article Influence: 2.5] [Reference Citation Analysis]
266 Comby E, Andre I, Troussard X, Lebrun E, Sola B, Ballet JJ, Leporrier M. In Vitro Evaluation of B-CLL Cells Apoptotic Responses to Irradiation. Leukemia & Lymphoma 2009;34:159-66. [DOI: 10.3109/10428199909083392] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
267 Faur N, Araud L, Laroche-Clary A, Kanno J, Toutain J, Yamori T, Robert J, Le Morvan V. The association between the T309G polymorphism of the MDM2 gene and sensitivity to anticancer drug is dependent on the p53 mutational status in cellular models. Br J Cancer 2009;101:350-6. [PMID: 19513075 DOI: 10.1038/sj.bjc.6605096] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
268 Westmoreland TJ, Wickramasekara SM, Guo AY, Selim AL, Winsor TS, Greenleaf AL, Blackwell KL, Olson JA Jr, Marks JR, Bennett CB. Comparative genome-wide screening identifies a conserved doxorubicin repair network that is diploid specific in Saccharomyces cerevisiae. PLoS One 2009;4:e5830. [PMID: 19503795 DOI: 10.1371/journal.pone.0005830] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 2.5] [Reference Citation Analysis]
269 Postiglione I, Chiaviello A, Palumbo G. Twilight effects of low doses of ionizing radiation on cellular systems: a bird's eye view on current concepts and research. Med Oncol 2010;27:495-509. [PMID: 19504191 DOI: 10.1007/s12032-009-9241-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
270 Carter BZ, Mak DH, Woessner R, Gross S, Schober WD, Estrov Z, Kantarjian H, Andreeff M. Inhibition of KSP by ARRY-520 induces cell cycle block and cell death via the mitochondrial pathway in AML cells. Leukemia 2009;23:1755-62. [PMID: 19458629 DOI: 10.1038/leu.2009.101] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 2.5] [Reference Citation Analysis]
271 Olsson I, Bergh G, Ehinger M, Gullberg U. Cell differentiation in acute myeloid leukemia. European Journal of Haematology 1996;57:1-16. [DOI: 10.1111/j.1600-0609.1996.tb00483.x] [Cited by in Crossref: 51] [Cited by in F6Publishing: 46] [Article Influence: 3.9] [Reference Citation Analysis]
272 Lu C, El-deiry WS. Targeting p53 for enhanced radio- and chemo-sensitivity. Apoptosis 2009;14:597-606. [DOI: 10.1007/s10495-009-0330-1] [Cited by in Crossref: 95] [Cited by in F6Publishing: 86] [Article Influence: 7.3] [Reference Citation Analysis]
273 Rehman S, Sameer A, Zahoor L, Abdullah S, Shah Z, Afroze D, Hussain I, Shaffi S, Syeed N, Rizvi M, Siddiqi M. Distinct pattern of mutations of conserved regions of TP53 in colorectal cancer patients in the Kashmir population: an emerging high-risk area. Ecancermedicalscience 2009;3:129. [PMID: 22275998 DOI: 10.3332/ecancer.2009.129] [Reference Citation Analysis]
274 Vazquez A, Bond EE, Levine AJ, Bond GL. The genetics of the p53 pathway, apoptosis and cancer therapy. Nat Rev Drug Discov 2008;7:979-87. [PMID: 19043449 DOI: 10.1038/nrd2656] [Cited by in Crossref: 438] [Cited by in F6Publishing: 409] [Article Influence: 31.3] [Reference Citation Analysis]
275 Pan JJ, Zhang SW, Chen CB, Xiao SW, Sun Y, Liu CQ, Su X, Li DM, Xu G, Xu B, Lu YY. Effect of recombinant adenovirus-p53 combined with radiotherapy on long-term prognosis of advanced nasopharyngeal carcinoma. J Clin Oncol 2009;27:799-804. [PMID: 19103729 DOI: 10.1200/JCO.2008.18.9670] [Cited by in Crossref: 83] [Cited by in F6Publishing: 35] [Article Influence: 5.9] [Reference Citation Analysis]
276 Murase D, Hachiya A, Amano Y, Ohuchi A, Kitahara T, Takema Y. The essential role of p53 in hyperpigmentation of the skin via regulation of paracrine melanogenic cytokine receptor signaling. J Biol Chem 2009;284:4343-53. [PMID: 19098008 DOI: 10.1074/jbc.M805570200] [Cited by in Crossref: 57] [Cited by in F6Publishing: 24] [Article Influence: 4.1] [Reference Citation Analysis]
277 Bachmann K, Shahmiri S, Kaifi J, Schurr P, Mann O, Rawnaq T, Block S, Kalinin V, Izbicki JR, Strate T. Polymorphism Arg290Arg in esophageal-cancer-related gene 1 (ECRG1) is a prognostic factor for survival in esophageal cancer. J Gastrointest Surg 2009;13:181-7. [PMID: 19052822 DOI: 10.1007/s11605-008-0766-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
278 Slee EA, Martin SJ. Regulation of caspase activation in apoptosis: implications for transformation and drug resistance. Cytotechnology 1998;27:309-20. [PMID: 19002801 DOI: 10.1023/A:1008014215581] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
279 Wang S. The promise of cancer therapeutics targeting the TNF-related apoptosis-inducing ligand and TRAIL receptor pathway. Oncogene 2008;27:6207-15. [DOI: 10.1038/onc.2008.298] [Cited by in Crossref: 161] [Cited by in F6Publishing: 136] [Article Influence: 11.5] [Reference Citation Analysis]
280 Millau JF, Bastien N, Drouin R. P53 transcriptional activities: a general overview and some thoughts. Mutat Res 2009;681:118-33. [PMID: 18639648 DOI: 10.1016/j.mrrev.2008.06.002] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 2.5] [Reference Citation Analysis]
281 Young KH, Leroy K, Møller MB, Colleoni GW, Sánchez-Beato M, Kerbauy FR, Haioun C, Eickhoff JC, Young AH, Gaulard P, Piris MA, Oberley TD, Rehrauer WM, Kahl BS, Malter JS, Campo E, Delabie J, Gascoyne RD, Rosenwald A, Rimsza L, Huang J, Braziel RM, Jaffe ES, Wilson WH, Staudt LM, Vose JM, Chan WC, Weisenburger DD, Greiner TC. Structural profiles of TP53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma: an international collaborative study. Blood 2008;112:3088-98. [PMID: 18559976 DOI: 10.1182/blood-2008-01-129783] [Cited by in Crossref: 117] [Cited by in F6Publishing: 112] [Article Influence: 8.4] [Reference Citation Analysis]
282 Huang RS, Duan S, Kistner EO, Bleibel WK, Delaney SM, Fackenthal DL, Das S, Dolan ME. Genetic variants contributing to daunorubicin-induced cytotoxicity. Cancer Res 2008;68:3161-8. [PMID: 18451141 DOI: 10.1158/0008-5472.CAN-07-6381] [Cited by in Crossref: 50] [Cited by in F6Publishing: 39] [Article Influence: 3.6] [Reference Citation Analysis]
283 Xing H, Cao Y, Weng D, Tao W, Song X, Wang W, Meng L, Xu G, Zhou J, Wang S, Ma D. Fibronectin-mediated activation of Akt2 protects human ovarian and breast cancer cells from docetaxel-induced apoptosis via inhibition of the p38 pathway. Apoptosis 2008;13:213-23. [PMID: 18158623 DOI: 10.1007/s10495-007-0158-5] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 1.4] [Reference Citation Analysis]
284 Prasad GA, Wang KK, Halling KC, Buttar NS, Wongkeesong LM, Zinsmeister AR, Brankley SM, Fritcher EG, Westra WM, Krishnadath KK, Lutzke LS, Borkenhagen LS. Utility of biomarkers in prediction of response to ablative therapy in Barrett's esophagus. Gastroenterology 2008;135:370-9. [PMID: 18538141 DOI: 10.1053/j.gastro.2008.04.036] [Cited by in Crossref: 60] [Cited by in F6Publishing: 49] [Article Influence: 4.3] [Reference Citation Analysis]
285 Kandioler D, Stamatis G, Eberhardt W, Kappel S, Zöchbauer-müller S, Kührer I, Mittlböck M, Zwrtek R, Aigner C, Bichler C, Tichy V, Hudec M, Bachleitner T, End A, Müller MR, Roth E, Klepetko W. Growing clinical evidence for the interaction of the p53 genotype and response to induction chemotherapy in advanced non–small cell lung cancer. The Journal of Thoracic and Cardiovascular Surgery 2008;135:1036-41. [DOI: 10.1016/j.jtcvs.2007.10.072] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 2.4] [Reference Citation Analysis]
286 Nahi H, Selivanova G, Lehmann S, Möllgård L, Bengtzen S, Concha H, Svensson A, Wiman KG, Merup M, Paul C. Mutated and non-mutated TP53 as targets in the treatment of leukaemia. Br J Haematol 2008;141:445-53. [DOI: 10.1111/j.1365-2141.2008.07046.x] [Cited by in Crossref: 43] [Cited by in F6Publishing: 36] [Article Influence: 3.1] [Reference Citation Analysis]
287 Al-Salam S, Algawi K, Alashari M. Malignant non-teratoid medulloepithelioma of ciliary body with retinoblastic differentiation: a case report and review of literature. Neuropathology 2008;28:551-6. [PMID: 18410270 DOI: 10.1111/j.1440-1789.2008.00886.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
288 Haeno H, Iwasa Y, Michor F. The evolution of two mutations during clonal expansion. Genetics. 2007;177:2209-2221. [PMID: 18073428 DOI: 10.1534/genetics.107.078915] [Cited by in Crossref: 47] [Cited by in F6Publishing: 40] [Article Influence: 3.4] [Reference Citation Analysis]
289 Donninger H, Binder A, Bohm L, Parker MI. Differential effects of novel tumour-derived p53 mutations on the transformation of NIH-3T3 cells. Biol Chem 2008;389:57-67. [PMID: 18095870 DOI: 10.1515/BC.2008.010] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
290 Luo W, Liu J, Li J, Zhang D, Liu M, Addo JK, Patil S, Zhang L, Yu J, Buolamwini JK, Chen J, Huang C. Anti-cancer effects of JKA97 are associated with its induction of cell apoptosis via a Bax-dependent and p53-independent pathway. J Biol Chem 2008;283:8624-33. [PMID: 18218619 DOI: 10.1074/jbc.M707860200] [Cited by in Crossref: 29] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
291 Cillessen SA, Reed JC, Welsh K, Pinilla C, Houghten R, Hooijberg E, Deurhof J, Castricum KC, Kortman P, Hess CJ, Ossenkoppele GJ, Meijer CJ, Oudejans JJ. Small-molecule XIAP antagonist restores caspase-9 mediated apoptosis in XIAP-positive diffuse large B-cell lymphoma cells. Blood 2008;111:369-75. [PMID: 17916749 DOI: 10.1182/blood-2007-04-085480] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 1.9] [Reference Citation Analysis]
292 Jeon JO, Yoo KH, Park JH. Expression of the Pkd1 gene is momentously regulated by Sp1. Nephron Exp Nephrol 2007;107:e57-64. [PMID: 17890878 DOI: 10.1159/000108643] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
293 Chan DA, Giaccia AJ. Hypoxia, gene expression, and metastasis. Cancer Metastasis Rev 2007;26:333-9. [PMID: 17458506 DOI: 10.1007/s10555-007-9063-1] [Cited by in Crossref: 201] [Cited by in F6Publishing: 170] [Article Influence: 13.4] [Reference Citation Analysis]
294 Guzman ML, Jordan CT. Considerations for targeting malignant stem cells in leukemia. Cancer Control 2004;11:97-104. [PMID: 15024346 DOI: 10.1177/107327480401100216] [Cited by in Crossref: 54] [Cited by in F6Publishing: 51] [Article Influence: 3.6] [Reference Citation Analysis]
295 Kurata K, Yanagisawa R, Ohira M, Kitagawa M, Nakagawara A, Kamijo T. Stress via p53 pathway causes apoptosis by mitochondrial Noxa upregulation in doxorubicin-treated neuroblastoma cells. Oncogene 2008;27:741-54. [DOI: 10.1038/sj.onc.1210672] [Cited by in Crossref: 24] [Cited by in F6Publishing: 27] [Article Influence: 1.6] [Reference Citation Analysis]
296 Schmitt E, Paquet C, Beauchemin M, Bertrand R. DNA-damage response network at the crossroads of cell-cycle checkpoints, cellular senescence and apoptosis. J Zhejiang Univ Sci B 2007;8:377-97. [PMID: 17565509 DOI: 10.1631/jzus.2007.B0377] [Cited by in Crossref: 69] [Cited by in F6Publishing: 29] [Article Influence: 4.6] [Reference Citation Analysis]
297 Arthur CR, Gupton JT, Kellogg GE, Yeudall WA, Cabot MC, Newsham IF, Gewirtz DA. Autophagic cell death, polyploidy and senescence induced in breast tumor cells by the substituted pyrrole JG-03-14, a novel microtubule poison. Biochem Pharmacol 2007;74:981-91. [PMID: 17692290 DOI: 10.1016/j.bcp.2007.07.003] [Cited by in Crossref: 60] [Cited by in F6Publishing: 56] [Article Influence: 4.0] [Reference Citation Analysis]
298 Marusyk A, Wheeler LJ, Mathews CK, DeGregori J. p53 mediates senescence-like arrest induced by chronic replicational stress. Mol Cell Biol. 2007;27:5336-5351. [PMID: 17515610 DOI: 10.1128/mcb.01316-06] [Cited by in Crossref: 51] [Cited by in F6Publishing: 35] [Article Influence: 3.4] [Reference Citation Analysis]
299 Pupa SM, Giuffré S, Castiglioni F, Bertola L, Cantú M, Bongarzone I, Baldassari P, Mortarini R, Argraves WS, Anichini A, Menard S, Tagliabue E. Regulation of breast cancer response to chemotherapy by fibulin-1. Cancer Res 2007;67:4271-7. [PMID: 17483339 DOI: 10.1158/0008-5472.CAN-06-4162] [Cited by in Crossref: 47] [Cited by in F6Publishing: 27] [Article Influence: 3.1] [Reference Citation Analysis]
300 Kamat CD, Green DE, Warnke L, Thorpe JE, Ceriello A, Ihnat MA. Mutant p53 facilitates pro-angiogenic, hyperproliferative phenotype in response to chronic relative hypoxia. Cancer Letters 2007;249:209-19. [DOI: 10.1016/j.canlet.2006.08.017] [Cited by in Crossref: 39] [Cited by in F6Publishing: 35] [Article Influence: 2.6] [Reference Citation Analysis]
301 Short SM, Yoder BJ, Tarr SM, Prescott NL, Laniauskas S, Coleman KA, Downs-Kelly E, Pettay JD, Choueiri TK, Crowe JP, Tubbs RR, Budd TG, Hicks DG. The expression of the cytoskeletal focal adhesion protein paxillin in breast cancer correlates with HER2 overexpression and may help predict response to chemotherapy: a retrospective immunohistochemical study. Breast J 2007;13:130-9. [PMID: 17319853 DOI: 10.1111/j.1524-4741.2007.00389.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 27] [Article Influence: 1.5] [Reference Citation Analysis]
302 Gu T, Li CX, Feng Y, Wang Q, Li CH, Li CF. Trans-arterial gene therapy for hepatocellular carcinoma in a rabbit model. World J Gastroenterol 2007; 13(14): 2113-2117 [PMID: 17465458 DOI: 10.3748/wjg.v13.i14.2113] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
303 Cui R, Widlund HR, Feige E, Lin JY, Wilensky DL, Igras VE, D'Orazio J, Fung CY, Schanbacher CF, Granter SR, Fisher DE. Central role of p53 in the suntan response and pathologic hyperpigmentation. Cell 2007;128:853-64. [PMID: 17350573 DOI: 10.1016/j.cell.2006.12.045] [Cited by in Crossref: 415] [Cited by in F6Publishing: 607] [Article Influence: 27.7] [Reference Citation Analysis]
304 Dhandapani KM, Mahesh VB, Brann DW. Curcumin suppresses growth and chemoresistance of human glioblastoma cells via AP-1 and NFκB transcription factors: Curcumin inhibits glioma survival via AP-1 and NFκB. Journal of Neurochemistry 2007;102:522-38. [DOI: 10.1111/j.1471-4159.2007.04633.x] [Cited by in Crossref: 190] [Cited by in F6Publishing: 178] [Article Influence: 12.7] [Reference Citation Analysis]
305 D'Amico TA. Molecular biologic staging of esophageal cancer. Thorac Surg Clin 2006;16:317-27. [PMID: 17240819 DOI: 10.1016/j.thorsurg.2006.09.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
306 Shen J, Huang C, Jiang L, Gao F, Wang Z, Zhang Y, Bai J, Zhou H, Chen Q. Enhancement of cisplatin induced apoptosis by suberoylanilide hydroxamic acid in human oral squamous cell carcinoma cell lines. Biochem Pharmacol 2007;73:1901-9. [PMID: 17445779 DOI: 10.1016/j.bcp.2007.03.009] [Cited by in Crossref: 58] [Cited by in F6Publishing: 48] [Article Influence: 3.9] [Reference Citation Analysis]
307 Schäfer R, Tchernitsa OI, Györffy B, Serra V, Abdul-Ghani R, Lund P, Sers C. Functional transcriptomics: an experimental basis for understanding the systems biology for cancer cells. Adv Enzyme Regul 2007;47:41-62. [PMID: 17335873 DOI: 10.1016/j.advenzreg.2006.12.001] [Reference Citation Analysis]
308 Doi R, Makino T, Adachi H, Ryoke K, Ito H. Pre-operative radio-chemotherapy enhances apoptotic cell death in oral squamous cell carcinoma. Journal of Oral Pathology & Medicine 1998;27:382-7. [DOI: 10.1111/j.1600-0714.1998.tb01971.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
309 Vallböhmer D, Lenz HJ. Predictive and prognostic molecular markers in outcome of esophageal cancer. Dis Esophagus. 2006;19:425-432. [PMID: 17069584 DOI: 10.1111/j.1442-2050.2006.00622.x] [Cited by in Crossref: 54] [Cited by in F6Publishing: 51] [Article Influence: 3.6] [Reference Citation Analysis]
310 Lønning PE, Knappskog S, Staalesen V, Chrisanthar R, Lillehaug JR. Breast cancer prognostication and prediction in the postgenomic era. Ann Oncol 2007;18:1293-306. [PMID: 17317675 DOI: 10.1093/annonc/mdm013] [Cited by in Crossref: 46] [Cited by in F6Publishing: 39] [Article Influence: 3.1] [Reference Citation Analysis]
311 Nithipongvanitch R, Ittarat W, Velez JM, Zhao R, St. Clair DK, Oberley TD. Evidence for p53 as Guardian of the Cardiomyocyte Mitochondrial Genome Following Acute Adriamycin Treatment. J Histochem Cytochem 2007;55:629-39. [DOI: 10.1369/jhc.6a7146.2007] [Cited by in Crossref: 52] [Cited by in F6Publishing: 27] [Article Influence: 3.5] [Reference Citation Analysis]
312 Mitsunaga M, Tsubota A, Nariai K, Namiki Y, Sumi M, Yoshikawa T, Fujise K. Early apoptosis and cell death induced by ATX-S10Na (II)-mediated photodynamic therapy are Bax- and p53-dependent in human colon cancer cells. World J Gastroenterol 2007; 13(5): 692-698 [PMID: 17278191 DOI: 10.3748/wjg.v13.i5.692] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.0] [Reference Citation Analysis]
313 Yamashita H, Toyama T, Nishio M, Ando Y, Hamaguchi M, Zhang Z, Kobayashi S, Fujii Y, Iwase H. p53 protein accumulation predicts resistance to endocrine therapy and decreased post-relapse survival in metastatic breast cancer. Breast Cancer Res 2006;8:R48. [PMID: 16869955 DOI: 10.1186/bcr1536] [Cited by in Crossref: 59] [Cited by in F6Publishing: 59] [Article Influence: 3.9] [Reference Citation Analysis]
314 Sun XX, Dai MS, Lu H. 5-fluorouracil activation of p53 involves an MDM2-ribosomal protein interaction. J Biol Chem 2007;282:8052-9. [PMID: 17242401 DOI: 10.1074/jbc.M610621200] [Cited by in Crossref: 117] [Cited by in F6Publishing: 96] [Article Influence: 7.8] [Reference Citation Analysis]
315 Sinicrope FA, Rego RL, Garrity-park MM, Foster NR, Sargent DJ, Goldberg RM, Wiesenfeld M, Witzig TE, Thibodeau SN, Burgart LJ. Alterations in cell proliferation and apoptosis in colon cancers with microsatellite instability. Int J Cancer 2007;120:1232-8. [DOI: 10.1002/ijc.22429] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 1.5] [Reference Citation Analysis]
316 Tsuzuki T, Kambe T, Shibata A, Kawakami Y, Nakagawa K, Miyazawa T. Conjugated EPA activates mutant p53 via lipid peroxidation and induces p53-dependent apoptosis in DLD-1 colorectal adenocarcinoma human cells. Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids 2007;1771:20-30. [DOI: 10.1016/j.bbalip.2006.11.006] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 2.0] [Reference Citation Analysis]
317 Cheng Q, Luo X, Zhang B, Jiang X, Yi B, Wu M. Distal bile duct carcinoma: prognostic factors after curative surgery. A series of 112 cases. Ann Surg Oncol. 2007;14:1212-1219. [PMID: 17176983 DOI: 10.1245/s10434-006-9260-0] [Cited by in Crossref: 51] [Cited by in F6Publishing: 45] [Article Influence: 3.2] [Reference Citation Analysis]
318 Rohini K, Mathivanan J, Prabhu PD, Subbakrishna DK, Gope ML, Chandramouli BA, Sampath S, Anandh B, Gope R. Loss of heterozygosity of the p53 gene and deregulated expression of its mRNA and protein in human brain tumors. Mol Cell Biochem 2007;300:101-11. [PMID: 17180249 DOI: 10.1007/s11010-006-9374-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
319 Merritt RL, Foran CM. Influence of Persistent Contaminants and Steroid Hormones on Glioblastoma Cell Growth. Journal of Toxicology and Environmental Health, Part A 2006;70:19-27. [DOI: 10.1080/15287390600748807] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 0.9] [Reference Citation Analysis]
320 van Geelen CM, Westra JL, de Vries EG, Boersma-van Ek W, Zwart N, Hollema H, Boezen HM, Mulder NH, Plukker JT, de Jong S, Kleibeuker JH, Koornstra JJ. Prognostic significance of tumor necrosis factor-related apoptosis-inducing ligand and its receptors in adjuvantly treated stage III colon cancer patients. J Clin Oncol 2006;24:4998-5004. [PMID: 17075118 DOI: 10.1200/JCO.2006.06.8809] [Cited by in Crossref: 54] [Cited by in F6Publishing: 25] [Article Influence: 3.4] [Reference Citation Analysis]
321 Henriksson E, Baldetorp B, Borg A, Kjellen E, Akervall J, Wennerberg J, Wahlberg P. p53 mutation and cyclin D1 amplification correlate with cisplatin sensitivity in xenografted human squamous cell carcinomas from head and neck. Acta Oncol 2006;45:300-5. [PMID: 16644573 DOI: 10.1080/02841860600547380] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 1.8] [Reference Citation Analysis]
322 Cordón-Preciado V, Ufano S, Bueno A. Limiting amounts of budding yeast Rad53 S-phase checkpoint activity results in increased resistance to DNA alkylation damage. Nucleic Acids Res 2006;34:5852-62. [PMID: 17062626 DOI: 10.1093/nar/gkl741] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 1.2] [Reference Citation Analysis]
323 Chuthapisith S, Eremin JM, El-Sheemy M, Eremin O. Neoadjuvant chemotherapy in women with large and locally advanced breast cancer: chemoresistance and prediction of response to drug therapy. Surgeon 2006;4:211-9. [PMID: 16892838 DOI: 10.1016/s1479-666x(06)80062-4] [Cited by in Crossref: 19] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
324 Yang WH, Kim JE, Nam HW, Ju JW, Kim HS, Kim YS, Cho JW. Modification of p53 with O-linked N-acetylglucosamine regulates p53 activity and stability. Nat Cell Biol. 2006;8:1074-1083. [PMID: 16964247 DOI: 10.1038/ncb1470] [Cited by in Crossref: 294] [Cited by in F6Publishing: 291] [Article Influence: 18.4] [Reference Citation Analysis]
325 Schmitt CA. Cellular senescence and cancer treatment. Biochim Biophys Acta 2007;1775:5-20. [PMID: 17027159 DOI: 10.1016/j.bbcan.2006.08.005] [Cited by in Crossref: 22] [Cited by in F6Publishing: 83] [Article Influence: 1.4] [Reference Citation Analysis]
326 Hernández-Vargas H, Ballestar E, Carmona-Saez P, von Kobbe C, Bañón-Rodríguez I, Esteller M, Moreno-Bueno G, Palacios J. Transcriptional profiling of MCF7 breast cancer cells in response to 5-Fluorouracil: relationship with cell cycle changes and apoptosis, and identification of novel targets of p53. Int J Cancer 2006;119:1164-75. [PMID: 16557594 DOI: 10.1002/ijc.21938] [Cited by in Crossref: 52] [Cited by in F6Publishing: 51] [Article Influence: 3.3] [Reference Citation Analysis]
327 Cillessen SA, Meijer CJ, Ossenkoppele GJ, Castricum KC, Westra AH, Niesten P, Muris JJ, Nijdam HF, van der Hem KG, Flens M, Hooijberg E, Oudejans JJ. Human soluble TRAIL/Apo2L induces apoptosis in a subpopulation of chemotherapy refractory nodal diffuse large B-cell lymphomas, determined by a highly sensitive in vitro apoptosis assay. Br J Haematol 2006;134:283-93. [DOI: 10.1111/j.1365-2141.2006.06186.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
328 Capponcelli S, Pedrini E, Cerone MA, Corti V, Fontanesi S, Alessio M, Bachi A, Soddu S, Ribatti D, Picci P, Helman LJ, Cantelli-Forti G, Sangiorgi L. Evaluation of the molecular mechanisms involved in the gain of function of a Li-Fraumeni TP53 mutation. Hum Mutat 2005;26:94-103. [PMID: 15977174 DOI: 10.1002/humu.20192] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
329 Tian Y, Song Y. Effects of inositol hexaphosphate on proliferation of HT-29 human colon carcinoma cell line. World J Gastroenterol 2006; 12(26): 4137-4142 [PMID: 16830361 DOI: 10.3748/wjg.v12.i26.4137] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
330 Mansilla S, Priebe W, Portugal J. Transcriptional changes facilitate mitotic catastrophe in tumour cells that contain functional p53. European Journal of Pharmacology 2006;540:34-45. [DOI: 10.1016/j.ejphar.2006.04.035] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 0.9] [Reference Citation Analysis]
331 Guo HR, Chen CH, Ho SY, Ho YS, Chen RJ, Wang YJ. Staurosporine modulates radiosensitivity and radiation-induced apoptosis in U937 cells. Int J Radiat Biol 2006;82:97-109. [PMID: 16546908 DOI: 10.1080/09553000600589149] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
332 De Galitiis F, Cannita K, Tessitore A, Martella F, Di Rocco Z, Russo A, Adamo V, Iacobelli S, Martinotti S, Marchetti P, Ficorella C, Ricevuto E. Novel P53 mutations detected by FAMA in colorectal cancers. Annals of Oncology 2006;17:vii78-83. [DOI: 10.1093/annonc/mdl957] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
333 Moule RN, Jhavar SG, Eeles RA. Genotype Phenotype Correlation in Li-Fraumeni Syndrome Kindreds and its Implications for Management. Familial Cancer 2006;5:129-33. [DOI: 10.1007/s10689-005-4522-8] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
334 Alchanati I, Nallar SC, Sun P, Gao L, Hu J, Stein A, Yakirevich E, Konforty D, Alroy I, Zhao X. A proteomic analysis reveals the loss of expression of the cell death regulatory gene GRIM-19 in human renal cell carcinomas. Oncogene. 2006;25:7138-7147. [PMID: 16732315 DOI: 10.1038/sj.onc.1209708] [Cited by in Crossref: 75] [Cited by in F6Publishing: 67] [Article Influence: 4.7] [Reference Citation Analysis]
335 Yang CH, Cristofanilli M. The role of p53 mutations as a prognostic factor and therapeutic target in inflammatory breast cancer. Future Oncol 2006;2:247-55. [PMID: 16563093 DOI: 10.2217/14796694.2.2.247] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
336 Masuya D, Huang C, Liu D, Nakashima T, Yokomise H, Ueno M, Nakashima N, Sumitomo S. The HAUSP gene plays an important role in non-small cell lung carcinogenesis through p53-dependent pathways. J Pathol 2006;208:724-32. [PMID: 16450335 DOI: 10.1002/path.1931] [Cited by in Crossref: 59] [Cited by in F6Publishing: 58] [Article Influence: 3.7] [Reference Citation Analysis]
337 Metzinger DS, Taylor DD, Gercel-taylor C. Induction of p53 and drug resistance following treatment with cisplatin or paclitaxel in ovarian cancer cell lines. Cancer Letters 2006;236:302-8. [DOI: 10.1016/j.canlet.2005.05.016] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 1.4] [Reference Citation Analysis]
338 Radhakrishnan SK, Gierut J, Gartel AL. Multiple alternate p21 transcripts are regulated by p53 in human cells. Oncogene 2006;25:1812-5. [PMID: 16261158 DOI: 10.1038/sj.onc.1209195] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 1.8] [Reference Citation Analysis]
339 Ohtsuka T, Liu XF, Koga Y, Kitajima Y, Nakafusa Y, Ha CW, Lee SW, Miyazaki K. Methylation-induced silencing of ASC and the effect of expressed ASC on p53-mediated chemosensitivity in colorectal cancer. Oncogene 2006;25:1807-11. [PMID: 16331272 DOI: 10.1038/sj.onc.1209204] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.0] [Reference Citation Analysis]
340 Dimas K, Papadaki M, Tsimplouli C, Hatziantoniou S, Alevizopoulos K, Pantazis P, Demetzos C. Labd-14-ene-8,13-diol (sclareol) induces cell cycle arrest and apoptosis in human breast cancer cells and enhances the activity of anticancer drugs. Biomedicine & Pharmacotherapy 2006;60:127-33. [DOI: 10.1016/j.biopha.2006.01.003] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 2.3] [Reference Citation Analysis]
341 Chang SC, Lin JK, Yang SH, Wang HS, Li AF, Chi CW. Relationship between genetic alterations and prognosis in sporadic colorectal cancer. Int J Cancer. 2006;118:1721-1727. [PMID: 16231316 DOI: 10.1002/ijc.21563] [Cited by in Crossref: 77] [Cited by in F6Publishing: 72] [Article Influence: 4.8] [Reference Citation Analysis]
342 Kemeny NE, Niedzwiecki D, Hollis DR, Lenz HJ, Warren RS, Naughton MJ, Weeks JC, Sigurdson ER, Herndon JE, Zhang C. Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481). J Clin Oncol. 2006;24:1395-1403. [PMID: 16505413 DOI: 10.1200/jco.2005.03.8166] [Cited by in Crossref: 251] [Cited by in F6Publishing: 91] [Article Influence: 15.7] [Reference Citation Analysis]
343 Hallgren O, Gustafsson L, Irjala H, Selivanova G, Orrenius S, Svanborg C. HAMLET triggers apoptosis but tumor cell death is independent of caspases, Bcl-2 and p53. Apoptosis 2006;11:221-33. [DOI: 10.1007/s10495-006-3607-7] [Cited by in Crossref: 51] [Cited by in F6Publishing: 45] [Article Influence: 3.2] [Reference Citation Analysis]
344 Fujiwara Y, Kawada K, Takano D, Tanimura S, Ozaki K, Kohno M. Inhibition of the PI3 kinase/Akt pathway enhances doxorubicin-induced apoptotic cell death in tumor cells in a p53-dependent manner. Biochemical and Biophysical Research Communications 2006;340:560-6. [DOI: 10.1016/j.bbrc.2005.12.039] [Cited by in Crossref: 29] [Cited by in F6Publishing: 20] [Article Influence: 1.8] [Reference Citation Analysis]
345 Hotta T, Suzuki H, Nagai S, Yamamoto K, Imakiire A, Takada E, Itoh M, Mizuguchi J. Chemotherapeutic agents sensitize sarcoma cell lines to tumor necrosis factor-related apoptosis-inducing ligand-induced caspase-8 activation, apoptosis and loss of mitochondrial membrane potential. J Orthop Res 2003;21:949-57. [DOI: 10.1016/s0736-0266(03)00062-7] [Cited by in Crossref: 21] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
346 Chung HJ, Yoon SI, Shin SH, Koh YA, Lee S, Lee Y, Bae S. p53-mediated enhancement of radiosensitivity by selenophosphate synthetase 1 overexpression. J Cell Physiol 2006;209:131-41. [DOI: 10.1002/jcp.20714] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.6] [Reference Citation Analysis]
347 Relph KL, Harrington KJ, Pandha H. Adenoviral Strategies for the Gene Therapy of Cancer. Seminars in Oncology 2005;32:573-82. [DOI: 10.1053/j.seminoncol.2005.09.001] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 1.4] [Reference Citation Analysis]
348 Smith FM, Reynolds JV, Miller N, Stephens RB, Kennedy MJ. Pathological and molecular predictors of the response of rectal cancer to neoadjuvant radiochemotherapy. Eur J Surg Oncol. 2006;32:55-64. [PMID: 16324817 DOI: 10.1016/j.ejso.2005.09.010] [Cited by in Crossref: 93] [Cited by in F6Publishing: 87] [Article Influence: 5.5] [Reference Citation Analysis]
349 Ho C, Li G. Mutant p53 melanoma cell lines respond differently to CP-31398-induced apoptosis. Br J Dermatol 2005;153:900-10. [DOI: 10.1111/j.1365-2133.2005.06810.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
350 van de Vijver MJ. Biological variables and prognosis of DCIS. Breast 2005;14:509-19. [PMID: 16246564 DOI: 10.1016/j.breast.2005.08.027] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
351 Kohno K, Uchiumi T, Niina I, Wakasugi T, Igarashi T, Momii Y, Yoshida T, Matsuo K, Miyamoto N, Izumi H. Transcription factors and drug resistance. Eur J Cancer 2005;41:2577-86. [PMID: 16209921 DOI: 10.1016/j.ejca.2005.08.007] [Cited by in Crossref: 50] [Cited by in F6Publishing: 41] [Article Influence: 2.9] [Reference Citation Analysis]
352 Park J, Kim T. Release of Cytochrome c from Isolated Mitochondria by Etoposide. BMB Reports 2005;38:619-23. [DOI: 10.5483/bmbrep.2005.38.5.619] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
353 Robert J, Morvan VL, Smith D, Pourquier P, Bonnet J. Predicting drug response and toxicity based on gene polymorphisms. Crit Rev Oncol Hematol. 2005;54:171-196. [PMID: 15890268 DOI: 10.1016/j.critrevonc.2005.01.005] [Cited by in Crossref: 77] [Cited by in F6Publishing: 66] [Article Influence: 4.5] [Reference Citation Analysis]
354 Lopez-Crapez E, Bibeau F, Thézenas S, Ychou M, Simony-Lafontaine J, Thirion A, Azria D, Grenier J, Senesse P. p53 status and response to radiotherapy in rectal cancer: a prospective multilevel analysis. Br J Cancer. 2005;92:2114-2121. [PMID: 15956964 DOI: 10.1038/sj.bjc.6602622] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 1.3] [Reference Citation Analysis]
355 Miller LD, Smeds J, George J, Vega VB, Vergara L, Ploner A, Pawitan Y, Hall P, Klaar S, Liu ET, Bergh J. An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci U S A 2005;102:13550-5. [PMID: 16141321 DOI: 10.1073/pnas.0506230102] [Cited by in Crossref: 871] [Cited by in F6Publishing: 806] [Article Influence: 51.2] [Reference Citation Analysis]
356 Saffari B, Bernstein L, Hong D, Sullivan-halley J, Runnebaum I, Grill H, Jones L, El-naggar A, Press M. Association of p53 mutations and a codon 72 single nucleotide polymorphism with lower overall survival and responsiveness to adjuvant radiotherapy in endometrioid endometrial carcinomas. Int J Gynecol Cancer 2005;15:952-63. [DOI: 10.1111/j.1525-1438.2005.00159.x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 1.5] [Reference Citation Analysis]
357 Chi TY, Chen GG, Ho LK, Lai PB. Establishment of a doxycycline-regulated cell line with inducible, doubly-stable expression of the wild-type p53 gene from p53-deleted hepatocellular carcinoma cells. Cancer Cell Int 2005;5:27. [PMID: 16117829 DOI: 10.1186/1475-2867-5-27] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 0.5] [Reference Citation Analysis]
358 Yonesaka K, Tamura K, Kurata T, Satoh T, Ikeda M, Fukuoka M, Nakagawa K. Small interfering RNA targeting survivin sensitizes lung cancer cell with mutant p53 to adriamycin. Int J Cancer 2006;118:812-20. [DOI: 10.1002/ijc.21350] [Cited by in Crossref: 63] [Cited by in F6Publishing: 59] [Article Influence: 3.7] [Reference Citation Analysis]
359 Györffy B, Serra V, Jürchott K, Abdul-ghani R, Garber M, Stein U, Petersen I, Lage H, Dietel M, Schäfer R. Prediction of doxorubicin sensitivity in breast tumors based on gene expression profiles of drug-resistant cell lines correlates with patient survival. Oncogene 2005;24:7542-51. [DOI: 10.1038/sj.onc.1208908] [Cited by in Crossref: 51] [Cited by in F6Publishing: 44] [Article Influence: 3.0] [Reference Citation Analysis]
360 Okumura H, Natsugoe S, Matsumoto M, Yokomakura N, Uchikado Y, Takatori H, Ishigami S, Takao S, Aikou T. Predictive value of p53 and 14-3-3sigma for the effect of chemoradiation therapy on esophageal squamous cell carcinoma. J Surg Oncol 2005;91:84-9. [PMID: 15999354 DOI: 10.1002/jso.20279] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.6] [Reference Citation Analysis]
361 Zacal N, Espiritu M, Singh G, Rainbow AJ. Increased BNip3 and decreased mutant p53 in cisplatin-sensitive PDT-resistant HT29 cells. Biochem Biophys Res Commun. 2005;331:648-657. [PMID: 15850808 DOI: 10.1016/j.bbrc.2005.03.213] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
362 Bykov VJ, Issaeva N, Zache N, Shilov A, Hultcrantz M, Bergman J, Selivanova G, Wiman KG. Reactivation of mutant p53 and induction of apoptosis in human tumor cells by maleimide analogs. J Biol Chem 2005;280:30384-91. [PMID: 15998635 DOI: 10.1074/jbc.M501664200] [Cited by in Crossref: 148] [Cited by in F6Publishing: 76] [Article Influence: 8.7] [Reference Citation Analysis]
363 Guan YS, Liu Y, Sun L, Li X, He Q. Successful management of postoperative recurrence of hepatocellular carcinoma with p53 gene therapy combining transcatheter arterial chemoembolization. World J Gastroenterol 2005; 11(24): 3803-3805 [PMID: 15968745 DOI: 10.3748/wjg.v11.i24.3803] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 12] [Article Influence: 0.6] [Reference Citation Analysis]
364 Dimopoulos MA, Souliotis VL, Anagnostopoulos A, Papadimitriou C, Sfikakis PP. Extent of damage and repair in the p53 tumor-suppressor gene after treatment of myeloma patients with high-dose melphalan and autologous blood stem-cell transplantation is individualized and may predict clinical outcome. J Clin Oncol 2005;23:4381-9. [PMID: 15883412 DOI: 10.1200/JCO.2005.07.385] [Cited by in Crossref: 17] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
365 Serafin AM, Bohm L. Influence of p53 and bcl-2 on chemosensitivity in benign and malignant prostatic cell lines. Urol Oncol 2005;23:123-9. [PMID: 15869997 DOI: 10.1016/j.urolonc.2004.11.007] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
366 Guan YS, Liu Y, Zhou XP, Li X, He Q, Sun L. p53 gene (Gendicine) and embolisation overcame recurrent hepatocellular carcinoma. Gut 2005;54:1318-9. [PMID: 15879012 DOI: 10.1136/gut.2005.069237] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 0.8] [Reference Citation Analysis]
367 Chae H, Choi T, Kim B, Jung JH, Bang Y, Shin DY. Oocyte-based screening of cytokinesis inhibitors and identification of pectenotoxin-2 that induces Bim/Bax-mediated apoptosis in p53-deficient tumors. Oncogene 2005;24:4813-9. [DOI: 10.1038/sj.onc.1208640] [Cited by in Crossref: 46] [Cited by in F6Publishing: 39] [Article Influence: 2.7] [Reference Citation Analysis]
368 Barraud L, Merle P, Soma E, Lefrançois L, Guerret S, Chevallier M, Dubernet C, Couvreur P, Trépo C, Vitvitski L. Increase of doxorubicin sensitivity by doxorubicin-loading into nanoparticles for hepatocellular carcinoma cells in vitro and in vivo. Journal of Hepatology 2005;42:736-43. [DOI: 10.1016/j.jhep.2004.12.035] [Cited by in Crossref: 150] [Cited by in F6Publishing: 142] [Article Influence: 8.8] [Reference Citation Analysis]
369 Imai Y, Ohnishi K, Yasumoto J, Kajiwara A, Yamakawa N, Takahashi A, Ohnishi T, Kirita T. Glycerol enhances radiosensitivity in a human oral squamous cell carcinoma cell line (Ca9-22) bearing a mutant p53 gene via Bax-mediated induction of apoptosis. Oral Oncol 2005;41:631-6. [PMID: 15975526 DOI: 10.1016/j.oraloncology.2005.02.006] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.6] [Reference Citation Analysis]
370 Colozza M, Cardoso F, Sotiriou C, Larsimont D, Piccart MJ. Bringing Molecular Prognosis and Prediction to the Clinic. Clinical Breast Cancer 2005;6:61-76. [DOI: 10.3816/cbc.2005.n.010] [Cited by in Crossref: 25] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
371 Wunder JS, Gokgoz N, Parkes R, Bull SB, Eskandarian S, Davis AM, Beauchamp CP, Conrad EU, Grimer RJ, Healey JH, Malkin D, Mangham DC, Rock MJ, Bell RS, Andrulis IL. TP53 mutations and outcome in osteosarcoma: a prospective, multicenter study. J Clin Oncol 2005;23:1483-90. [PMID: 15735124 DOI: 10.1200/JCO.2005.04.074] [Cited by in Crossref: 94] [Cited by in F6Publishing: 39] [Article Influence: 5.5] [Reference Citation Analysis]
372 Okumura H, Natsugoe S, Matsumoto M, Mataki Y, Takatori H, Ishigami S, Takao S, Aikou T. The predictive value of p53, p53R2, and p21 for the effect of chemoradiation therapy on oesophageal squamous cell carcinoma. Br J Cancer 2005;92:284-9. [PMID: 15655547 DOI: 10.1038/sj.bjc.6602322] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 1.8] [Reference Citation Analysis]
373 Brown JM, Attardi LD. The role of apoptosis in cancer development and treatment response. Nat Rev Cancer 2005;5:231-7. [PMID: 15738985 DOI: 10.1038/nrc1560] [Cited by in Crossref: 577] [Cited by in F6Publishing: 553] [Article Influence: 33.9] [Reference Citation Analysis]
374 Danen-van Oorschot AA, Voskamp P, Seelen MC, van Miltenburg MH, Bolk MW, Tait SW, Boesen-de Cock JG, Rohn JL, Borst J, Noteborn MH. Human death effector domain-associated factor interacts with the viral apoptosis agonist Apoptin and exerts tumor-preferential cell killing. Cell Death Differ 2004;11:564-73. [PMID: 14765135 DOI: 10.1038/sj.cdd.4401391] [Cited by in Crossref: 61] [Cited by in F6Publishing: 57] [Article Influence: 3.6] [Reference Citation Analysis]
375 Freytag SO, Kim JH, Brown SL, Barton K, Lu M, Chung M. Gene therapy strategies to improve the effectiveness of cancer radiotherapy. Expert Opinion on Biological Therapy 2005;4:1757-70. [DOI: 10.1517/14712598.4.11.1757] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
376 Zabkiewicz J, Clarke AR. DNA damage-induced apoptosis: insights from the mouse. Biochim Biophys Acta 2004;1705:17-25. [PMID: 15585170 DOI: 10.1016/j.bbcan.2004.09.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 8] [Article Influence: 0.1] [Reference Citation Analysis]
377 Pucciarelli S, Toppan P, Friso ML, Russo V, Pasetto L, Urso E, Marino F, Ambrosi A, Lise M. Complete pathologic response following preoperative chemoradiation therapy for middle to lower rectal cancer is not a prognostic factor for a better outcome. Dis Colon Rectum. 2004;47:1798-1807. [PMID: 15622571 DOI: 10.1007/s10350-004-0681-1] [Cited by in Crossref: 114] [Cited by in F6Publishing: 108] [Article Influence: 6.7] [Reference Citation Analysis]
378 Chhieng DC, Frost AR, Niwas S, Weiss H, Grizzle WE, Beeken S. Intratumor heterogeneity of biomarker expression in breast carcinomas. Biotech Histochem 2004;79:25-36. [PMID: 15223751 DOI: 10.1080/10520290410001715237] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
379 Licitra L, Suardi S, Bossi P, Locati LD, Mariani L, Quattrone P, Lo Vullo S, Oggionni M, Olmi P, Cantù G, Pierotti MA, Pilotti S. Prediction of TP53 status for primary cisplatin, fluorouracil, and leucovorin chemotherapy in ethmoid sinus intestinal-type adenocarcinoma. J Clin Oncol 2004;22:4901-6. [PMID: 15611505 DOI: 10.1200/JCO.2004.05.071] [Cited by in Crossref: 69] [Cited by in F6Publishing: 19] [Article Influence: 4.1] [Reference Citation Analysis]
380 Thiery J, Abouzahr S, Dorothee G, Jalil A, Richon C, Vergnon I, Mami-chouaib F, Chouaib S. p53 Potentiation of Tumor Cell Susceptibility to CTL Involves Fas and Mitochondrial Pathways. J Immunol 2005;174:871-8. [DOI: 10.4049/jimmunol.174.2.871] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 1.2] [Reference Citation Analysis]
381 Krajinovic M, Moghrabi A. Pharmacogenetics of methotrexate. Pharmacogenomics 2004;5:819-34. [PMID: 15469405 DOI: 10.1517/14622416.5.7.819] [Cited by in Crossref: 54] [Cited by in F6Publishing: 50] [Article Influence: 3.0] [Reference Citation Analysis]
382 Fischer JR, Lahm H. Validation of molecular and immunological factors with predictive importance in lung cancer. Lung Cancer 2004;45 Suppl 2:S151-61. [PMID: 15552796 DOI: 10.1016/j.lungcan.2004.07.978] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 0.7] [Reference Citation Analysis]
383 Lara PN Jr, Gumerlock PH, Mack PC, Lau DH, Gandour-Edwards R, Edelman MJ, Albain KS, Law LY, Longmate J, Frankel P, Reddy GP, Israel V, Doroshow JH, Gandara DR. Gemcitabine in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: a phase II California cancer consortium trial. Clin Lung Cancer 2004;6:102-7. [PMID: 15476595 DOI: 10.3816/CLC.2004.n.023] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
384 Sejima T, Isoyama T, Miyagawa I. Comparative Study of Apoptotic Antitumor Effect between Angiogenesis Inhibitor AGM-1470 and MVAC Chemotherapy on Rat Urinary Bladder Cancer. Urol Int 2004;73:226-33. [DOI: 10.1159/000080832] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
385 Lindskog M, Spenger C, Jarvet J, Graslund A, Kogner P. Predicting Resistance or Response to Chemotherapy by Proton Magnetic Resonance Spectroscopy in Neuroblastoma. JNCI Journal of the National Cancer Institute 2004;96:1457-66. [DOI: 10.1093/jnci/djh273] [Cited by in Crossref: 32] [Cited by in F6Publishing: 24] [Article Influence: 1.8] [Reference Citation Analysis]
386 Gosslau A, Chen KY. Nutraceuticals, apoptosis, and disease prevention. Nutrition 2004;20:95-102. [PMID: 14698022 DOI: 10.1016/j.nut.2003.09.017] [Cited by in Crossref: 75] [Cited by in F6Publishing: 56] [Article Influence: 4.2] [Reference Citation Analysis]
387 Layfield LJ, Elsheikh TM, Fili A, Nayar R, Shidham V; Papanicolaou Society of Cytopathology. Review of the state of the art and recommendations of the Papanicolaou Society of Cytopathology for urinary cytology procedures and reporting : the Papanicolaou Society of Cytopathology Practice Guidelines Task Force. Diagn Cytopathol 2004;30:24-30. [PMID: 14696141 DOI: 10.1002/dc.10401] [Cited by in Crossref: 71] [Cited by in F6Publishing: 61] [Article Influence: 3.9] [Reference Citation Analysis]
388 Broll R, Busch P, Duchrow M, Oevermann E, Schwandner O, Farke S, Bruch HP, Windhövel U. Influence of thymidylate synthase and p53 protein expression on clinical outcome in patients with colorectal cancer. Int J Colorectal Dis 2005;20:94-102. [PMID: 15309465 DOI: 10.1007/s00384-004-0621-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
389 Komarova EA, Kondratov RV, Wang K, Christov K, Golovkina TV, Goldblum JR, Gudkov AV. Dual effect of p53 on radiation sensitivity in vivo: p53 promotes hematopoietic injury, but protects from gastro-intestinal syndrome in mice. Oncogene 2004;23:3265-71. [PMID: 15064735 DOI: 10.1038/sj.onc.1207494] [Cited by in Crossref: 164] [Cited by in F6Publishing: 152] [Article Influence: 9.1] [Reference Citation Analysis]
390 Kühnel F, Zender L, Wirth T, Schulte B, Trautwein C, Manns M, Kubicka S. Tumor-specific adenoviral gene therapy: transcriptional repression of gene expression by utilizing p53-signal transduction pathways. Cancer Gene Ther 2004;11:28-40. [PMID: 14681724 DOI: 10.1038/sj.cgt.7700632] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
391 Vassaux G, Martin-Duque P. Use of suicide genes for cancer gene therapy: study of the different approaches. Expert Opin Biol Ther. 2004;4:519-530. [PMID: 15102601 DOI: 10.1517/14712598.4.4.519] [Cited by in Crossref: 33] [Cited by in F6Publishing: 36] [Article Influence: 1.8] [Reference Citation Analysis]
392 Tang R, Wang JY, Fan CW, Tsao KC, Chen HH, Wu CM, Chen JS, Changchien CR, Hsieh LL. p53 is an independent pre-treatment markers for long-term survival in stage II and III colorectal cancers: an analysis of interaction between genetic markers and fluorouracil-based adjuvant therapy. Cancer Lett. 2004;210:101-109. [PMID: 15172127 DOI: 10.1016/j.canlet.2004.01.006] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 1.4] [Reference Citation Analysis]
393 Wang T, Chen F, Chen Z, Wu YF, Xu XL, Zheng S, Hu X. Honokiol induces apoptosis through p53-independent pathway in human colorectal cell line RKO. World J Gastroenterol 2004; 10(15): 2205-2208 [PMID: 15259066 DOI: 10.3748/wjg.v10.i15.2205] [Cited by in CrossRef: 94] [Cited by in F6Publishing: 76] [Article Influence: 5.2] [Reference Citation Analysis]
394 Di Leo A, Chan S, Paesmans M, Friedrichs K, Pinter T, Cocquyt V, Murray E, Bodrogi I, Walpole E, Lesperance B, Korec S, Crown J, Simmonds P, Von Minckwitz G, Leroy J, Durbecq V, Isola J, Aapro M, Piccart M, Larsimont D. HER-2/neu as a Predictive Marker in a Population of Advanced Breast Cancer Patients Randomly Treated Either with Single-agent Doxorubicin or Single-agent Docetaxel. Breast Cancer Res Treat 2004;86:197-206. [DOI: 10.1023/b:brea.0000036783.88387.47] [Cited by in Crossref: 45] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
395 Donnelly JG. Pharmacogenetics in cancer chemotherapy: balancing toxicity and response. Ther Drug Monit 2004;26:231-5. [PMID: 15228171 DOI: 10.1097/00007691-200404000-00026] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 1.8] [Reference Citation Analysis]
396 Mariggiò MA, Cafaggi S, Ottone M, Parodi B, Vannozzi MO, Mandys V, Viale M. Inhibition of cell growth, induction of apoptosis and mechanism of action of the novel platinum compound cis-diaminechloro-[2-(diethylamino) ethyl 4-amino-benzoate, N(4)]-chloride platinum (II) monohydrochloride monohydrate. Invest New Drugs. 2004;22:3-16. [PMID: 14707490 DOI: 10.1023/b:drug.0000006170.38419.c9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
397 Densmore CL. Polyethyleneimine-based gene therapy by inhalation. Expert Opin Biol Ther 2003;3:1083-92. [PMID: 14519073 DOI: 10.1517/14712598.3.7.1083] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 1.1] [Reference Citation Analysis]
398 Rutgers EJ, Meijnen P, Bonnefoi H; European Organization for Research and Treatment of Cancer Breast Cancer Group. Clinical trials update of the European Organization for Research and Treatment of Cancer Breast Cancer Group. Breast Cancer Res 2004;6:165-9. [PMID: 15217489 DOI: 10.1186/bcr906] [Cited by in Crossref: 58] [Cited by in F6Publishing: 47] [Article Influence: 3.2] [Reference Citation Analysis]
399 Wang S, Konorev EA, Kotamraju S, Joseph J, Kalivendi S, Kalyanaraman B. Doxorubicin Induces Apoptosis in Normal and Tumor Cells via Distinctly Different Mechanisms. Journal of Biological Chemistry 2004;279:25535-43. [DOI: 10.1074/jbc.m400944200] [Cited by in Crossref: 417] [Cited by in F6Publishing: 153] [Article Influence: 23.2] [Reference Citation Analysis]
400 Koike M, Fujita F, Komori K, Katoh F, Sugimoto T, Sakamoto Y, Matsuda M, Fujita M. Dependence of chemotherapy response on p53 mutation status in a panel of human cancer lines maintained in nude mice. Cancer Science 2004;95:541-6. [DOI: 10.1111/j.1349-7006.2004.tb03246.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
401 Liu H, Dibling B, Spike B, Dirlam A, Macleod K. New roles for the RB tumor suppressor protein. Curr Opin Genet Dev 2004;14:55-64. [PMID: 15108806 DOI: 10.1016/j.gde.2003.11.005] [Cited by in Crossref: 72] [Cited by in F6Publishing: 61] [Article Influence: 4.0] [Reference Citation Analysis]
402 Garcia del Muro X, Condom E, Vigués F, Castellsagué X, Figueras A, Muñoz J, Solá J, Soler T, Capellà G, Germà JR. p53 and p21 Expression levels predict organ preservation and survival in invasive bladder carcinoma treated with a combined-modality approach. Cancer 2004;100:1859-67. [PMID: 15112266 DOI: 10.1002/cncr.20200] [Cited by in Crossref: 51] [Cited by in F6Publishing: 43] [Article Influence: 2.8] [Reference Citation Analysis]
403 Tanno S, Yanagawa N, Habiro A, Koizumi K, Nakano Y, Osanai M, Mizukami Y, Okumura T, Testa JR, Kohgo Y. Serine/threonine kinase AKT is frequently activated in human bile duct cancer and is associated with increased radioresistance. Cancer Res 2004;64:3486-90. [PMID: 15150102 DOI: 10.1158/0008-5472.CAN-03-1788] [Cited by in Crossref: 77] [Cited by in F6Publishing: 39] [Article Influence: 4.3] [Reference Citation Analysis]
404 Tang HJ, Qian D, Sondak VK, Stachura S, Lin J. A modified p53 enhances apoptosis in sarcoma cell lines mediated by doxorubicin. Br J Cancer 2004;90:1285-92. [PMID: 15026814 DOI: 10.1038/sj.bjc.6601653] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
405 Wang Y, Yamaguchi Y, Watanabe H, Ohtsubo K, Motoo Y, Sawabu N. Detection of p53 gene mutations in the supernatant of pancreatic juice and plasma from patients with pancreatic carcinomas. Pancreas. 2004;28:13-19. [PMID: 14707724 DOI: 10.1097/00006676-200401000-00002] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 1.6] [Reference Citation Analysis]
406 Debatin K, Krammer PH. Death receptors in chemotherapy and cancer. Oncogene 2004;23:2950-66. [DOI: 10.1038/sj.onc.1207558] [Cited by in Crossref: 336] [Cited by in F6Publishing: 313] [Article Influence: 18.7] [Reference Citation Analysis]
407 Sullivan A, Syed N, Gasco M, Bergamaschi D, Trigiante G, Attard M, Hiller L, Farrell PJ, Smith P, Lu X, Crook T. Polymorphism in wild-type p53 modulates response to chemotherapy in vitro and in vivo. Oncogene 2004;23:3328-37. [DOI: 10.1038/sj.onc.1207428] [Cited by in Crossref: 174] [Cited by in F6Publishing: 162] [Article Influence: 9.7] [Reference Citation Analysis]
408 Fondevila C, Metges JP, Fuster J, Grau JJ, Palacín A, Castells A, Volant A, Pera M. p53 and VEGF expression are independent predictors of tumour recurrence and survival following curative resection of gastric cancer. Br J Cancer. 2004;90:206-215. [PMID: 14710231 DOI: 10.1038/sj.bjc.6601455] [Cited by in Crossref: 125] [Cited by in F6Publishing: 122] [Article Influence: 6.9] [Reference Citation Analysis]
409 Iwasa Y, Michor F, Nowak MA. Evolutionary dynamics of escape from biomedical intervention. Proc Biol Sci 2003;270:2573-8. [PMID: 14728779 DOI: 10.1098/rspb.2003.2539] [Cited by in Crossref: 69] [Cited by in F6Publishing: 53] [Article Influence: 3.8] [Reference Citation Analysis]
410 Al-Mohanna MA, Manogaran PS, Al-Mukhalafi Z, A Al-Hussein K, Aboussekhra A. The tumor suppressor p16(INK4a) gene is a regulator of apoptosis induced by ultraviolet light and cisplatin. Oncogene 2004;23:201-12. [PMID: 14712225 DOI: 10.1038/sj.onc.1206927] [Cited by in Crossref: 42] [Cited by in F6Publishing: 41] [Article Influence: 2.3] [Reference Citation Analysis]
411 Dicker AP, Williams TL, Iliakis G, Grant DS. Targeting angiogenic processes by combination low-dose paclitaxel and radiation therapy. Am J Clin Oncol 2003;26:e45-53. [PMID: 12796615 DOI: 10.1097/01.COC.0000072504.22544.3C] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
412 Ziyaie D, Hupp TR, Thompson AM. P53 and breast cancer. Breast 2000;9:239-46. [PMID: 14732173 DOI: 10.1054/brst.2000.0199] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
413 Baird RD, Kaye SB. Drug resistance reversal--are we getting closer? Eur J Cancer 2003;39:2450-61. [PMID: 14602131 DOI: 10.1016/s0959-8049(03)00619-1] [Cited by in Crossref: 90] [Cited by in F6Publishing: 27] [Article Influence: 5.0] [Reference Citation Analysis]
414 Watanabe T, Katayama Y, Komine C, Yoshino A, Ogino A, Ohta T, Fukushima T. O6-methylguanine-DNA methyltransferase methylation andTP53 mutation in malignant astrocytomas and their relationships with clinical course. Int J Cancer 2005;113:581-7. [DOI: 10.1002/ijc.20625] [Cited by in Crossref: 53] [Cited by in F6Publishing: 43] [Article Influence: 2.9] [Reference Citation Analysis]
415 Henning T, Kraus M, Brischwein M, Otto AM, Wolf B. Relevance of tumor microenvironment for progression, therapy and drug development: . Anti-Cancer Drugs 2004;15:7-14. [DOI: 10.1097/00001813-200401000-00002] [Cited by in Crossref: 45] [Cited by in F6Publishing: 38] [Article Influence: 2.5] [Reference Citation Analysis]
416 Haseba M, Hidaka S, Tsuji T, Yano H, Komatsu H, Sawai T, Yasutake T, Nakagoe T, Tagawa Y, Ayabe H. Detection of p53 gene mutations by nonisotopic RNase cleavage assay as a predictor of poor prognosis in colorectal cancers. Dig Dis Sci 2003;48:1984-9. [PMID: 14627345 DOI: 10.1023/a:1026126522278] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
417 Datta K, Mathur SG, Srivastava T, Shah P, Chattopadhyay P, Sinha S. Hydroxylamine potentiates the effect of low dose hydrogen peroxide in glioma cells independent of p53. The International Journal of Biochemistry & Cell Biology 2003;35:1639-44. [DOI: 10.1016/s1357-2725(03)00141-9] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
418 Bukholm IR, Husdal A, Nesland JM, Langerød A, Bukholm G. Overexpression of cyclin A overrides the effect of p53 alterations in breast cancer patients with long follow-up time. Breast Cancer Res Treat 2003;80:199-206. [PMID: 12908823 DOI: 10.1023/A:1024527220362] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
419 Seo Y, Shin JN, Ko KH, Cha JH, Park JY, Lee BR, Yun C, Kim YM, Seol D, Kim D, Yin X, Kim T. The Molecular Mechanism of Noxa-induced Mitochondrial Dysfunction in p53-Mediated Cell Death. Journal of Biological Chemistry 2003;278:48292-9. [DOI: 10.1074/jbc.m308785200] [Cited by in Crossref: 93] [Cited by in F6Publishing: 38] [Article Influence: 4.9] [Reference Citation Analysis]
420 Garg AK, Hortobagyi GN, Aggarwal BB, Sahin AA, Buchholz TA. Nuclear factor-κB as a predictor of treatment response in breast cancer: . Current Opinion in Oncology 2003;15:405-11. [DOI: 10.1097/00001622-200311000-00001] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 1.2] [Reference Citation Analysis]
421 Takeuchi K, Ito F. Suppression of adriamycin-induced apoptosis by sustained activation of the phosphatidylinositol-3’-OH kinase-Akt pathway. J Biol Chem. 2004;279:892-900. [PMID: 14570904 DOI: 10.1074/jbc.m306615200] [Cited by in Crossref: 25] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
422 Mullen JT, Tanabe KK. Viral oncolysis for malignant liver tumors. Ann Surg Oncol. 2003;10:596-605. [PMID: 12839843 DOI: 10.1245/aso.2003.07.020] [Cited by in Crossref: 15] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
423 Aubert M, Blaho JA. Viral oncoapoptosis of human tumor cells. Gene Ther 2003;10:1437-45. [PMID: 12900758 DOI: 10.1038/sj.gt.3302004] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 1.2] [Reference Citation Analysis]
424 Bergamaschi D, Gasco M, Hiller L, Sullivan A, Syed N, Trigiante G, Yulug I, Merlano M, Numico G, Comino A. p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis. Cancer Cell. 2003;3:387-402. [PMID: 12726864 DOI: 10.1016/s1535-6108(03)00079-5] [Cited by in Crossref: 298] [Cited by in F6Publishing: 118] [Article Influence: 15.7] [Reference Citation Analysis]
425 Yamazaki Y, Chiba I, Hirai A, Notani K, Kashiwazaki H, Tei K, Totsuka Y, Iizuka T, Kohgo T, Fukuda H. Radioresistance in Oral Squamous Cell Carcinoma With p 53 DNA Contact Mutation. American Journal of Clinical Oncology 2003;26:e124-9. [DOI: 10.1097/01.coc.0000091352.60347.f8] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
426 Tachibana M, Yoshimura H, Kinugasa S, Shibakita M, Dhar D, Ueda S, Fujii T, Nagasue N. Postoperative chemotherapy vs. chemoradiotherapy for thoracic esophageal cancer: a prospective randomized clinical trial. European Journal of Surgical Oncology (EJSO) 2003;29:580-7. [DOI: 10.1016/s0748-7983(03)00111-2] [Cited by in Crossref: 42] [Cited by in F6Publishing: 14] [Article Influence: 2.2] [Reference Citation Analysis]
427 Vermeulen K, Van Bockstaele DR, Berneman ZN. The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer. Cell Prolif 2003;36:131-49. [PMID: 12814430 DOI: 10.1046/j.1365-2184.2003.00266.x] [Cited by in Crossref: 977] [Cited by in F6Publishing: 895] [Article Influence: 51.4] [Reference Citation Analysis]
428 Di Leo A, Isola J. Topoisomerase IIα as a Marker Predicting the Efficacy of Anthracyclines in Breast Cancer: Are We at the End of the Beginning? Clinical Breast Cancer 2003;4:179-86. [DOI: 10.1016/s1526-8209(11)70623-1] [Cited by in Crossref: 3] [Article Influence: 0.2] [Reference Citation Analysis]
429 Sandberg AA, Bridge JA. Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors: osteosarcoma and related tumors. Cancer Genetics and Cytogenetics 2003;145:1-30. [DOI: 10.1016/s0165-4608(03)00105-5] [Cited by in Crossref: 176] [Article Influence: 9.3] [Reference Citation Analysis]
430 Chen GG, Merchant JL, Lai PB, Ho RL, Hu X, Okada M, Huang SF, Chui AK, Law DJ, Li YG. Mutation of p53 in recurrent hepatocellular carcinoma and its association with the expression of ZBP-89. Am J Pathol. 2003;162:1823-1829. [PMID: 12759240 DOI: 10.1016/s0002-9440(10)64317-9] [Cited by in Crossref: 31] [Cited by in F6Publishing: 20] [Article Influence: 1.6] [Reference Citation Analysis]
431 Thallinger C, Wolschek MF, Wacheck V, Maierhofer H, Günsberg P, Polterauer P, Pehamberger H, Monia BP, Selzer E, Wolff K, Jansen B. Mcl-1 antisense therapy chemosensitizes human melanoma in a SCID mouse xenotransplantation model. J Invest Dermatol 2003;120:1081-6. [PMID: 12787138 DOI: 10.1046/j.1523-1747.2003.12252.x] [Cited by in Crossref: 79] [Cited by in F6Publishing: 70] [Article Influence: 4.2] [Reference Citation Analysis]
432 Hostanska K, Vuong V, Rocha S, Soengas MS, Glanzmann C, Saller R, Bodis S, Pruschy M. Recombinant mistletoe lectin induces p53-independent apoptosis in tumour cells and cooperates with ionising radiation. Br J Cancer 2003;88:1785-92. [PMID: 12771996 DOI: 10.1038/sj.bjc.6600982] [Cited by in Crossref: 42] [Cited by in F6Publishing: 39] [Article Influence: 2.2] [Reference Citation Analysis]
433 Uramoto H, Izumi H, Nagatani G, Ohmori H, Nagasue N, Ise T, Yoshida T, Yasumoto K, Kohno K. Physical interaction of tumour suppressor p53/p73 with CCAAT-binding transcription factor 2 (CTF2) and differential regulation of human high-mobility group 1 (HMG1) gene expression. Biochem J 2003;371:301-10. [PMID: 12534345 DOI: 10.1042/BJ20021646] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 1.6] [Reference Citation Analysis]
434 Sheen IS, Jeng KS, Wu JY. Is p53 gene mutation an indicatior of the biological behaviors of recurrence of hepatocellular carcinoma? World J Gastroenterol 2003; 9(6): 1202-1207 [PMID: 12800224 DOI: 10.3748/wjg.v9.i6.1202] [Cited by in CrossRef: 20] [Cited by in F6Publishing: 24] [Article Influence: 1.1] [Reference Citation Analysis]
435 Cote RJ, Datar RH. Therapeutic approaches to bladder cancer: identifying targets and mechanisms. Critical Reviews in Oncology/Hematology 2003;46:67-83. [DOI: 10.1016/s1040-8428(03)00066-0] [Cited by in Crossref: 34] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
436 Danen-Van Oorschot AA, Zhang YH, Leliveld SR, Rohn JL, Seelen MC, Bolk MW, Van Zon A, Erkeland SJ, Abrahams JP, Mumberg D. Importance of nuclear localization of apoptin for tumor-specific induction of apoptosis. J Biol Chem. 2003;278:27729-27736. [PMID: 12754198 DOI: 10.1074/jbc.M303114200] [Cited by in Crossref: 100] [Cited by in F6Publishing: 49] [Article Influence: 5.3] [Reference Citation Analysis]
437 Schmitt CA. Senescence, apoptosis and therapy--cutting the lifelines of cancer. Nat Rev Cancer. 2003;3:286-295. [PMID: 12671667 DOI: 10.1038/nrc1044] [Cited by in Crossref: 200] [Cited by in F6Publishing: 181] [Article Influence: 10.5] [Reference Citation Analysis]
438 Schmidt M, Bachhuber A, Victor A, Steiner E, Mahlke M, Lehr HA, Pilch H, Weikel W, Knapstein PG. p53 expression and resistance against paclitaxel in patients with metastatic breast cancer. J Cancer Res Clin Oncol 2003;129:295-302. [DOI: 10.1007/s00432-003-0430-1] [Cited by in Crossref: 31] [Cited by in F6Publishing: 24] [Article Influence: 1.6] [Reference Citation Analysis]
439 Shimada K, Nakamura M, Ishida E, Kishi M, Yonehara S, Konishi N. c-Jun NH2-terminal kinase-dependent fas activation contributes to etoposide-induced apoptosis in p53-mutated prostate cancer cells. Prostate 2003;55:265-80. [DOI: 10.1002/pros.10227] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 1.5] [Reference Citation Analysis]
440 Itoh M, Noutomi T, Toyota H, Mizuguchi J. Etoposide-mediated sensitization of squamous cell carcinoma cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced loss in mitochondrial membrane potential. Oral Oncology 2003;39:269-76. [DOI: 10.1016/s1368-8375(02)00114-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
441 Tsuchiya Y, Onda M, Sasajima K, Yamashita K, Nomura T, Makino H, Maruyama H, Hagiwara N, Takubo K, Miyashita M. Effects of preoperative chemotherapy on metastatic lymph nodes in esophageal squamous cell carcinoma. Dis Esophagus 2002;15:226-31. [PMID: 12444995 DOI: 10.1046/j.1442-2050.2002.00260.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
442 Gunther EJ, Moody SE, Belka GK, Hahn KT, Innocent N, Dugan KD, Cardiff RD, Chodosh LA. Impact of p53 loss on reversal and recurrence of conditional Wnt-induced tumorigenesis. Genes Dev 2003;17:488-501. [PMID: 12600942 DOI: 10.1101/gad.1051603] [Cited by in Crossref: 147] [Cited by in F6Publishing: 137] [Article Influence: 7.7] [Reference Citation Analysis]
443 Gudkov AV, Komarova EA. The role of p53 in determining sensitivity to radiotherapy. Nat Rev Cancer 2003;3:117-29. [PMID: 12563311 DOI: 10.1038/nrc992] [Cited by in Crossref: 388] [Cited by in F6Publishing: 358] [Article Influence: 20.4] [Reference Citation Analysis]
444 Junker K, Müller K, Bosse U, Klinke F, Heinecke A, Thomas M. Apoptose und Tumorregression bei neoadjuvant behandelten lokal fortgeschrittenen nichtkleinzelligen Lungenkarzinomen. Pathologe 2003;24:214-9. [DOI: 10.1007/s00292-002-0607-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
445 Aas T, Geisler S, Eide G, Haugen D, Varhaug J, Bassøe A, Thorsen T, Berntsen H, Børresen-dale A, Akslen L, Lønning P. Predictive value of tumour cell proliferation in locally advanced breast cancer treated with neoadjuvant chemotherapy. European Journal of Cancer 2003;39:438-46. [DOI: 10.1016/s0959-8049(02)00732-3] [Cited by in Crossref: 35] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
446 Bonnefoi H, Diebold-berger S, Therasse P, Hamilton A, van de Vijver M, Macgrogan G, Shepherd L, Amaral N, Duval C, Drijkoningen R, Larsimont D, Piccart M. Locally advanced/inflammatory breast cancers treated with intensive epirubicin-based neoadjuvant chemotherapy: are there molecular markers in the primary tumour that predict for 5-year clinical outcome? Annals of Oncology 2003;14:406-13. [DOI: 10.1093/annonc/mdg108] [Cited by in Crossref: 49] [Cited by in F6Publishing: 43] [Article Influence: 2.6] [Reference Citation Analysis]
447 Parant JM, Lozano G. DisruptingTP53 in mouse models of human cancers. Hum Mutat 2003;21:321-6. [DOI: 10.1002/humu.10186] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 1.6] [Reference Citation Analysis]
448 Mendrysa SM, McElwee MK, Michalowski J, O'Leary KA, Young KM, Perry ME. mdm2 Is critical for inhibition of p53 during lymphopoiesis and the response to ionizing irradiation. Mol Cell Biol 2003;23:462-72. [PMID: 12509446 DOI: 10.1128/MCB.23.2.462-473.2003] [Cited by in Crossref: 159] [Cited by in F6Publishing: 98] [Article Influence: 8.4] [Reference Citation Analysis]
449 Villamarín S, Mansilla S, Ferrer-miralles N, Priebe W, Portugal J. A comparative analysis of the time-dependent antiproliferative effects of daunorubicin and WP631: Antiproliferative effects of daunorubicin and WP631. European Journal of Biochemistry 2003;270:764-70. [DOI: 10.1046/j.1432-1033.2003.03442.x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 1.1] [Reference Citation Analysis]
450 Dolivet G, Merlin JL, Barberi-Heyob M, Ramacci C, Erbacher P, Parache RM, Behr JP, Guillemin F. In vivo growth inhibitory effect of iterative wild-type p53 gene transfer in human head and neck carcinoma xenografts using glucosylated polyethylenimine nonviral vector. Cancer Gene Ther 2002;9:708-14. [PMID: 12136433 DOI: 10.1038/sj.cgt.7700485] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 1.5] [Reference Citation Analysis]
451 Leroy K, Haioun C, Lepage E, Le Métayer N, Berger F, Labouyrie E, Meignin V, Petit B, Bastard C, Salles G, Gisselbrecht C, Reyes F, Gaulard P; Groupe d'Etude des Lymphomes de l'Adulte. p53 gene mutations are associated with poor survival in low and low-intermediate risk diffuse large B-cell lymphomas. Ann Oncol 2002;13:1108-15. [PMID: 12176791 DOI: 10.1093/annonc/mdf185] [Cited by in Crossref: 67] [Cited by in F6Publishing: 60] [Article Influence: 3.5] [Reference Citation Analysis]
452 Heesters MA, Koudstaal J, Go KG, Molenaar WM. Proliferation and apoptosis in long-term surviving low grade gliomas in relation to radiotherapy. J Neurooncol 2002;58:157-65. [PMID: 12164688 DOI: 10.1023/a:1016046125698] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
453 Donahue JM, Mullen JT, Tanabe KK. Viral oncolysis. Surg Oncol Clin N Am 2002;11:661-80. [PMID: 12487061 DOI: 10.1016/s1055-3207(02)00025-x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
454 Casado S, Forteza J, Dominguez S, Abad MT, Perez I, Intxaurbe I, del Campo JM, Lopez R. Predictive Value of P53, BCL-2, and BAX in Advanced Head and Neck Carcinoma: . American Journal of Clinical Oncology 2002;25:588-90. [DOI: 10.1097/00000421-200212000-00012] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 0.8] [Reference Citation Analysis]
455 Galmarini CM, Voorzanger N, Falette N, Jordheim L, Cros E, Puisieux A, Dumontet C. Influence of p53 and p21WAF1 expression on sensitivity of cancer cells to cladribine. Biochemical Pharmacology 2003;65:121-9. [DOI: 10.1016/s0006-2952(02)01448-x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
456 Blumenthal RD, Leone E, Goldenberg DM, Rodriguez M, Modrak D. Anin vitro model to optimize dose scheduling of multimodal radioimmunotherapy and chemotherapy: Effects of p53 expression. Int J Cancer 2004;108:293-300. [DOI: 10.1002/ijc.11534] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
457 Wolff RA. Exploiting molecular targets in pancreatic cancer. Hematol Oncol Clin North Am 2002;16:139-57. [PMID: 12063824 DOI: 10.1016/s0889-8588(01)00012-0] [Cited by in Crossref: 9] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
458 Lai CM, Lai YKY, Rakoczy PE. Adenovirus and Adeno-Associated Virus Vectors. DNA and Cell Biology 2002;21:895-913. [DOI: 10.1089/104454902762053855] [Cited by in Crossref: 110] [Cited by in F6Publishing: 93] [Article Influence: 5.5] [Reference Citation Analysis]
459 Guzman ML, Swiderski CF, Howard DS, Grimes BA, Rossi RM, Szilvassy SJ, Jordan CT. Preferential induction of apoptosis for primary human leukemic stem cells. Proc Natl Acad Sci USA. 2002;99:16220-16225. [PMID: 12451177 DOI: 10.1073/pnas.252462599] [Cited by in Crossref: 309] [Cited by in F6Publishing: 281] [Article Influence: 15.5] [Reference Citation Analysis]
460 Sotto-mayor R. Biologia do cancro do pulmão: conceitos actuais. Revista Portuguesa de Pneumologia 2002;8:655-79. [DOI: 10.1016/s0873-2159(15)30798-4] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
461 Seger YR, Garcı́a-cao M, Piccinin S, Cunsolo CL, Doglioni C, Blasco MA, Hannon GJ, Maestro R. Transformation of normal human cells in the absence of telomerase activation. Cancer Cell 2002;2:401-13. [DOI: 10.1016/s1535-6108(02)00183-6] [Cited by in Crossref: 112] [Cited by in F6Publishing: 53] [Article Influence: 5.6] [Reference Citation Analysis]
462 Michel P, Magois K, Robert V, Chiron A, Lepessot F, Bodenant C, Roque I, Seng SK, Frebourg T, Paillot B. Prognostic value of TP53 transcriptional activity on p21 and bax in patients with esophageal squamous cell carcinomas treated by definitive chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2002;54:379-385. [PMID: 12243811 DOI: 10.1016/s0360-3016(02)02911-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
463 Ohnishi K, Ota I, Yane K, Takahashi A, Yuki K, Emoto M, Hosoi H, Ohnishi T. Glycerol as a chemical chaperone enhances radiation-induced apoptosis in anaplastic thyroid carcinoma cells. Mol Cancer 2002;1:4. [PMID: 12423550 DOI: 10.1186/1476-4598-1-4] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 0.7] [Reference Citation Analysis]
464 Homaidan FR, El-Sabban ME, Chakroun I, El-Sibai M, Dbaibo GS. IL-1 stimulates ceramide accumulation without inducing apoptosis in intestinal epithelial cells. Mediators Inflamm 2002;11:39-45. [PMID: 11926594 DOI: 10.1080/09629350210313] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 0.7] [Reference Citation Analysis]
465 Wang QF, Chen JC, Hsieh SJ, Cheng CC, Hsu SL. Regulation of Bcl-2 family molecules and activation of caspase cascade involved in gypenosides-induced apoptosis in human hepatoma cells. Cancer Lett. 2002;183:169-178. [PMID: 12065092 DOI: 10.1016/s0304-3835(01)00828-x] [Cited by in Crossref: 64] [Cited by in F6Publishing: 19] [Article Influence: 3.2] [Reference Citation Analysis]
466 Abbas T, Olivier M, Lopez J, Houser S, Xiao G, Kumar GS, Tomasz M, Bargonetti J. Differential activation of p53 by the various adducts of mitomycin C. J Biol Chem 2002;277:40513-9. [PMID: 12183457 DOI: 10.1074/jbc.M205495200] [Cited by in Crossref: 43] [Cited by in F6Publishing: 15] [Article Influence: 2.2] [Reference Citation Analysis]
467 Kitange GJ, Smith JS, Jenkins RB. Genetic alterations and chemotherapeutic response in human diffuse gliomas. Expert Rev Anticancer Ther. 2001;1:595-605. [PMID: 12113092 DOI: 10.1586/14737140.1.4.595] [Cited by in Crossref: 22] [Cited by in F6Publishing: 15] [Article Influence: 1.1] [Reference Citation Analysis]
468 Mullally JE, Fitzpatrick FA. Pharmacophore Model for Novel Inhibitors of Ubiquitin Isopeptidases That Induce p53-Independent Cell Death. Mol Pharmacol 2002;62:351-8. [DOI: 10.1124/mol.62.2.351] [Cited by in Crossref: 70] [Cited by in F6Publishing: 63] [Article Influence: 3.5] [Reference Citation Analysis]
469 Lan KH, Sheu ML, Hwang SJ, Yen SH, Chen SY, Wu JC, Wang YJ, Kato N, Omata M, Chang FY, Lee SD. HCV NS5A interacts with p53 and inhibits p53-mediated apoptosis. Oncogene. 2002;21:4801-4811. [PMID: 12101418 DOI: 10.1038/sj.onc.1205589] [Cited by in Crossref: 160] [Cited by in F6Publishing: 155] [Article Influence: 8.0] [Reference Citation Analysis]
470 Walker JV, Nitiss JL. DNA topoisomerase II as a target for cancer chemotherapy. Cancer Invest 2002;20:570-89. [PMID: 12094551 DOI: 10.1081/cnv-120002156] [Cited by in Crossref: 84] [Cited by in F6Publishing: 37] [Article Influence: 4.2] [Reference Citation Analysis]
471 Yang SE, Hsieh MT, Tsai TH, Hsu SL. Down-modulation of Bcl-XL, release of cytochrome c and sequential activation of caspases during honokiol-induced apoptosis in human squamous lung cancer CH27 cells. Biochem Pharmacol. 2002;63:1641-1651. [PMID: 12007567 DOI: 10.1016/s0006-2952(02)00894-8] [Cited by in Crossref: 105] [Cited by in F6Publishing: 26] [Article Influence: 5.3] [Reference Citation Analysis]
472 Liu MC, Gelmann EP. P53 gene mutations: case study of a clinical marker for solid tumors. Semin Oncol. 2002;29:246-257. [PMID: 12063677 DOI: 10.1053/sonc.2002.32900] [Cited by in Crossref: 55] [Cited by in F6Publishing: 42] [Article Influence: 2.8] [Reference Citation Analysis]
473 Condon LT, Ashman JN, Ell SR, Stafford ND, Greenman J, Cawkwell L. Overexpression of Bcl-2 in squamous cell carcinoma of the larynx: A marker of radioresistance. Int J Cancer 2002;100:472-5. [DOI: 10.1002/ijc.10503] [Cited by in Crossref: 51] [Cited by in F6Publishing: 42] [Article Influence: 2.6] [Reference Citation Analysis]
474 Fagard R, Mouas H, Dusanter-fourt I, Devillers C, Bissières P, Martin A, Lenoir G, Tan HV, Feuillard J, Raphaël M. Resistance to fludarabine-induced apoptosis in Epstein-Barr virus infected B cells. Oncogene 2002;21:4473-80. [DOI: 10.1038/sj.onc.1205554] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 0.7] [Reference Citation Analysis]
475 MacLachlan TK, El-Deiry WS. Apoptotic threshold is lowered by p53 transactivation of caspase-6. Proc Natl Acad Sci U S A 2002;99:9492-7. [PMID: 12089322 DOI: 10.1073/pnas.132241599] [Cited by in Crossref: 105] [Cited by in F6Publishing: 107] [Article Influence: 5.3] [Reference Citation Analysis]
476 Datta K, Babbar P, Srivastava T, Sinha S, Chattopadhyay P. p53 dependent apoptosis in glioma cell lines in response to hydrogen peroxide induced oxidative stress. Int J Biochem Cell Biol 2002;34:148-57. [PMID: 11809417 DOI: 10.1016/s1357-2725(01)00106-6] [Cited by in Crossref: 69] [Cited by in F6Publishing: 19] [Article Influence: 3.5] [Reference Citation Analysis]
477 Mabuchi S, Ohmichi M, Kimura A, Hisamoto K, Hayakawa J, Nishio Y, Adachi K, Takahashi K, Arimoto-Ishida E, Nakatsuji Y. Inhibition of phosphorylation of BAD and Raf-1 by Akt sensitizes human ovarian cancer cells to paclitaxel. J Biol Chem. 2002;277:33490-33500. [PMID: 12087097 DOI: 10.1074/jbc.m204042200] [Cited by in Crossref: 123] [Cited by in F6Publishing: 49] [Article Influence: 6.2] [Reference Citation Analysis]
478 Minter LM, Dickinson ES, Naber SP, Jerry DJ. Epithelial cell cycling predicts p53 responsiveness to γ-irradiation during post-natal mammary gland development. Development 2002;129:2997-3008. [DOI: 10.1242/dev.129.12.2997] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
479 Ma J, Murphy M, O'Dwyer PJ, Berman E, Reed K, Gallo JM. Biochemical changes associated with a multidrug-resistant phenotype of a human glioma cell line with temozolomide-acquired resistance. Biochem Pharmacol 2002;63:1219-28. [PMID: 11960598 DOI: 10.1016/s0006-2952(02)00876-6] [Cited by in Crossref: 40] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
480 Nakajima Y, Nakamura T, Enomoto T, Murata Y. Loss of one allele of the p53 gene in the lens epithelial tumor in transgenic mice suppresses apoptosis induced by a topoisomerase I inhibitor (CPT-11). Cancer Lett 2002;179:165-73. [PMID: 11888671 DOI: 10.1016/s0304-3835(02)00008-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
481 Mullen JT, Tanabe KK. Viral oncolysis. Oncologist. 2002;7:106-119. [PMID: 11961194 DOI: 10.1634/theoncologist.7-2-106] [Cited by in Crossref: 89] [Cited by in F6Publishing: 74] [Article Influence: 4.5] [Reference Citation Analysis]
482 Igney FH, Krammer PH. Death and anti-death: tumour resistance to apoptosis. Nat Rev Cancer. 2002;2:277-288. [PMID: 12001989 DOI: 10.1038/nrc776] [Cited by in Crossref: 1243] [Cited by in F6Publishing: 1151] [Article Influence: 62.2] [Reference Citation Analysis]
483 Cherbonnier C, Déas O, Vassal G, Merlin JL, Haeffner A, Senik A, Charpentier B, Dürrbach A, Bénard J, Hirsch F. Human growth hormone gene transfer into tumor cells may improve cancer chemotherapy. Cancer Gene Ther 2002;9:497-504. [DOI: 10.1038/sj.cgt.7700467] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
484 Rebischung C, Gérard J, Gayet J, Thomas G, Hamelin R, Laurent-puig P. Prognostic value of P53 mutations in rectal carcinoma: p53 and Rectal Carcinoma. Int J Cancer 2002;100:131-5. [DOI: 10.1002/ijc.10480] [Cited by in Crossref: 43] [Cited by in F6Publishing: 39] [Article Influence: 2.2] [Reference Citation Analysis]
485 Gautam A, Waldrep JC, Densmore CL, Koshkina N, Melton S, Roberts L, Gilbert B, Knight V. Growth inhibition of established B16-F10 lung metastases by sequential aerosol delivery of p53 gene and 9-nitrocamptothecin. Gene Ther 2002;9:353-7. [PMID: 11938455 DOI: 10.1038/sj.gt.3301662] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 1.5] [Reference Citation Analysis]
486 Violette S, Poulain L, Dussaulx E, Pepin D, Faussat AM, Chambaz J, Lacorte JM, Staedel C, Lesuffleur T. Resistance of colon cancer cells to long-term 5-fluorouracil exposure is correlated to the relative level of Bcl-2 and Bcl-X(L) in addition to Bax and p53 status. Int J Cancer. 2002;98:498-504. [PMID: 11920608 DOI: 10.1002/ijc.10146] [Cited by in Crossref: 144] [Cited by in F6Publishing: 136] [Article Influence: 7.2] [Reference Citation Analysis]
487 Kim ES, Kies M, Herbst RS. Novel therapeutics for head and neck cancer: . Current Opinion in Oncology 2002;14:334-42. [DOI: 10.1097/00001622-200205000-00014] [Cited by in Crossref: 43] [Cited by in F6Publishing: 33] [Article Influence: 2.2] [Reference Citation Analysis]
488 Tjebbes GW, Kreijveld PA, Tilanus MG, Hordijk GJ, Slootweg PJ. P53 tumor suppressor gene mutations in laryngeal cancer and in recurrent disease following radiation therapy. Oral Oncol 2002;38:296-300. [PMID: 11978553 DOI: 10.1016/s1368-8375(01)00059-8] [Cited by in Crossref: 7] [Article Influence: 0.4] [Reference Citation Analysis]
489 Kandioler D, Zwrtek R, Ludwig C, Janschek E, Ploner M, Hofbauer F, Kührer I, Kappel S, Wrba F, Horvath M, Karner J, Renner K, Bergmann M, Karner-Hanusch J, Pötter R, Jakesz R, Teleky B, Herbst F. TP53 genotype but not p53 immunohistochemical result predicts response to preoperative short-term radiotherapy in rectal cancer. Ann Surg 2002;235:493-8. [PMID: 11923604 DOI: 10.1097/00000658-200204000-00006] [Cited by in Crossref: 61] [Cited by in F6Publishing: 53] [Article Influence: 3.1] [Reference Citation Analysis]
490 Ohnishi T, Ohnishi K, Takahashi A. Glycerol restores heat-induced p53-dependent apoptosis of human glioblastoma cells bearing mutant p53. BMC Biotechnol. 2002;2:6. [PMID: 11965244 DOI: 10.1186/1472-6750-2-6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 0.5] [Reference Citation Analysis]
491 Vasey PA, Shulman LN, Campos S, Davis J, Gore M, Johnston S, Kirn DH, O'Neill V, Siddiqui N, Seiden MV, Kaye SB. Phase I trial of intraperitoneal injection of the E1B-55-kd-gene-deleted adenovirus ONYX-015 (dl1520) given on days 1 through 5 every 3 weeks in patients with recurrent/refractory epithelial ovarian cancer. J Clin Oncol 2002;20:1562-9. [PMID: 11896105 DOI: 10.1200/JCO.2002.20.6.1562] [Cited by in Crossref: 8] [Cited by in F6Publishing: 60] [Article Influence: 0.4] [Reference Citation Analysis]
492 Kuttler F, Valnet-rabier M, Angonin R, Ferrand C, Deconinck E, Mougin C, Cahn J, Fest T. Relationship between expression of genes involved in cell cycle control and apoptosis in diffuse large B cell lymphoma: a preferential survivin–cyclin B link. Leukemia 2002;16:726-35. [DOI: 10.1038/sj.leu.2402427] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 1.4] [Reference Citation Analysis]
493 Butler LM, Hewett PJ, Fitridge RA, Cowled PA. DEREGULATION OF APOPTOSIS IN COLORECTAL CARCINOMA: THEORETICAL AND THERAPEUTIC IMPLICATIONS. Aust N Z J Surg 2002;69:88-94. [DOI: 10.1046/j.1440-1622.1999.01498.x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 1.6] [Reference Citation Analysis]
494 Bykov VJ, Issaeva N, Shilov A, Hultcrantz M, Pugacheva E, Chumakov P, Bergman J, Wiman KG, Selivanova G. Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat Med. 2002;8:282-288. [PMID: 11875500 DOI: 10.1038/nm0302-282] [Cited by in Crossref: 660] [Cited by in F6Publishing: 623] [Article Influence: 33.0] [Reference Citation Analysis]
495 Vorburger SA, Hunt KK. Adenoviral gene therapy. Oncologist. 2002;7:46-59. [PMID: 11854546 DOI: 10.1634/theoncologist.7-1-46] [Cited by in Crossref: 127] [Cited by in F6Publishing: 116] [Article Influence: 6.4] [Reference Citation Analysis]
496 Bonnefoi H, Ducraux A, Movarekhi S, Pelte MF, Bongard S, Lurati E, Iggo R. p53 as a potential predictive factor of response to chemotherapy: feasibility of p53 assessment using a functional test in yeast from trucut biopsies in breast cancer patients. Br J Cancer. 2002;86:750-755. [PMID: 11875738 DOI: 10.1038/sj.bjc.6600105] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
497 Coe JP, Rahman I, Sphyris N, Clarke AR, Harrison DJ. Glutathione and p53 independently mediate responses against oxidative stress in ES cells. Free Radic Biol Med 2002;32:187-96. [PMID: 11796208 DOI: 10.1016/s0891-5849(01)00792-4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
498 De Siervi A, Vazquez ES, Rezaval C, Rossetti MV, del Batlle AM. Delta-aminolevulinic acid cytotoxic effects on human hepatocarcinoma cell lines. BMC Cancer 2002;2:6. [PMID: 11914144 DOI: 10.1186/1471-2407-2-6] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 0.7] [Reference Citation Analysis]
499 Kruczynski A, Etiévant C, Perrin D, Chansard N, Duflos A, Hill BT. Characterization of cell death induced by vinflunine, the most recent Vinca alkaloid in clinical development. Br J Cancer 2002;86:143-50. [PMID: 11857026 DOI: 10.1038/sj.bjc.6600025] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 1.1] [Reference Citation Analysis]
500 Couture C, Raybaud-Diogène H, Têtu B, Bairati I, Murry D, Allard J, Fortin A. p53 and Ki-67 as markers of radioresistance in head and neck carcinoma. Cancer 2002;94:713-22. [PMID: 11857304 DOI: 10.1002/cncr.10232] [Cited by in Crossref: 78] [Cited by in F6Publishing: 67] [Article Influence: 3.9] [Reference Citation Analysis]
501 Sun Y, Tan M, Duan H, Swaroop M. SAG/ROC/Rbx/Hrt, a zinc RING finger gene family: molecular cloning, biochemical properties, and biological functions. Antioxid Redox Signal. 2001;3:635-650. [PMID: 11554450 DOI: 10.1089/15230860152542989] [Cited by in Crossref: 66] [Cited by in F6Publishing: 67] [Article Influence: 3.3] [Reference Citation Analysis]
502 de Vries A, Flores ER, Miranda B, Hsieh HM, van Oostrom CT, Sage J, Jacks T. Targeted point mutations of p53 lead to dominant-negative inhibition of wild-type p53 function. Proc Natl Acad Sci U S A 2002;99:2948-53. [PMID: 11867759 DOI: 10.1073/pnas.052713099] [Cited by in Crossref: 130] [Cited by in F6Publishing: 125] [Article Influence: 6.5] [Reference Citation Analysis]
503 Wu GS, Ding Z. Caspase 9 is required for p53-dependent apoptosis and chemosensitivity in a human ovarian cancer cell line. Oncogene 2002;21:1-8. [PMID: 11791171 DOI: 10.1038/sj.onc.1205020] [Cited by in Crossref: 60] [Cited by in F6Publishing: 54] [Article Influence: 3.0] [Reference Citation Analysis]
504 El-Deiry WS. Insights into cancer therapeutic design based on p53 and TRAIL receptor signaling. Cell Death Differ. 2001;8:1066-1075. [PMID: 11687885 DOI: 10.1038/sj.cdd.4400943] [Cited by in Crossref: 93] [Cited by in F6Publishing: 83] [Article Influence: 4.7] [Reference Citation Analysis]
505 Liang JT, Huang KC, Cheng YM, Hsu HC, Cheng AL, Hsu CH, Yeh KH, Wang SM, Chang KJ. P53 overexpression predicts poor chemosensitivity to high-dose 5-fluorouracil plus leucovorin chemotherapy for stage IV colorectal cancers after palliative bowel resection. Int J Cancer. 2002;97:451-457. [PMID: 11802206 DOI: 10.1002/ijc.1637] [Cited by in Crossref: 47] [Cited by in F6Publishing: 41] [Article Influence: 2.4] [Reference Citation Analysis]
506 Hiroshi F, Kazuo K. Recent developments and future aspects of nuclear medicine in oncology. International Congress Series 2002;1228:107-16. [DOI: 10.1016/s0531-5131(01)00553-2] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
507 Gautam A, Densmore CL, Melton S, Golunski E, Waldrep JC. Aerosol delivery of PEI–p53 complexes inhibits B16-F10 lung metastases through regulation of angiogenesis. Cancer Gene Ther 2002;9:28-36. [DOI: 10.1038/sj.cgt.7700405] [Cited by in Crossref: 53] [Cited by in F6Publishing: 50] [Article Influence: 2.7] [Reference Citation Analysis]
508 Fisher GH, Wellen SL, Klimstra D, Lenczowski JM, Tichelaar JW, Lizak MJ, Whitsett JA, Koretsky A, Varmus HE. Induction and apoptotic regression of lung adenocarcinomas by regulation of a K-Ras transgene in the presence and absence of tumor suppressor genes. Genes Dev 2001;15:3249-62. [PMID: 11751631 DOI: 10.1101/gad.947701] [Cited by in Crossref: 443] [Cited by in F6Publishing: 384] [Article Influence: 22.2] [Reference Citation Analysis]
509 Sharp JG, Bishop MR, Copple B, Greiner TC, Iversen PL, Jackson JD, Joshi SS, Benner EJ, Mann SL, Rao AK, Vose JM. Oligonucleotide enhanced cytotoxicity of Idarubicin for lymphoma cells. Leuk Lymphoma 2001;42:417-27. [PMID: 11699407 DOI: 10.3109/10428190109064599] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
510 Galmarini CM, Clarke ML, Falette N, Puisieux A, Mackey JR, Dumontet C. Expression of a non-functional p53 affects the sensitivity of cancer cells to gemcitabine. Int J Cancer 2002;97:439-45. [DOI: 10.1002/ijc.1628] [Cited by in Crossref: 64] [Cited by in F6Publishing: 62] [Article Influence: 3.2] [Reference Citation Analysis]
511 Mahyar-Roemer M, Katsen A, Mestres P, Roemer K. Resveratrol induces colon tumor cell apoptosis independently of p53 and precede by epithelial differentiation, mitochondrial proliferation and membrane potential collapse. Int J Cancer. 2001;94:615-622. [PMID: 11745454 DOI: 10.1002/ijc.1516] [Cited by in Crossref: 115] [Cited by in F6Publishing: 100] [Article Influence: 5.8] [Reference Citation Analysis]
512 Sasaki R, Shirakawa T, Zhang ZJ, Tamekane A, Matsumoto A, Sugimura K, Matsuo M, Kamidono S, Gotoh A. Additional gene therapy with Ad5CMV-p53 enhanced the efficacy of radiotherapy in human prostate cancer cells. Int J Radiat Oncol Biol Phys 2001;51:1336-45. [PMID: 11728695 DOI: 10.1016/s0360-3016(01)01803-x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
513 Fijal BA, Idury RM, Witte JS. Analysis of mutational spectra: locating hotspots and clusters of mutations using recursive segmentation. Statist Med 2002;21:1867-85. [DOI: 10.1002/sim.1145] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
514 Ganguly T, Khar A. Induction of apoptosis in a human erythroleukemic cell line K562 by Tylophora alkaloids involves release of cytochrome c and activation of caspase 3. Phytomedicine 2002;9:288-95. [DOI: 10.1078/0944-7113-00146] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 1.5] [Reference Citation Analysis]
515 Arceci RJ. Can multidrug resistance mechanisms be modified?: Review. British Journal of Haematology 2000;110:285-91. [DOI: 10.1046/j.1365-2141.2000.02063.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 0.9] [Reference Citation Analysis]
516 Cadwell C, Zambetti GP. The effects of wild-type p53 tumor suppressor activity and mutant p53 gain-of-function on cell growth. Gene 2001;277:15-30. [PMID: 11602342 DOI: 10.1016/s0378-1119(01)00696-5] [Cited by in Crossref: 156] [Cited by in F6Publishing: 63] [Article Influence: 7.4] [Reference Citation Analysis]
517 Natsugoe S, Matsumoto M, Okumura H, Nakashima S, Sakamoto F, Sakita H, Baba M, Takao S, Aikou T. Bax and Bcl-X(L) expression are not related to prognosis in patients with advanced esophageal squamous cell carcinoma. Cancer Lett 2001;174:91-7. [PMID: 11675156 DOI: 10.1016/s0304-3835(01)00590-0] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
518 Wang XW. Microinjection technique used to study functional interaction between p53 and hepatitis B virus X gene in apoptosis. Mol Biotechnol. 2001;18:169-177. [PMID: 11471458 DOI: 10.1385/mb:18:2:169] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
519 Ball HM, Hupp TR, Ziyaie D, Purdie CA, Kernohan NM, Thompson AM. Differential p53 protein expression in breast cancer fine needle aspirates: the potential for in vivo monitoring. Br J Cancer 2001;85:1102-5. [PMID: 11710820 DOI: 10.1054/bjoc.2001.2064] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
520 Lee KH, Rudolph KL, Ju YJ, Greenberg RA, Cannizzaro L, Chin L, Weiler SR, DePinho RA. Telomere dysfunction alters the chemotherapeutic profile of transformed cells. Proc Natl Acad Sci USA. 2001;98:3381-3386. [PMID: 11248087 DOI: 10.1073/pnas.051629198] [Cited by in Crossref: 73] [Cited by in F6Publishing: 76] [Article Influence: 3.5] [Reference Citation Analysis]
521 Hwang PM, Bunz F, Yu J, Rago C, Chan TA, Murphy MP, Kelso GF, Smith RA, Kinzler KW, Vogelstein B. Ferredoxin reductase affects p53-dependent, 5-fluorouracil-induced apoptosis in colorectal cancer cells. Nat Med. 2001;7:1111-1117. [PMID: 11590433 DOI: 10.1038/nm1001-1111] [Cited by in Crossref: 282] [Cited by in F6Publishing: 271] [Article Influence: 13.4] [Reference Citation Analysis]
522 Galmarini CM, Falette N, Tabone E, Levrat C, Britten R, Voorzanger-Rousselot N, Roesch-Gateau O, Vanier-Viornery A, Puisieux A, Dumontet C. Inactivation of wild-type p53 by a dominant negative mutant renders MCF-7 cells resistant to tubulin-binding agent cytotoxicity. Br J Cancer 2001;85:902-8. [PMID: 11556844 DOI: 10.1054/bjoc.2001.2017] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 1.4] [Reference Citation Analysis]
523 Kim NK, Park JK, Lee KY, Yang WI, Yun SH, Sung J, Min JS. p53, BCL-2, and Ki-67 expression according to tumor response after concurrent chemoradiotherapy for advanced rectal cancer. Ann Surg Oncol 2001;8:418-24. [PMID: 11407516 DOI: 10.1007/s10434-001-0418-5] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 1.7] [Reference Citation Analysis]
524 Smith KJ, Williams J, Skelton H. Metastatic adenocarcinoma of the esophagus to the skin: new patterns of tumor recurrence and alternate treatments for palliation. J Cutan Pathol 2001;28:425-31. [PMID: 11493381 DOI: 10.1034/j.1600-0560.2001.028008425.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
525 Schmitt CA, Lowe SW. Bcl-2 mediates chemoresistance in matched pairs of primary E(mu)-myc lymphomas in vivo. Blood Cells Mol Dis 2001;27:206-16. [PMID: 11358381 DOI: 10.1006/bcmd.2000.0372] [Cited by in Crossref: 63] [Cited by in F6Publishing: 59] [Article Influence: 3.0] [Reference Citation Analysis]
526 Matsui Y, Tsuchida Y, Keng PC. Effects of p53 Mutations on Cellular Sensitivity to Ionizing Radiation: . American Journal of Clinical Oncology 2001;24:486-90. [DOI: 10.1097/00000421-200110000-00014] [Cited by in Crossref: 34] [Cited by in F6Publishing: 29] [Article Influence: 1.6] [Reference Citation Analysis]
527 Olivier M, Hainaut P. TP53 mutation patterns in breast cancers: searching for clues of environmental carcinogenesis. Seminars in Cancer Biology 2001;11:353-60. [DOI: 10.1006/scbi.2001.0390] [Cited by in Crossref: 36] [Cited by in F6Publishing: 29] [Article Influence: 1.7] [Reference Citation Analysis]
528 Matas D, Sigal A, Stambolsky P, Milyavsky M, Weisz L, Schwartz D, Goldfinger N, Rotter V. Integrity of the N-terminal transcription domain of p53 is required for mutant p53 interference with drug-induced apoptosis. EMBO J 2001;20:4163-72. [PMID: 11483519 DOI: 10.1093/emboj/20.15.4163] [Cited by in Crossref: 65] [Cited by in F6Publishing: 63] [Article Influence: 3.1] [Reference Citation Analysis]
529 Zhan M, Yu D, Lang A, Li L, Pollock RE. Wild typep53 sensitizes soft tissue sarcoma cells to doxorubicin by down-regulating multidrug resistance-1 expression. Cancer 2001;92:1556-66. [DOI: 10.1002/1097-0142(20010915)92:6<1556::aid-cncr1482>3.0.co;2-s] [Cited by in Crossref: 46] [Cited by in F6Publishing: 15] [Article Influence: 2.2] [Reference Citation Analysis]
530 Røtterud R, Berner A, Holm R, Skovlund E, Fosså SD. p53, p21 and mdm2 expression vs the response to radiotherapy in transitional cell carcinoma of the bladder. BJU Int. 2001;88:202-208. [PMID: 11488730 DOI: 10.1046/j.1464-410x.2001.02268.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.5] [Reference Citation Analysis]
531 Zhu J, Nozell S, Wang J, Jiang J, Zhou W, Chen X. p73 cooperates with DNA damage agents to induce apoptosis in MCF7 cells in a p53-dependent manner. Oncogene 2001;20:4050-7. [PMID: 11494133 DOI: 10.1038/sj.onc.1204516] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 1.5] [Reference Citation Analysis]
532 Laurent G, Jaffrézou J. Signaling pathways activated by daunorubicin. Blood 2001;98:913-24. [DOI: 10.1182/blood.v98.4.913] [Cited by in Crossref: 131] [Cited by in F6Publishing: 41] [Article Influence: 6.2] [Reference Citation Analysis]
533 Nomura M, Kaji A, Ma W, Miyamoto K, Dong Z. Suppression of cell transformation and induction of apoptosis by caffeic acid phenethyl ester. Mol Carcinog. 2001;31:83-89. [PMID: 11429785 DOI: 10.1002/mc.1043] [Cited by in Crossref: 61] [Cited by in F6Publishing: 51] [Article Influence: 2.9] [Reference Citation Analysis]
534 Huo TI, Wang XW, Forgues M, Wu CG, Spillare EA, Giannini C, Brechot C, Harris CC. Hepatitis B virus X mutants derived from human hepatocellular carcinoma retain the ability to abrogate p53-induced apoptosis. Oncogene. 2001;20:3620-3628. [PMID: 11439325 DOI: 10.1038/sj.onc.1204495] [Cited by in Crossref: 63] [Cited by in F6Publishing: 62] [Article Influence: 3.0] [Reference Citation Analysis]
535 Bredel M. Anticancer drug resistance in primary human brain tumors. Brain Res Brain Res Rev. 2001;35:161-204. [PMID: 11336781 DOI: 10.1016/S0165-0173(01)00045-5] [Cited by in Crossref: 100] [Cited by in F6Publishing: 32] [Article Influence: 4.8] [Reference Citation Analysis]
536 Bai L, Merchant JL. ZBP-89 promotes growth arrest through stabilization of p53. Mol Cell Biol 2001;21:4670-83. [PMID: 11416144 DOI: 10.1128/MCB.21.14.4670-4683.2001] [Cited by in Crossref: 72] [Cited by in F6Publishing: 37] [Article Influence: 3.4] [Reference Citation Analysis]
537 Shinoura N, Sakurai S, Asai A, Kirino T, Hamada H. Co-transduction of Apaf-1 and caspase-9 augments etoposide-induced apoptosis in U-373MG glioma cells. Jpn J Cancer Res 2001;92:467-74. [PMID: 11346470 DOI: 10.1111/j.1349-7006.2001.tb01117.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
538 Maurici D, Monti P, Campomenosi P, North S, Frebourg T, Fronza G, Hainaut P. Amifostine (WR2721) restores transcriptional activity of specific p53 mutant proteins in a yeast functional assay. Oncogene 2001;20:3533-40. [DOI: 10.1038/sj.onc.1204428] [Cited by in Crossref: 39] [Cited by in F6Publishing: 36] [Article Influence: 1.9] [Reference Citation Analysis]
539 Mahyar-roemer M, Roemer K. p21 Waf1/Cip1 can protect human colon carcinoma cells against p53-dependent and p53-independent apoptosis induced by natural chemopreventive and therapeutic agents. Oncogene 2001;20:3387-98. [DOI: 10.1038/sj.onc.1204440] [Cited by in Crossref: 117] [Cited by in F6Publishing: 110] [Article Influence: 5.6] [Reference Citation Analysis]
540 Tentori L, Portarena I, Bonmassar E, Graziani G. Combined effects of adenovirus-mediated wild-type p53 transduction, temozolomide and poly (ADP-ribose) polymerase inhibitor in mismatch repair deficient and non-proliferating tumor cells. Cell Death Differ 2001;8:457-69. [DOI: 10.1038/sj.cdd.4400832] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 1.0] [Reference Citation Analysis]
541 Sheridan MT, West CM. Ability to undergo apoptosis does not correlate with the intrinsic radiosensitivity (SF2) of human cervix tumor cell lines. Int J Radiat Oncol Biol Phys 2001;50:503-9. [PMID: 11380240 DOI: 10.1016/s0360-3016(01)01496-1] [Cited by in Crossref: 16] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
542 Hegde U, Wilson WH. Gene expression profiling of lymphomas. Curr Oncol Rep 2001;3:243-9. [DOI: 10.1007/s11912-001-0057-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
543 Giatromanolaki A, Stathopoulos GP, Koukourakis MI, Rigatos S, Vrettou E, Kittas C, Fountzilas G, Sivridis E. Angiogenesis and Apoptosis-Related Protein (p53, bcl-2, and bax) Expression Versus Response of Gastric Adenocarcinomas to Paclitaxel and Carboplatin Chemotherapy: . American Journal of Clinical Oncology 2001;24:222-6. [DOI: 10.1097/00000421-200106000-00002] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.4] [Reference Citation Analysis]
544 Sturm I, Petrowsky H, Volz R, Lorenz M, Radetzki S, Hillebrand T, Wolff G, Hauptmann S, Dörken B, Daniel PT. Analysis of p53/BAX/p16(ink4a/CDKN2) in esophageal squamous cell carcinoma: high BAX and p16(ink4a/CDKN2) identifies patients with good prognosis. J Clin Oncol 2001;19:2272-81. [PMID: 11304781 DOI: 10.1200/JCO.2001.19.8.2272] [Cited by in Crossref: 79] [Cited by in F6Publishing: 21] [Article Influence: 3.8] [Reference Citation Analysis]
545 Fallows S, Price J, Atkinson RJ, Johnston PG, Hickey I, Russell SE. P53 mutation does not affect prognosis in ovarian epithelial malignancies. J Pathol 2001;194:68-75. [PMID: 11329143 DOI: 10.1002/path.857] [Cited by in Crossref: 43] [Cited by in F6Publishing: 40] [Article Influence: 2.0] [Reference Citation Analysis]
546 Rosty C, Chazal M, Etienne MC, Letoublon C, Bourgeon A, Delpero JR, Pezet D, Beaune P, Laurent-Puig P, Milano G. Determination of microsatellite instability, p53 and K-RAS mutations in hepatic metastases from patients with colorectal cancer: relationship with response to 5-fluorouracil and survival. Int J Cancer 2001;95:162-7. [PMID: 11307149 DOI: 10.1002/1097-0215(20010520)95:3<162::aid-ijc1028>3.0.co;2-j] [Cited by in Crossref: 31] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
547 Al-Mohanna MA, Al-Khodairy FM, Krezolek Z, Bertilsson PA, Al-Houssein KA, Aboussekhra A. p53 is dispensable for UV-induced cell cycle arrest at late G(1) in mammalian cells. Carcinogenesis 2001;22:573-8. [PMID: 11285191 DOI: 10.1093/carcin/22.4.573] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 1.0] [Reference Citation Analysis]
548 Koukourakis MI, Giatromanolaki A, Kakolyris S, Sivridis E, Georgoulias V, Funtzilas G, Hickson ID, Gatter KC, Harris AL. Nuclear expression of human apurinic/apyrimidinic endonuclease (HAP1/Ref-1) in head-and-neck cancer is associated with resistance to chemoradiotherapy and poor outcome. International Journal of Radiation Oncology*Biology*Physics 2001;50:27-36. [DOI: 10.1016/s0360-3016(00)01561-3] [Cited by in Crossref: 74] [Cited by in F6Publishing: 43] [Article Influence: 3.5] [Reference Citation Analysis]
549 Alsner J, Sørensen SB, Overgaard J. TP53 mutation is related to poor prognosis after radiotherapy, but not surgery, in squamous cell carcinoma of the head and neck. Radiotherapy and Oncology 2001;59:179-85. [DOI: 10.1016/s0167-8140(01)00301-2] [Cited by in Crossref: 69] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
550 Slaton JW, Benedict WF, Dinney CP. p53 in bladder cancer: mechanism of action, prognostic value, and target for therapy. Urology 2001;57:852-9. [DOI: 10.1016/s0090-4295(01)00968-2] [Cited by in Crossref: 29] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
551 Catalano V, Baldelli AM, Giordani P, Cascinu S. Molecular markers predictive of response to chemotherapy in gastrointestinal tumors. Critical Reviews in Oncology/Hematology 2001;38:93-104. [DOI: 10.1016/s1040-8428(00)00114-1] [Cited by in Crossref: 13] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
552 Bleeker WA, Hayes VM, Karrenbeld A, Hofstra RM, Verlind E, Hermans J, Poppema S, Buys CH, Plukker JT. Prognostic significance of K-ras and TP53 mutations in the role of adjuvant chemotherapy on survival in patients with Dukes C colon cancer. Dis Colon Rectum 2001;44:358-63. [PMID: 11289281 DOI: 10.1007/BF02234733] [Cited by in Crossref: 19] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
553 Borst P, Borst J, Smets LA. Does resistance to apoptosis affect clinical response to antitumor drugs? Drug Resistance Updates 2001;4:129-31. [DOI: 10.1054/drup.2001.0187] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 1.5] [Reference Citation Analysis]
554 Schmitt CA, Lowe SW. Apoptosis is critical for drug response in vivo. Drug Resistance Updates 2001;4:132-4. [DOI: 10.1054/drup.2001.0188] [Cited by in Crossref: 54] [Cited by in F6Publishing: 47] [Article Influence: 2.6] [Reference Citation Analysis]
555 Bampoe J, Glen J, Hubbard SL, Salhia B, Shannon P, Rutka J, Bernstein M. Adenoviral vector-mediated gene transfer: timing of wild-type p53 gene expression in vivo and effect of tumor transduction on survival in a rat glioma brachytherapy model. J Neurooncol. 2000;49:27-39. [PMID: 11131984 DOI: 10.1023/A:1006476608036] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
556 Tanaka F, Otake Y, Yanagihara K, Yamada T, Miyahara R, Kawano Y, Li M, Inui K, Wada H. Apoptosis and p53 status predict the efficacy of postoperative administration of UFT in non-small cell lung cancer. Br J Cancer 2001;84:263-9. [PMID: 11161386 DOI: 10.1054/bjoc.2000.1579] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 1.0] [Reference Citation Analysis]
557 Ding H, Fisher DE. p53, Caspase 8, and Regulation of Apoptosis After Ionizing Radiation: . Journal of Pediatric Hematology/Oncology 2001;23:185-8. [DOI: 10.1097/00043426-200103000-00014] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 0.7] [Reference Citation Analysis]
558 Bras–gonçalves RA, Pocard M, Poirson–bichat F, de Pinieux G, Pandrea I, Arvelo F, Ronco G, Villa P, Coquelle A, Milano G, Dutrillaux B, Poupon M, Formento J, Lesuffleur T. Synergistic efficacy of 3n-butyrate and 5-fluorouracil in human colorectal cancer xenografts via modulation of DNA synthesis. Gastroenterology 2001;120:874-88. [DOI: 10.1053/gast.2001.22440] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 1.5] [Reference Citation Analysis]
559 Keshelava N, Zuo JJ, Waidyaratne NS, Triche TJ, Reynolds CP. p53 mutations and loss of p53 function confer multidrug resistance in neuroblastoma. Med Pediatr Oncol 2000;35:563-8. [PMID: 11107118 DOI: 10.1002/1096-911x(20001201)35:6<563::aid-mpo15>3.0.co;2-j] [Cited by in Crossref: 41] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
560 Edström S, Cvetkovska E, Westin T, Young C. Overexpression of p53-related proteins predicts rapid growth rate of head and neck cancer. Laryngoscope 2001;111:124-30. [PMID: 11192880 DOI: 10.1097/00005537-200101000-00022] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.4] [Reference Citation Analysis]
561 Pruschy M, Rocha S, Zaugg K, Tenzer A, Hess C, Fisher DE, Glanzmann C, Bodis S. Key targets for the execution of radiation-induced tumor cell apoptosis: the role of p53 and caspases. International Journal of Radiation Oncology*Biology*Physics 2001;49:561-7. [DOI: 10.1016/s0360-3016(00)01480-2] [Cited by in Crossref: 31] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
562 Safran H, Gaissert H, Akerman P, Hesketh PJ, Chen M, Moore T, Koness J, Graziano S, Wanebo HJ. Paclitaxel, Cisplatin, and Concurrent Radiation for Esophageal Cancer. Cancer Investigation 2001;19:1-7. [DOI: 10.1081/cnv-100000068] [Cited by in Crossref: 48] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
563 Pirollo KF, Bouker KB, Chang EH. Does p53 status influence tumor response to anticancer therapies? Anticancer Drugs 2000;11:419-32. [PMID: 11001382 DOI: 10.1097/00001813-200007000-00002] [Cited by in Crossref: 44] [Cited by in F6Publishing: 39] [Article Influence: 2.1] [Reference Citation Analysis]
564 Ding HF, Lin YL, McGill G, Juo P, Zhu H, Blenis J, Yuan J, Fisher DE. Essential role for caspase-8 in transcription-independent apoptosis triggered by p53. J Biol Chem 2000;275:38905-11. [PMID: 10988287 DOI: 10.1074/jbc.M004714200] [Cited by in Crossref: 96] [Cited by in F6Publishing: 24] [Article Influence: 4.6] [Reference Citation Analysis]
565 Koelbl O, Rosenwald A, Haberl M, Müller J, Reuther J, Flentje M. p53 and Ki-67 as predictive markers for radiosensitivity in squamous cell carcinoma of the oral cavity? an immunohistochemical and clinicopathologic study. International Journal of Radiation Oncology*Biology*Physics 2001;49:147-54. [DOI: 10.1016/s0360-3016(00)01356-0] [Cited by in Crossref: 22] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
566 Natsume T, Kobayashi M, Fujimoto S. Association of p53 gene mutations with sensitivity to TZT-1027 in patients with clinical lung and renal carcinoma. Cancer 2001;92:386-94. [DOI: 10.1002/1097-0142(20010715)92:2<386::aid-cncr1334>3.0.co;2-v] [Cited by in Crossref: 12] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
567 Shimada M, Kigawa J, Kanamori Y, Itamochi H, Takahashi M, Kamazawa S, Sato S, Terakawa N. Mechanism of the combination effect of wild-type TP53 gene transfection and cisplatin treatment for ovarian cancer xenografts. Eur J Cancer 2000;36:1869-75. [PMID: 10974636 DOI: 10.1016/s0959-8049(00)00161-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
568 Ding BC, Whetstine JR, Witt TL, Schuetz JD, Matherly LH. Repression of human reduced folate carrier gene expression by wild type p53. J Biol Chem 2001;276:8713-9. [PMID: 11106643 DOI: 10.1074/jbc.M005248200] [Cited by in Crossref: 20] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
569 Svingen PA, Karp JE, Krajewski S, Mesner PW, Gore SD, Burke PJ, Reed JC, Lazebnik YA, Kaufmann SH. Evaluation of Apaf-1 and procaspases-2, -3, -7, -8, and -9 as potential prognostic markers in acute leukemia. Blood 2000;96:3922-31. [DOI: 10.1182/blood.v96.12.3922] [Cited by in Crossref: 37] [Article Influence: 1.7] [Reference Citation Analysis]
570 Svingen PA, Karp JE, Krajewski S, Mesner PW, Gore SD, Burke PJ, Reed JC, Lazebnik YA, Kaufmann SH. Evaluation of Apaf-1 and procaspases-2, -3, -7, -8, and -9 as potential prognostic markers in acute leukemia. Blood 2000;96:3922-31. [DOI: 10.1182/blood.v96.12.3922.h8003922_3922_3931] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
571 Ries SJ, Brandts CH, Chung AS, Biederer CH, Hann BC, Lipner EM, McCormick F, Korn WM. Loss of p14ARF in tumor cells facilitates replication of the adenovirus mutant dl1520 (ONYX-015). Nat Med 2000;6:1128-33. [PMID: 11017144 DOI: 10.1038/80466] [Cited by in Crossref: 133] [Cited by in F6Publishing: 124] [Article Influence: 6.0] [Reference Citation Analysis]
572 Elsaleh H, Robbins P, Joseph D, Powell B, Grieu F, Menso L, Iacopetta B. Can p53 alterations be used to predict tumour response to pre-operative chemo-radiotherapy in locally advanced rectal cancer? Radiother Oncol. 2000;56:239-244. [PMID: 10927144 DOI: 10.1016/s0167-8140(00)00184-5] [Cited by in Crossref: 27] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
573 Grabenbauer GG, Mühlfriedel C, Rödel F, Niedobitek G, Hornung J, Rödel C, Martus P, Iro H, Kirchner T, Steininger H, Sauer R, Weidenbecher M, Distel L. Squamous cell carcinoma of the oropharynx: Ki-67 and p53 can identify patients at high risk for local recurrence after surgery and postoperative radiotherapy. International Journal of Radiation Oncology*Biology*Physics 2000;48:1041-50. [DOI: 10.1016/s0360-3016(00)00737-9] [Cited by in Crossref: 32] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
574 Okumura H, Natsugoe S, Nakashima S, Matsumoto M, Sakita H, Nakano S, Kusano C, Baba M, Takao S, Furukawa T. Apoptosis and cell proliferation in esophageal sqamous cell carcinoma treated by chemotherapy. Cancer Lett. 2000;158:211-216. [PMID: 10960772 DOI: 10.1016/s0304-3835(00)00526-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
575 Shahin MS, Hughes JH, Sood AK, Buller RE. The prognostic significance of p53 tumor suppressor gene alterations in ovarian carcinoma: p53 Alterations and Ovarian Carcinoma Prognosis. Cancer 2000;89:2006-17. [DOI: 10.1002/1097-0142(20001101)89:9<2006::aid-cncr18>3.0.co;2-7] [Cited by in Crossref: 9] [Article Influence: 0.4] [Reference Citation Analysis]
576 Solary E, Droin N, Bettaieb A, Corcos L, Dimanche-boitrel M, Garrido C. Positive and negative regulation of apoptotic pathways by cytotoxic agents in hematological malignancies. Leukemia 2000;14:1833-49. [DOI: 10.1038/sj.leu.2401902] [Cited by in Crossref: 92] [Cited by in F6Publishing: 86] [Article Influence: 4.2] [Reference Citation Analysis]
577 Ferrero JM, Ramaioli A, Formento JL, Francoual M, Etienne MC, Peyrottes I, Ettore F, Leblanc-Talent P, Namer M, Milano G. p53 determination alongside classical prognostic factors in node-negative breast cancer: an evaluation at more than 10-year follow-up. Ann Oncol. 2000;11:393-397. [PMID: 10847456 DOI: 10.1023/a:1008359722254] [Cited by in Crossref: 21] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
578 Huang L, Pardee AB. Suberoylanilide Hydroxamic Acid as a Potential Therapeutic Agent for Human Breast Cancer Treatment. Mol Med 2000;6:849-66. [DOI: 10.1007/bf03401823] [Cited by in Crossref: 110] [Article Influence: 5.0] [Reference Citation Analysis]
579 Zeimet AG, Riha K, Berger J, Widschwendter M, Hermann M, Daxenbichler G, Marth C. New insights into p53 regulation and gene therapy for cancer. Biochemical Pharmacology 2000;60:1153-63. [DOI: 10.1016/s0006-2952(00)00442-1] [Cited by in Crossref: 22] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
580 Chang EH, Pirollo KF, Bouker KB. Tp53 gene therapy: a key to modulating resistance to anticancer therapies? Molecular Medicine Today 2000;6:358-65. [DOI: 10.1016/s1357-4310(00)01767-6] [Cited by in Crossref: 14] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
581 Sundaram S, Chaudhry M, Reardon D, Gupta M, Gewirtz D. The vitamin D3 analog EB 1089 enhances the antiproliferative and apoptotic effects of adriamycin in MCF-7 breast tumor cells. Breast Cancer Res Treat 2000;63:1-10. [DOI: 10.1023/a:1006420708806] [Cited by in Crossref: 44] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
582 Shimoji H, Miyazato H, Nakachi A, Kuniyoshi S, Isa T, Shiraishi M, Muto Y, Toda T. Expression of p53, bcl-2, and bax as predictors of response to radiotherapy in esophageal cancer. Dis Esophagus 2000;13:185-90. [DOI: 10.1046/j.1442-2050.2000.00097.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.4] [Reference Citation Analysis]
583 Szumilo J, Chibowski D, Dabrowski A. Assessment of the predictive value of clinical and histopathological factors as well as the immunoexpression of p53 and bcl-2 proteins in response to preoperative chemotherapy for esophageal squamous cell carcinoma. Dis Esophagus 2000;13:191-7. [DOI: 10.1046/j.1442-2050.2000.00110.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.3] [Reference Citation Analysis]
584 Steinwaerder DS, Carlson CA, Lieber A. DNA Replication of First-Generation Adenovirus Vectors in Tumor Cells. Human Gene Therapy 2000;11:1933-48. [DOI: 10.1089/10430340050129549] [Cited by in Crossref: 55] [Cited by in F6Publishing: 45] [Article Influence: 2.5] [Reference Citation Analysis]
585 Khuri FR, Nemunaitis J, Ganly I, Arseneau J, Tannock IF, Romel L, Gore M, Ironside J, MacDougall RH, Heise C. a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med. 2000;6:879-885. [PMID: 10932224 DOI: 10.1038/78638] [Cited by in Crossref: 771] [Cited by in F6Publishing: 664] [Article Influence: 35.0] [Reference Citation Analysis]
586 Metcalfe S, Wheeler TK, Picken S, Negus S, Jo Milner A. P53 autoantibodies in 1006 patients followed up for breast cancer. Breast Cancer Res 2000;2:438-43. [PMID: 11056691 DOI: 10.1186/bcr91] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 1.2] [Reference Citation Analysis]
587 King TC, Akerley W, Fan AC, Moore T, Mangray S, Hsiu Chen M, Safran H. p53 mutations do not predict response to paclitaxel in metastatic nonsmall cell lung carcinoma. Cancer 2000;89:769-73. [DOI: 10.1002/1097-0142(20000815)89:4<769::aid-cncr8>3.0.co;2-6] [Cited by in Crossref: 23] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
588 de Alava E, Antonescu CR, Panizo A, Leung D, Meyers PA, Huvos AG, Pardo-mind�n FJ, Healey JH, Ladanyi M. Prognostic impact of P53 status in Ewing sarcoma. Cancer 2000;89:783-92. [DOI: 10.1002/1097-0142(20000815)89:4<783::aid-cncr10>3.0.co;2-q] [Cited by in Crossref: 103] [Article Influence: 4.7] [Reference Citation Analysis]
589 Li PX, Wong J, Ayed A, Ngo D, Brade AM, Arrowsmith C, Austin RC, Klamut HJ. Placental transforming growth factor-beta is a downstream mediator of the growth arrest and apoptotic response of tumor cells to DNA damage and p53 overexpression. J Biol Chem. 2000;275:20127-20135. [PMID: 10777512 DOI: 10.1074/jbc.m909580199] [Cited by in Crossref: 193] [Cited by in F6Publishing: 71] [Article Influence: 8.8] [Reference Citation Analysis]
590 Gewirtz DA. Growth arrest and cell death in the breast tumor cell in response to ionizing radiation and chemotherapeutic agents which induce DNA damage. Breast Cancer Res Treat 2000;62:223-35. [DOI: 10.1023/a:1006414422919] [Cited by in Crossref: 51] [Cited by in F6Publishing: 20] [Article Influence: 2.3] [Reference Citation Analysis]
591 Jahnson S, Karlsson MG. Tumor mapping of regional immunostaining for p21, p53, and mdm2 in locally advanced bladder carcinoma. Cancer 2000;89:619-29. [DOI: 10.1002/1097-0142(20000801)89:3<619::aid-cncr18>3.0.co;2-4] [Cited by in Crossref: 14] [Article Influence: 0.6] [Reference Citation Analysis]
592 Petrasch S, Reinacher-schick A, Busemann B, Radtke J, Philippou S, Dörr T, Kemmeries G, Eufinger H, Schmiegel W. Neoadjuvant, hyperfractionated irradiation induces apoptosis and decreases proliferation in squamous cell cancer of the oral cavity. International Journal of Oral and Maxillofacial Surgery 2000;29:285-9. [DOI: 10.1016/s0901-5027(00)80030-2] [Cited by in Crossref: 4] [Article Influence: 0.2] [Reference Citation Analysis]
593 Uchida D, Kawamata H, Omotehara F, Miwa Y, Hino S, Begum NM, Yoshida H, Sato M. Over-expression of TSC-22 (TGF-beta stimulated clone-22) markedly enhances 5-fluorouracil-induced apoptosis in a human salivary gland cancer cell line. Lab Invest 2000;80:955-63. [PMID: 10879745 DOI: 10.1038/labinvest.3780098] [Cited by in Crossref: 32] [Cited by in F6Publishing: 34] [Article Influence: 1.5] [Reference Citation Analysis]
594 Wunder JS, Bull SB, Aneliunas V, Lee PD, Davis AM, Beauchamp CP, Conrad EU, Grimer RJ, Healey JH, Rock MJ, Bell RS, Andrulis IL. MDR1 Gene Expression and Outcome in Osteosarcoma: A Prospective, Multicenter Study. JCO 2000;18:2685-94. [DOI: 10.1200/jco.2000.18.14.2685] [Cited by in Crossref: 63] [Cited by in F6Publishing: 11] [Article Influence: 2.9] [Reference Citation Analysis]
595 Shadan F, Villarreal L. Parvovirus-mediated antineoplastic activity exploits genome instability. Medical Hypotheses 2000;55:1-4. [DOI: 10.1054/mehy.1999.0887] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
596 Giannakakou P, Poy G, Zhan Z, Knutsen T, Blagosklonny MV, Fojo T. Paclitaxel selects for mutant or pseudo-null p53 in drug resistance associated with tubulin mutations in human cancer. Oncogene 2000;19:3078-85. [DOI: 10.1038/sj.onc.1203642] [Cited by in Crossref: 45] [Cited by in F6Publishing: 42] [Article Influence: 2.0] [Reference Citation Analysis]
597 Sato N, Mizumoto K, Kusumoto M, Nishio S, Maehara N, Urashima T, Ogawa T, Tanaka M. Up-regulation of telomerase activity in human pancreatic cancer cells after exposure to etoposide. Br J Cancer 2000;82:1819-26. [PMID: 10839297 DOI: 10.1054/bjoc.2000.1117] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 1.3] [Reference Citation Analysis]
598 Tokunaga E, Maehara Y, Oki E, Kitamura K, Kakeji Y, Ohno S, Sugimachi K. Diminished expression of ING1 mRNA and the correlation with p53 expression in breast cancers. Cancer Lett. 2000;152:15-22. [PMID: 10754201 DOI: 10.1016/s0304-3835(99)00434-6] [Cited by in Crossref: 37] [Cited by in F6Publishing: 15] [Article Influence: 1.7] [Reference Citation Analysis]
599 Pradheepkumar CP, Panneerselvam N, Shanmugam G. Cleistanthin A causes DNA strand breaks and induces apoptosis in cultured cells. Mutat Res 2000;464:185-93. [PMID: 10648905 DOI: 10.1016/s1383-5718(99)00179-5] [Cited by in Crossref: 18] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
600 Chang BD, Watanabe K, Broude EV, Fang J, Poole JC, Kalinichenko TV, Roninson IB. Effects of p21Waf1/Cip1/Sdi1 on cellular gene expression: implications for carcinogenesis, senescence, and age-related diseases. Proc Natl Acad Sci U S A 2000;97:4291-6. [PMID: 10760295 DOI: 10.1073/pnas.97.8.4291] [Cited by in Crossref: 294] [Cited by in F6Publishing: 278] [Article Influence: 13.4] [Reference Citation Analysis]
601 Ramirez CD, Sleiman RJ, Catchpoole DR, Stewart BW. Morphological and molecular evidence of differentiation during etoposide-induced apoptosis in human lymphoblastoid cells. Cell Death Differ 2000;7:548-55. [DOI: 10.1038/sj.cdd.4400686] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
602 Zellars R, Hilsenbeck S, Clark G, Allred D, Herman T, Chamness G, Elledge R. Prognostic Value of p53 for Local Failure in Mastectomy-Treated Breast Cancer Patients. JCO 2000;18:1906-13. [DOI: 10.1200/jco.2000.18.9.1906] [Cited by in Crossref: 44] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
603 Qiu H, Sirivongs P, Rothenberger M, Rothenberger DA, Garciá-Aguilar J. Molecular prognostic factors in rectal cancer treated by radiation and surgery. Dis Colon Rectum. 2000;43:451-459. [PMID: 10789738 DOI: 10.1007/bf02237186] [Cited by in Crossref: 54] [Cited by in F6Publishing: 16] [Article Influence: 2.5] [Reference Citation Analysis]
604 Yang X, Hao Y, Ding Z, Pater A. BAG-1 Promotes Apoptosis Induced by N-(4-hydroxyphenyl)retinamide in Human Cervical Carcinoma Cells. Experimental Cell Research 2000;256:491-9. [DOI: 10.1006/excr.2000.4829] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 1.0] [Reference Citation Analysis]
605 Thor AD, Liu S, Moore Ii DH, Shi Q, Edgerton SM. p21WAF1/CIP1 Expression in breast cancers: associations with p53 and outcome. Breast Cancer Res Treat 2000;61:33-43. [DOI: 10.1023/a:1006455526894] [Cited by in Crossref: 19] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
606 Burchardt M, Burchardt T, Shabsigh A, De La Taille A, Benson MC, Sawczuk I. Current Concepts in Biomarker Technology for Bladder Cancers. Clinical Chemistry 2000;46:595-605. [DOI: 10.1093/clinchem/46.5.595] [Cited by in Crossref: 64] [Cited by in F6Publishing: 43] [Article Influence: 2.9] [Reference Citation Analysis]
607 Koukourakis MI, Giatromanolaki A, Kalokyris S, Froudarakis M, Georgoulias V, Retalis G, Bahlitzanakis N. Phase I/II dose escalation study of docetaxel and carboplatin combination supported with amifostine and GM-CSF in patients with incomplete response following docetaxel chemo-radiotherapy: additional chemotherapy enhances regression of residual cancer. Med Oncol 2000;17:135-43. [DOI: 10.1007/bf02796209] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
608 El-Mahdy MA, Hamada FM, Wani MA, Zhu Q, Wani AA. p53-degradation by HPV-16 E6 preferentially affects the removal of cyclobutane pyrimidine dimers from non-transcribed strand and sensitizes mammary epithelial cells to UV-irradiation. Mutat Res 2000;459:135-45. [PMID: 10725664 DOI: 10.1016/s0921-8777(99)00066-x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
609 Lowe SW, Lin AW. Apoptosis in cancer. Carcinogenesis. 2000;21:485-495. [PMID: 10688869 DOI: 10.1093/carcin/21.3.485] [Cited by in Crossref: 1180] [Cited by in F6Publishing: 1065] [Article Influence: 53.6] [Reference Citation Analysis]
610 Kano Y, Akutsu M, Tsunoda S, Suzuki K, Ichikawa A, Furukawa Y, Bai L, Kon K. In vitro cytotoxic effects of fludarabine (2-F-ara-A) in combination with commonly used antileukemic agents by isobologram analysis. Leukemia 2000;14:379-88. [PMID: 10720130 DOI: 10.1038/sj.leu.2401684] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 1.0] [Reference Citation Analysis]
611 Cabelguenne A, Blons H, de Waziers I, Carnot F, Houllier A, Soussi T, Brasnu D, Beaune P, Laccourreye O, Laurent-puig P. p53 Alterations Predict Tumor Response to Neoadjuvant Chemotherapy in Head and Neck Squamous Cell Carcinoma: A Prospective Series. JCO 2000;18:1465-73. [DOI: 10.1200/jco.2000.18.7.1465] [Cited by in Crossref: 130] [Cited by in F6Publishing: 32] [Article Influence: 5.9] [Reference Citation Analysis]
612 Bras-Gonçalves RA, Rosty C, Laurent-Puig P, Soulié P, Dutrillaux B, Poupon MF. Sensitivity to CPT-11 of xenografted human colorectal cancers as a function of microsatellite instability and p53 status. Br J Cancer 2000;82:913-23. [PMID: 10732766 DOI: 10.1054/bjoc.1999.1019] [Cited by in Crossref: 53] [Cited by in F6Publishing: 51] [Article Influence: 2.4] [Reference Citation Analysis]
613 Safran H, Wanebo HJ, Hesketh PJ, Akerman P, Ianitti D, Cioffi W, DiPetrillo T, Wolf B, Koness J, McAnaw R. Paclitaxel and concurrent radiation for gastric cancer. Int J Radiat Oncol Biol Phys. 2000;46:889-894. [PMID: 10705010 DOI: 10.1016/S0360-3016(99)00436-8] [Cited by in Crossref: 19] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
614 Fisher DE. Turning p53 on or off: either way may treat cancer. Drug Resistance Updates 2000;3:77-9. [DOI: 10.1054/drup.2000.0128] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
615 Elkhuizen PH, van Slooten HJ, Clahsen PC, Hermans J, van de Velde CJ, van den Broek LC, van de Vijver MJ. High local recurrence risk after breast-conserving therapy in node-negative premenopausal breast cancer patients is greatly reduced by one course of perioperative chemotherapy: A European Organization for Research and Treatment of Cancer Breast Cancer Cooperative Group Study. J Clin Oncol 2000;18:1075-83. [PMID: 10694560 DOI: 10.1200/JCO.2000.18.5.1075] [Cited by in Crossref: 62] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
616 Bullock AN, Henckel J, Fersht AR. Quantitative analysis of residual folding and DNA binding in mutant p53 core domain: definition of mutant states for rescue in cancer therapy. Oncogene 2000;19:1245-56. [PMID: 10713666 DOI: 10.1038/sj.onc.1203434] [Cited by in Crossref: 270] [Cited by in F6Publishing: 260] [Article Influence: 12.3] [Reference Citation Analysis]
617 Blaszyk H, Hartmann A, Cunningham JM, Schaid D, Wold LE, Kovach JS, Sommer SS. A prospective trial of midwest breast cancer patients: a p53 gene mutation is the most important predictor of adverse outcome. Int J Cancer 2000;89:32-8. [PMID: 10719728 DOI: 10.1002/(sici)1097-0215(20000120)89:1<32::aid-ijc6>3.0.co;2-g] [Cited by in Crossref: 27] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
618 Attardi LD, Reczek EE, Cosmas C, Demicco EG, Mccurrach ME, Lowe SW, Jacks T. PERP, an apoptosis-associated target of p53, is a novel member of the PMP-22/gas3 family. Genes Dev 2000;14:704-18. [DOI: 10.1101/gad.14.6.704] [Cited by in Crossref: 114] [Cited by in F6Publishing: 3] [Article Influence: 5.2] [Reference Citation Analysis]
619 Cowell IG, Okorokov AL, Cutts SA, Padget K, Bell M, Milner J, Austin CA. Human topoisomerase IIalpha and IIbeta interact with the C-terminal region of p53. Exp Cell Res 2000;255:86-94. [PMID: 10666337 DOI: 10.1006/excr.1999.4772] [Cited by in Crossref: 41] [Cited by in F6Publishing: 43] [Article Influence: 1.9] [Reference Citation Analysis]
620 Blagosklonny MV, Robey R, Bates S, Fojo T. Pretreatment with DNA-damaging agents permits selective killing of checkpoint-deficient cells by microtubule-active drugs. J Clin Invest 2000;105:533-9. [PMID: 10683383 DOI: 10.1172/JCI8625] [Cited by in Crossref: 68] [Cited by in F6Publishing: 31] [Article Influence: 3.1] [Reference Citation Analysis]
621 Lai SL, Perng RP, Hwang J. p53 gene status modulates the chemosensitivity of non-small cell lung cancer cells. J Biomed Sci 2000;7:64-70. [PMID: 10644891 DOI: 10.1007/BF02255920] [Cited by in Crossref: 56] [Cited by in F6Publishing: 25] [Article Influence: 2.5] [Reference Citation Analysis]
622 Mujoo K, Zhang L, Klostergaard J, Donato NJ. Emergence of cisplatin-resistant cells from the OVCAR-3 ovarian carcinoma cell line with p53 mutations, altered tumorigenicity, and increased apoptotic sensitivity to p53 gene replacement. Int J Gynecol Cancer 2000;10:105-14. [DOI: 10.1046/j.1525-1438.2000.00018.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 0.6] [Reference Citation Analysis]
623 Paradiso A, Simone G, Petroni S, Leone B, Vallejo C, Lacava J, Romero A, Machiavelli M, De Lena M, Allegra CJ. Thymidilate synthase and p53 primary tumour expression as predictive factors for advanced colorectal cancer patients. Br J Cancer. 2000;82:560-567. [PMID: 10682666 DOI: 10.1054/bjoc.1999.0964] [Cited by in Crossref: 103] [Cited by in F6Publishing: 95] [Article Influence: 4.7] [Reference Citation Analysis]
624 Debatin K. Activation of apoptosis pathways by anticancer treatment. Toxicology Letters 2000;112-113:41-8. [DOI: 10.1016/s0378-4274(99)00252-0] [Cited by in Crossref: 82] [Cited by in F6Publishing: 22] [Article Influence: 3.7] [Reference Citation Analysis]
625 Turner BC, Gumbs AA, Carbone CJ, Carter D, Glazer PM, Haffty BG. Mutant p53 protein overexpression in women with ipsilateral breast tumor recurrence following lumpectomy and radiation therapy. Cancer 2000;88:1091-8. [DOI: 10.1002/(sici)1097-0142(20000301)88:5<1091::aid-cncr21>3.0.co;2-y] [Cited by in Crossref: 26] [Article Influence: 1.2] [Reference Citation Analysis]
626 Lebedeva IV, Stein CA. Antisense Oligonucleotides in Cancer: Recent Advances. BioDrugs 2000;13:195-216. [DOI: 10.2165/00063030-200013030-00005] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
627 Wade M, Allday MJ. Epstein-Barr virus suppresses a G(2)/M checkpoint activated by genotoxins. Mol Cell Biol 2000;20:1344-60. [PMID: 10648620 DOI: 10.1128/MCB.20.4.1344-1360.2000] [Cited by in Crossref: 40] [Cited by in F6Publishing: 21] [Article Influence: 1.8] [Reference Citation Analysis]
628 Ferreira CG, Tolis C, Giaccone G. p53 and chemosensitivity. Ann Oncol 1999;10:1011-21. [PMID: 10572598 DOI: 10.1023/a:1008361818480] [Cited by in Crossref: 114] [Cited by in F6Publishing: 34] [Article Influence: 5.2] [Reference Citation Analysis]
629 Ferrero JM, Etienne MC, Formento JL, Francoual M, Rostagno P, Peyrottes I, Ettore F, Teissier E, Leblanc-Talent P, Namer M, Milano G. Application of an original RT-PCR-ELISA multiplex assay for MDR1 and MRP, along with p53 determination in node-positive breast cancer patients. Br J Cancer 2000;82:171-7. [PMID: 10638986 DOI: 10.1054/bjoc.1999.0896] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 0.5] [Reference Citation Analysis]
630 May P, May E. Twenty years of p53 research: structural and functional aspects of the p53 protein. Oncogene. 1999;18:7621-7636. [PMID: 10618702 DOI: 10.1038/sj.onc.1203285] [Cited by in Crossref: 397] [Cited by in F6Publishing: 386] [Article Influence: 18.0] [Reference Citation Analysis]
631 Sellers WR, Fisher DE. Apoptosis and cancer drug targeting. J Clin Invest. 1999;104:1655-1661. [PMID: 10606616 DOI: 10.1172/jci9053] [Cited by in Crossref: 145] [Cited by in F6Publishing: 38] [Article Influence: 6.6] [Reference Citation Analysis]
632 Seong J, Chung EJ, Kim H, Kim GE, Kim NK, Sohn SK, Min JS, Suh CO. Assessment of biomarkers in paired primary and recurrent colorectal adenocarcinomas. Int J Radiat Oncol Biol Phys. 1999;45:1167-1173. [PMID: 10613309 DOI: 10.1016/S0360-3016(99)00302-8] [Cited by in Crossref: 16] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
633 Chehab NH, Malikzay A, Stavridi ES, Halazonetis TD. Phosphorylation of Ser-20 mediates stabilization of human p53 in response to DNA damage. Proc Natl Acad Sci USA. 1999;96:13777-13782. [PMID: 10570149 DOI: 10.1073/pnas.96.24.13777] [Cited by in Crossref: 369] [Cited by in F6Publishing: 364] [Article Influence: 16.8] [Reference Citation Analysis]
634 O'Neill CF, Koberle B, Masters JR, Kelland LR. Gene-specific repair of Pt/DNA lesions and induction of apoptosis by the oral platinum drug JM216 in three human ovarian carcinoma cell lines sensitive and resistant to cisplatin. Br J Cancer 1999;81:1294-303. [PMID: 10604725 DOI: 10.1038/sj.bjc.6694381] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.2] [Reference Citation Analysis]
635 Bennett J, Fong Y. Viral-based therapies for liver cancer. HPB 2000;2:289-98. [DOI: 10.1016/s1365-182x(17)30749-9] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
636 Sturm I, Papadopoulos S, Hillebrand T, Benter T, Lück H, Wolff G, Dörken B, Daniel PT. Impaired BAX protein expression in breast cancer: Mutational analysis of the BAX and thep53 gene. Int J Cancer 2000;87:517-21. [DOI: 10.1002/1097-0215(20000815)87:4<517::aid-ijc9>3.0.co;2-b] [Cited by in Crossref: 36] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
637 Harima Y, Nagata K, Harima K, Oka A, Ostapenko VV, Shikata N, Ohnishi T, Tanaka Y. Bax and Bcl-2 protein expression following radiation therapy versus radiation plus thermoradiotherapy in stage IIIB cervical carcinoma. Cancer 2000;88:132-8. [DOI: 10.1002/(sici)1097-0142(20000101)88:1<132::aid-cncr18>3.0.co;2-h] [Cited by in Crossref: 30] [Article Influence: 1.4] [Reference Citation Analysis]
638 González-cámpora R, Ruiz MRG, Ramírez FV, Martín JJR, Santos JMF, Martos MDMR, Pascual AG. Apoptosis in Breast Carcinoma. Pathology - Research and Practice 2000;196:167-74. [DOI: 10.1016/s0344-0338(00)80097-7] [Cited by in Crossref: 16] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
639 Gao C, Nakajima T, Taya Y, Tsuchida N. Activation of p53 in MDM2-overexpressing cells through phosphorylation. Biochem Biophys Res Commun 1999;264:860-4. [PMID: 10544021 DOI: 10.1006/bbrc.1999.1611] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 0.5] [Reference Citation Analysis]
640 Chappuis PO, Estreicher A, Dieterich B, Bonnefoi H, Otter M, Sappino A, Iggo R. Prognostic significance ofp53 mutation in breast cancer: Frequent detection of non-missense mutations by yeast functional assay. Int J Cancer 1999;84:587-93. [DOI: 10.1002/(sici)1097-0215(19991222)84:6<587::aid-ijc8>3.0.co;2-8] [Cited by in Crossref: 27] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
641 Chen Z, Naito M, Hori S, Mashima T, Yamori T, Tsuruo T. A human IAP-family gene, apollon, expressed in human brain cancer cells. Biochem Biophys Res Commun. 1999;264:847-854. [PMID: 10544019 DOI: 10.1006/bbrc.1999.1585] [Cited by in Crossref: 155] [Cited by in F6Publishing: 140] [Article Influence: 6.7] [Reference Citation Analysis]
642 Pollack IF, Bredel M, Erff M, Hamilton AD, Sebti SM. Inhibition of Ras and related guanosine triphosphate-dependent proteins as a therapeutic strategy for blocking malignant glioma growth: II--preclinical studies in a nude mouse model. Neurosurgery 1999;45:1208-14; discussion 1214-5. [PMID: 10549939 DOI: 10.1097/00006123-199911000-00039] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 1.4] [Reference Citation Analysis]
643 Wouters BG, Wang LH, Brown JM. Tirapazamine: a new drug producing tumor specific enhancement of platinum-based chemotherapy in non-small-cell lung cancer. Ann Oncol 1999;10 Suppl 5:S29-33. [PMID: 10582136 DOI: 10.1093/annonc/10.suppl_5.s29] [Cited by in Crossref: 18] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
644 Lam V, McPherson JP, Salmena L, Lees J, Chu W, Sexsmith E, Hedley DW, Freedman MH, Reed JC, Malkin D. p53 gene status and chemosensitivity of childhood acute lymphoblastic leukemia cells to adriamycin. Leuk Res. 1999;23:871-880. [PMID: 10573131 DOI: 10.1016/s0145-2126(99)00102-2] [Cited by in Crossref: 21] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
645 Greaves M. Molecular genetics, natural history and the demise of childhood leukaemia. European Journal of Cancer 1999;35:1941-53. [DOI: 10.1016/s0959-8049(99)00296-8] [Cited by in Crossref: 104] [Cited by in F6Publishing: 28] [Article Influence: 4.5] [Reference Citation Analysis]
646 Xirodimas DP, Lane DP. Molecular evolution of the thermosensitive PAb1620 epitope of human p53 by DNA shuffling. J Biol Chem 1999;274:28042-9. [PMID: 10488156 DOI: 10.1074/jbc.274.39.28042] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 0.8] [Reference Citation Analysis]
647 Kouraklis G. Progress in cancer gene therapy. Acta Oncol 1999;38:675-83. [PMID: 10522756 DOI: 10.1080/028418699432815] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 0.8] [Reference Citation Analysis]
648 Hochhauser D, Valkov NI, Gump JL, Wei I, O'hare C, Hartley J, Fan J, Bertino JR, Banerjee D, Sullivan DM. Effects of wild-type p53 expression on the quantity and activity of topoisomerase II? and ? in various human cancer cell lines. J Cell Biochem 1999;75:245-57. [DOI: 10.1002/(sici)1097-4644(19991101)75:2<245::aid-jcb7>3.0.co;2-g] [Cited by in Crossref: 13] [Article Influence: 0.6] [Reference Citation Analysis]
649 Huang L, Pardee AB. β-Lapachone Induces Cell Cycle Arrest and Apoptosis in Human Colon Cancer Cells. Mol Med 1999;5:711-20. [DOI: 10.1007/bf03402095] [Cited by in Crossref: 49] [Article Influence: 2.1] [Reference Citation Analysis]
650 Sugo H, Takamori S, Kojima K, Beppu T, Futagawa S. The significance of p53 mutations as an indicator of the biological behavior of recurrent hepatocellular carcinomas. Surg Today 1999;29:849-55. [PMID: 10489124 DOI: 10.1007/BF02482774] [Cited by in Crossref: 29] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
651 Roemer K. Mutant p53: gain-of-function oncoproteins and wild-type p53 inactivators. Biol Chem 1999;380:879-87. [PMID: 10494837 DOI: 10.1515/BC.1999.108] [Cited by in Crossref: 56] [Cited by in F6Publishing: 16] [Article Influence: 2.4] [Reference Citation Analysis]
652 Giatromanolaki A, Stathopoulos GP, Tsiobanou E, Papadimitriou C, Georgoulias V, Gatter KC, Harris AL, Koukourakis MI. Combined role of tumor angiogenesis,bcl-2, and p53 expression in the prognosis of patients with colorectal carcinoma. Cancer 1999;86:1421-30. [DOI: 10.1002/(sici)1097-0142(19991015)86:8<1421::aid-cncr6>3.0.co;2-x] [Cited by in Crossref: 62] [Cited by in F6Publishing: 22] [Article Influence: 2.7] [Reference Citation Analysis]
653 Robles AI, Wang XW, Harris CC. Drug-induced apoptosis is delayed and reduced in XPD lymphoblastoid cell lines: possible role of TFIIH in p53-mediated apoptotic cell death. Oncogene 1999;18:4681-8. [PMID: 10467415 DOI: 10.1038/sj.onc.1202862] [Cited by in Crossref: 31] [Cited by in F6Publishing: 33] [Article Influence: 1.3] [Reference Citation Analysis]
654 Czarnota GJ, Kolios MC, Abraham J, Portnoy M, Ottensmeyer FP, Hunt JW, Sherar MD. Ultrasound imaging of apoptosis: high-resolution non-invasive monitoring of programmed cell death in vitro, in situ and in vivo. Br J Cancer 1999;81:520-7. [PMID: 10507779 DOI: 10.1038/sj.bjc.6690724] [Cited by in Crossref: 152] [Cited by in F6Publishing: 104] [Article Influence: 6.6] [Reference Citation Analysis]
655 te Poele RH, Okorokov AL, Joel SP. RNA synthesis block by 5,6-dichloro-1-β-D-ribofuranosylbenzimidazole (DRB) triggers p53-dependent apoptosis in human colon carcinoma cells. Oncogene 1999;18:5765-72. [DOI: 10.1038/sj.onc.1202961] [Cited by in Crossref: 45] [Cited by in F6Publishing: 41] [Article Influence: 2.0] [Reference Citation Analysis]
656 Sato S, Kigawa J, Minagawa Y, Okada M, Shimada M, Takahashi M, Kamazawa S, Terakawa N. Chemosensitivity and p53-dependent apoptosis in epithelial ovarian carcinoma. Cancer 1999;86:1307-13. [DOI: 10.1002/(sici)1097-0142(19991001)86:7<1307::aid-cncr28>3.0.co;2-f] [Cited by in Crossref: 34] [Article Influence: 1.5] [Reference Citation Analysis]
657 Davies C, Loizidou M, Cooper A, Taylor I. Effect of γ-linolenic acid on cellular uptake of structurally related anthracyclines in human drug sensitive and multidrug resistant bladder and breast cancer cell lines. European Journal of Cancer 1999;35:1534-40. [DOI: 10.1016/s0959-8049(99)00181-1] [Cited by in Crossref: 24] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
658 Harima Y, Shirahama S, Harima K, Aoki S, Ohnishi T, Tanaka Y. Genetic alterations on chromosome 17p associated with response to radiotherapy in bulky cervical cancer. Br J Cancer 1999;81:108-13. [PMID: 10487620 DOI: 10.1038/sj.bjc.6690658] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
659 Pratesi G, Perego P, Polizzi D, Righetti SC, Supino R, Caserini C, Manzotti C, Giuliani FC, Pezzoni G, Tognella S, Spinelli S, Farrell N, Zunino F. A novel charged trinuclear platinum complex effective against cisplatin-resistant tumours: hypersensitivity of p53-mutant human tumour xenografts. Br J Cancer 1999;80:1912-9. [PMID: 10471039 DOI: 10.1038/sj.bjc.6690620] [Cited by in Crossref: 83] [Cited by in F6Publishing: 84] [Article Influence: 3.6] [Reference Citation Analysis]
660 Greaves M. Molecular genetics, natural history and the demise of childhood leukaemia. Eur J Cancer 1999;35:173-85. [PMID: 10448256 DOI: 10.1016/s0959-8049(98)00433-x] [Cited by in Crossref: 91] [Cited by in F6Publishing: 19] [Article Influence: 4.0] [Reference Citation Analysis]
661 Bunz F, Hwang PM, Torrance C, Waldman T, Zhang Y, Dillehay L, Williams J, Lengauer C, Kinzler KW, Vogelstein B. Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J Clin Invest. 1999;104:263-269. [PMID: 10430607 DOI: 10.1172/jci6863] [Cited by in Crossref: 695] [Cited by in F6Publishing: 305] [Article Influence: 30.2] [Reference Citation Analysis]
662 McGill G, Fisher DE. p53 and cancer therapy: a double-edged sword. J Clin Invest 1999;104:223-5. [PMID: 10430602 DOI: 10.1172/JCI7861] [Cited by in Crossref: 23] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
663 Zhu GH, Wong BC, Ching CK, Lai KC, Lam SK. Differential apoptosis by indomethacin in gastric epithelial cells through the constitutive expression of wild-type p53 and/or up-regulation of c-myc. Biochem Pharmacol. 1999;58:193-200. [PMID: 10403534 DOI: 10.1016/s0006-2952(99)00058-1] [Cited by in Crossref: 27] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
664 Elkhuizen PH, Voogd AC, van den Broek LC, Tan IT, van Houwelingen HC, Leer JH, van de Vijver MJ. Risk factors for local recurrence after breast-conserving therapy for invasive carcinomas: a case-control study of histological factors and alterations in oncogene expression. International Journal of Radiation Oncology*Biology*Physics 1999;45:73-83. [DOI: 10.1016/s0360-3016(99)00158-3] [Cited by in Crossref: 55] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
665 Nieves-neira W, Pommier Y. Apoptotic response to camptothecin and 7-hydroxystaurosporine (UCN-01) in the 8 human breast cancer cell lines of the NCI anticancer drug screen: Multifactorial relationships with topoisomerase i, protein kinase C, Bcl-2, p53, MDM-2 and caspase pathways. Int J Cancer 1999;82:396-404. [DOI: 10.1002/(sici)1097-0215(19990730)82:3<396::aid-ijc13>3.0.co;2-z] [Cited by in Crossref: 84] [Cited by in F6Publishing: 30] [Article Influence: 3.7] [Reference Citation Analysis]
666 Ahrendt SA, Halachmi S, Chow JT, Wu L, Halachmi N, Yang SC, Wehage S, Jen J, Sidransky D. Rapid p53 sequence analysis in primary lung cancer using an oligonucleotide probe array. Proc Natl Acad Sci U S A 1999;96:7382-7. [PMID: 10377423 DOI: 10.1073/pnas.96.13.7382] [Cited by in Crossref: 143] [Cited by in F6Publishing: 139] [Article Influence: 6.2] [Reference Citation Analysis]
667 Mezzelani A, Alasio L, Bartoli C, Bonora MG, Pierotti MA, Rilke F, Pilotti S. c-erbB2/neu gene and chromosome 17 analysis in breast cancer by FISH on archival cytological fine-needle aspirates. Br J Cancer 1999;80:519-25. [PMID: 10408862 DOI: 10.1038/sj.bjc.6690387] [Cited by in Crossref: 48] [Cited by in F6Publishing: 39] [Article Influence: 2.1] [Reference Citation Analysis]
668 Tanaka F, Yanagihara K, Ohtake Y, Miyahara R, Kawano Y, Fukuse T, Hitomi S, Wada H. p53 status predicts the efficacy of postoperative oral administration of tegafur for completely resected non-small cell lung cancer. Jpn J Cancer Res 1999;90:432-8. [PMID: 10363582 DOI: 10.1111/j.1349-7006.1999.tb00766.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 0.6] [Reference Citation Analysis]
669 Evans TR, Kaye SB. Retinoids: present role and future potential. Br J Cancer. 1999;80:1-8. [PMID: 10389969 DOI: 10.1038/sj.bjc.6690312] [Cited by in Crossref: 138] [Cited by in F6Publishing: 127] [Article Influence: 6.0] [Reference Citation Analysis]
670 Quirke P, Mapstone N. The new biology: histopathology. The Lancet 1999;354:S26-31. [DOI: 10.1016/s0140-6736(99)90246-5] [Cited by in Crossref: 11] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
671 Suzuki K, Kazui T, Yoshida M, Uno T, Kobayashi T, Kimura T, Yoshida T, Sugimura H. Drug-induced Apoptosis and p53, BCL-2 and BAX Expression in Breast Cancer Tissues In Vivo and in Fibroblast Cells In Vitro. Japanese Journal of Clinical Oncology 1999;29:323-31. [DOI: 10.1093/jjco/29.7.323] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 0.7] [Reference Citation Analysis]
672 Pruschy M, Resch H, Shi YQ, Aalame N, Glanzmann C, Bodis S. Ceramide triggers p53-dependent apoptosis in genetically defined fibrosarcoma tumour cells. Br J Cancer 1999;80:693-8. [PMID: 10360645 DOI: 10.1038/sj.bjc.6690411] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 0.8] [Reference Citation Analysis]
673 Mcclelland RA, Gee JMW, O'sullivan L, Barnes DM, Robertson JFR, Ellis IO, Nicholson RI. p21WAF1 expression and endocrine response in breast cancer. J Pathol 1999;188:126-32. [DOI: 10.1002/(sici)1096-9896(199906)188:2<126::aid-path340>3.0.co;2-o] [Cited by in Crossref: 16] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
674 Takeda A, Nakajima K, Shimada H, Imaseki H, Takayama W, Hayashi H, Suzuki T, Ochiai T, Isono K. Clinical significance of serum p53 antibody detection on chemosensitivity assay in human colorectal cancer. J Surg Oncol 1999;71:112-6. [DOI: 10.1002/(sici)1096-9098(199906)71:2<112::aid-jso10>3.0.co;2-p] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
675 Wickremasinghe RG, Hoffbrand AV. Biochemical and Genetic Control of Apoptosis: Relevance to Normal Hematopoiesis and Hematological Malignancies. Blood 1999;93:3587-600. [DOI: 10.1182/blood.v93.11.3587.411k46_3587_3600] [Cited by in Crossref: 3] [Article Influence: 0.1] [Reference Citation Analysis]
676 Wickremasinghe RG, Hoffbrand AV. Biochemical and Genetic Control of Apoptosis: Relevance to Normal Hematopoiesis and Hematological Malignancies. Blood 1999;93:3587-600. [DOI: 10.1182/blood.v93.11.3587] [Cited by in Crossref: 96] [Article Influence: 4.2] [Reference Citation Analysis]
677 Pietersen AM, van der Eb MM, Rademaker HJ, van den Wollenberg DJM, Rabelink MJWE, Kuppen PJK, van Dierendonck JH, van Ormondt H, Masman D, van de Velde CJH, van der Eb AJ, Hoeben RC, Noteborn MHM. Specific tumor-cell killing with adenovirus vectors containing the apoptin gene. Gene Ther 1999;6:882-92. [DOI: 10.1038/sj.gt.3300876] [Cited by in Crossref: 73] [Cited by in F6Publishing: 68] [Article Influence: 3.2] [Reference Citation Analysis]
678 Cui W, Gusterson B, Clark AJ. Nitroreductase-mediated cell ablation is very rapid and mediated by a p53-independent apoptotic pathway. Gene Ther 1999;6:764-70. [DOI: 10.1038/sj.gt.3300873] [Cited by in Crossref: 33] [Cited by in F6Publishing: 35] [Article Influence: 1.4] [Reference Citation Analysis]
679 Caporale LH. Chance Favors the Prepared Genome. Annals NY Acad Sci 1999;870:1-21. [DOI: 10.1111/j.1749-6632.1999.tb08860.x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 1.1] [Reference Citation Analysis]
680 Han JY, Chung YJ, Park SW, Kim JS, Rhyu MG, Kim HK, Lee KS. The relationship between cisplatin-induced apoptosis and p53, bcl-2 and bax expression in human lung cancer cells. Korean J Intern Med 1999;14:42-52. [PMID: 10063313 DOI: 10.3904/kjim.1999.14.1.42] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 0.9] [Reference Citation Analysis]
681 Debatin KM. The role of CD95 system in chemotherapy. Drug Resist Updat 1999;2:85-90. [PMID: 11504475 DOI: 10.1054/drup.1999.0073] [Cited by in Crossref: 14] [C